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ABSTRACT
To investigate the mechanism and functional significance of infection of CD8
lymphocytes by human immunodeficiency virus type 1 (HIV-1) in vivo, frequencies
of infection and genetic relationships between HIV-1 variants infecting naive
(CD45RA+) and memory (CD45RO+) CD4 and CD8 lymphocytes were determined.
CD4 and CD8 lymphocytes were purified from peripheral blood mononuclear cells
in 16 study subjects by negative selection, followed by positive selection of each of
the two subsets with anti-CD45RA and -RO monoclonal antibody-coated beads. The
contribution to total proviral load by the naive and memory subsets was estimated by
quantitiative PCR combined with measurement of their frequency in total T
lymphocytes. In this analysis we found that HIV preferentially infects the naive
subset of CD8+ lymphocytes along with the naive and memory populations of CD4+
cells.
Sequence comparisons of the V1/V2 and V3 region of the envelope gene
were also carried out on the naive and memory subsets of CD4 and CD8 cells.
Variants infecting CD8 lymphocytes were partially or completely genetically distinct
in the V3 region from those recovered from CD4 lymphocytes, and showed a greater
degree of compartmentalisation than observed between naive and memory subsets of
CD4 lymphocytes. A preferential distribution of syncytium-inducing, CXCR4-
dependent variants was also observed within CD4 lymphocytes. Even more marked
sequence differences were observed between CD4 and CD8 T lymphocytes upon
sequence comparison of the V1/V2 hypervariable region, with some evidence for
recombination between V1/V2 and V3 regions. Population differences may have
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originated through different times of infection rather than necessarily indicating a
difference in their biological properties.
Provirus-containing lymphocytes in PBMCs and in lymph nodes are not
generally transcriptionally active and not destroyed by HIV infection, either because
of infection with a defective virus or because virus expression is inhibited. A series
of immunocytochemical techniques was used to determine whether any infected cells
in the lymphoid population were in fact productive and to allow comparison with the
frequencies detected by PCR. Sequential incubations with monoclonal antibodies and
labelling with fast red, fast blue, and diaminobenzidine (DAB) allowed the
distribution of three cell surface or internal markers to be determined. Staining of
CD4, CD8 and HIV p24 antigen was achieved in cultured cells by this method. In-
situ PCR was also used to detect HIV proviral sequences in lymph node and spleen
tissue sections.
In this study we provide evidence for the widespread infection of CD4 and
CD8 naive and memory cell populations within the peripheral blood of HIV
seropositive individuals, indicating that HIV has a broader tropism for cell types in
vivo than described previously. The preferential distribution of HIV-1 in naive CD8
lymphocytes suggests that infection occurred early in T lymphocyte ontogeny, such
as during maturation in the thymus. Destruction of cells destined to become CD8
lymphocytes may be a major factor in the decline of CD8 lymphocyte frequencies
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CHAPTER ONE: INTRODUCTION
1.1 BACKGROUND
Human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) are human
lentiviruses belonging to the Retroviridae family. Infection with HIV-1, HIV-2 or in
some cases co-infection with both viruses is now widely accepted to be causally
associated with the subsequent progression to a state of severe immunodeficiency
known as the acquired immune deficiency syndrome (AIDS). Type 1 HIV is
recognised as the agent of the global AIDS pandemic, with HIV-2 mostly confined to
the countries of West Africa (DeCock et al., 1993).
The first recognised cases of AIDS occurred in the United States in 1981
when outbreaks of previously rare diseases, such as Pneumocystis carinii pneumonia
(PCP) and Kaposi's sarcoma, were observed in a few homosexual men. Similar
outbreaks of other immunodeficiency associated conditions such as mucosal
candidiasis, disseminsated cytomegalovirus infection and chronic herpes simplex virus
ulcers were described a short time later. All patients had evidence of a severe T-
lymphotropic dysfunction manifested by hyperresponsiveness to mitogens and
antigens. This outbreak was not limited to populations within the United States. By
the end of 1982 reports of this immunodeficiency syndrome expanded to include
Haitian immigrants, haemophiliacs, transfusion recipients, and sex partners of risk-
group members and children born to mothers at risk. Epidemiological studies
suggested that an infectious agent was responsible for this newly described
immunodeficiency syndrome. In 1983 Montagnier and colleagues first isolated a
retrovirus from the lymph nodes of a patient in Paris with multiple lymphadenopathy.
This virus was designated lymphadenopathy-associated-virus (LAV). LAV was
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shown to replicate and cause cytopathology in cultures of human peripheral blood
lymphocytes (Barre-Sinoussi et al., 1983). The following year, scientists at the
National Cancer Institute in Bethesda confirmed the isolation of a cytopathic T-
lymphotropic retrovirus, designated human T-lymphotropic virus III (HTLV-III)
from peripheral blood mononuclear cells (PBMCs) in patients with acquired
immunodeficiency syndrome (AIDS) (Gallo el al., 1984). At the same time Levy and
colleagues cultured an AIDS-associated retrovirus (ARV) from PBMCs of an AIDS
patient (Levy et al., 1985). Molecular cloning and sequence analysis revealed that the
genomes of LAV and HTLV-III were almost identical. Electron microscopy
demonstrated that these viruses from AIDS patients were morphologically similar to
members of the lentivirus genus of the family Retroviridiae. As there was a certain
degree of confusion regarding the nomenclature of this virus implicated in AIDS, it
was renamed human immunodeficiency virus type 1 (HIV-1). In 1985, a lentivirus
was isolated from captive Asian macaques with an AIDS-like illness (Daniel et al.,
1985). Because of morphologic similarity and serologic cross-reactivity with HTLV-
III, this macaque virus was designated simian T-lymphotropic virus type III (STLV-
III). It was later re-designated simian immunodeficiency virus (SIV).
In 1986, Clavel, Montagier and colleagues discovered a second HIV (HIV-2)
in West Africa (Clavel et al., 1986). Although both HIV-1 and HIV-2 can cause
AIDS, individuals infected with HIV-2 exhibit a longer period of clinical latency and
lower morbidity. At present the origins of HIV-1 and HIV-2 infection in man remains
unclear although it is possible that both of these viruses arose from zoonotic
transmissions from nonhuman primates (for more detailed discussion, see section 1.6).
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1.2 CLASSIFICATION OF RETROVIRUSES
The Retroviridae comprise a large family of viruses, primarily infecting
vertebrates, although they are also found in other animals such as insects and
molluscs. All retrovirus isolates are quite similar in virion structure, genome
organisation and mode of replication. They belong to seven distinct genera (Table 1.1)
(Luciw et al., 1996). The genome of retroviruses consists of two, usually identical,
molecules of single-stranded RNA, and the enzyme reverse transcriptase which
converts genetic information from single-stranded RNA to double-stranded DNA
(Figure 1.1). Retroviruses also contain another enzyme, integrase, which is necessary
for covalently joining virus to cell DNA to form the provirus.
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Figure 1.1 Simplified Structure of HTV-1.
(Modified from Fields Virology, 1996)
Table 1.1 Retrovirus Genera
Genus Example Isolates
Avian-leukosis-sarcoma Rous sarcoma virus (RSV)




Mammalian C-type Moloney murine leukemia virus (Mo-MLV)
Harvey murine sarcoma virus (Ha-MSV)
Abelson murine leukemia virus (A-MuLV)
AKR-MuLV
Feline leukemia virus (FeLV)
Simian sarcoma virus (SSV)s
Reticuloendotheliosis virus (REV)
B-Type viruses Mouse mammary tumor virus (MMTV)
D-Type viruses Mason-Pfizer monkey virus (MPMV)
HTLV-BLV group Human T-cell leukemia (or lymphotropic) virus
(HTLV)-l and-2
Bovine leukemia virus (BIV)
Lentivirus Human immunodeficiency virus (HIV)-l and -2
Simian immunodeficiency virus (SIV)
Feline immunodeficiency virus (FIV)
Visna/maedi virus
Bovine immunodeficiency virus (BIV)
Spumavirus Simian foamy virus (SFV)
Human foamy virus (HFV)
renne syncyuum-ioimmsg vuus (reo v ;
HIV-1, HIV-2 and SIV belong to the genus lentiviruses. This genus includes
complex exogenous viruses responsible for a variety of neurological and
immunological diseases, but not directly implicated in malignancies. HIV and SIV,
like the other retroviruses have two genomic forms: single-stranded RNA in the
extracellular phase of the viral life cycle (i.e. virions) and double-stranded DNA (i.e.
provirus) within the cell. The replication cycle initiates with entry of the virion core
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into the cytoplasm, synthesis of double-stranded DNA using the single-stranded
genome as template, transfer of the core structure to the nucleus, and integration of
the DNA into the host genome. These steps are mediated by proteins found within the
virion and proceed in the absence of viral gene expression. Next, mRNAs, viral
genomes and proteins are synthesised and processed using host T-cell systems
including RNA polymerase and specific viral gene products. Virion assembly proceeds
by encapsidation of the genome by unprocessed precursors of the gag, pro and pol
genes, association of the nucleocapsids with the cell membrane, release of the virion
by budding and finally processing of the precursors to the finished products.
1.3 VIRION STRUCTURE
H3V-1 is an enveloped virion 100-1 lOnm in diameter and spherical in shape. A
lipid bilayer envelope surrounds a cone-shaped nucleocapsid, which is connected at
the narrow end to the lipid bilayer. The region between the viral envelope and
nucleocapsid has been termed the paranucleoid region, core shell, or lateral body
(figure 1.1). Each mature virion is composed of two identical RNA strands
encapsulated by the proteolytic proteins processed from the gag precursor
polypeptide. The gag gene products are the matrix protein (MA), which is located
between the nucleocapsid and the virion envelope (membrane); the main capsid
protein (CA), which forms the capsid shell, and the nucleocapsid protein (NC), which
binds tightly to the RNA genome. In each virion the 5' ends of the two molecules of
genomic single-stranded viral RNA interact with each other through hydrogen bonds
between molecules aligned in the same polarity or through short antiparallel
arrangements.
I
A transfer RNA molecule is positioned near the 5' end of each genomic RNA
strand and serves as the primer for initiation of negative strand viral DNA synthesis by
reverse transcriptase (RT). The gag gene encodes the precursor for several virion
capsid proteins, the pol gene encodes the precursor for several virion enzymes
[protease (PR), RT, RNase H, and integrase (IN)], and the env gene encodes for the
envelope glycoprotein (env gp). The transcriptional transactivator {tat) and the
regulator of viral expression {rev) genes are encoded by two overlapping exons and
produce small nonvirion proteins, which are essential for viral replication. These
include viral protein R {vpr), viral infectivity factor {vif), vpu, vpx and tev. The viral
surface of HIV-1 is made up of 72 knob-like projections containing trimers or
tetramers derived from the envelope glycoproteins (gpl60). Proteolytic cleavage of
gpl60 produces gpl20, which is the glycoprotein responsible for interactions of
virions with the cellular receptors, and gp41, the transmembrane (TM) glycoprotein
that anchors the complex gpl20/gp41 to the membrane (reviewed in Levy et al.,
1993., Luciw, 1996 and references within)..
1.3.1 Genomic organisation of HIV-1
With their complement of 10 genes, HIV and related lentiviruses are
genetically much more complicated than murine and avian C-type retroviruses. Every
HIV particle has two identical positive strands of RNA, each of which is
approximately 9.2 kb long. In the early steps of replication, the virus RNA is
converted into double-stranded DNA, which is then integrated into the host genome.
The reverse transcription and synthesis of a double-stranded DNA results in the
formation of two identical long terminsal repeats (LTRs) flanking the main viral
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genes. HIV and SIV have therefore two genetic forms, single-stranded RNA in
virions and double-stranded DNA (provirus) within the cell. The provirus behaves as
a cellular gene, with the promoter and transcriptional start site located in the 5' LTR,
and a terminsation/polyadenylation site located in the 3' LTR. Viral replication
depends on the activation of the LTR and on the expression from the 9.2 kb provirus,
of the nine different open reading frames (ORFs) (Figure 1.2). Of these, three encode
structural proteins, and six encode regulatory and accessory proteins. The three
structural genes consist ofgag (group antigen), pol (polymerase) and env (envelope)
and are essential for virus replication. The three regulatory genes consist of rev
(regulator of viral gene expression), tat (transcriptional transactivator), and nef
(negative regulatory factor). In addition, HIV also encodes five accessory/auxiliary
proteins believed to be involved in virus maturation and release, virion infectivity
factor (vif), viral protein U(vpu), viral protein R (Vpr), and vpx and tev as accessory
genes. In spite of the difference in regulatory capacity, the basic life cycle of HIV is
similar to that of avian and murine retroviruses.
In order to facilitate the synthesis of 11 distinct proteins from a genome of less
than 10 kb, HIV displays great economy in its coding potential, employing a complex
array of differential RNA splicing and overlapping translational reading frames. In T-
cells or macrophages which support replication of HIV-1, three sizes of viral mRNAs
are produced: unspliced (9.0kb), single-spliced (4.5kb) and multiply spliced, (1.8-
2.2kb). The unspliced 9kb transcripts which represent the genomic mRNA, are
homogenous in size and serve two purposes: they are the viral RNA which is
packaged into new virions; and they translate the structural gag proteins and the
enzymatic pol polyprotein, comprising reverse transcriptase, protease and integrase.
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The 4kb transcripts are singly spliced, heterogeneous in their size and code for env,
vif, vpr, and vpu genes and the first exon of tat. The 2kb transcripts are multiply
spliced and code for tat, rev, nef and tev genes. The appearance of the 2kb species
precedes that of the 4kb and 9kb species: they are referred to as early and late
transcripts respectively. Early transcripts such as the tat and rev genes control late
events in viral replication. Mutations affecting tat or rev genes can abrogate viral
replication as these proteins control the expression and localisation ofviral transcripts.
1.3.2 Structural genes of HIV-1
The gag gene codes for the main non-glycosylated structural components of
the virus particle. They are initially made as a 55 kilodalton precursor, which is
translated from full length mRNA. Subsequent cleavage of the gag gene polyprotein
(p55) by the viral protease gives rise to the more mature capsid proteins of HIV; the
matrix protein (MA, pi7), the capsid protein (CA, p24), p2, nucleocapsid (NC, p7),
the nucleic acid binding protein (p9) and the proline-rich protein (p6).
The matrix protein (pi7) contains about 130 aminso acids, has a molecular
weight of 17 to 18 kDa and is located between the virion capsid and envelope. MA is
cleaved from the N-terminsus of p55 by viral PR. MA is part of the viral
nucleoprotein complex (i.e. preintegration complex), produced after reverse
transcription and it can mediate nuclear import of this complex. Deletions in MA do
not affect the processing of gag polyprotein, virion assembly or release; however
these deletions can impair the incorporation of env gp into virions resulting in the
production of non-infectious virus particles.
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The capsid (p24) protein contains about 240 aminso acids, has a molecular
weight of 24 to 27kDa, a high degree of hydrophobicity and is the major subunit of
the capsid shell. The capsid protein is released from the central portion of the gag
polyprotein by two cleavages mediated by the viral PR. Specific interactions of CA
with the viral RNA genome, other gag proteins as well as posttranslational
modifications are presumed to play important roles in CA function during capsid
assembly. Small deletions in the C-terminsal half of CA reduce viral particle
formation. Mutagenesis studies have shown that the domain governing nucleocapsid
assembly is located in the C-terminsal portion of CA.
Protease-mediated cleavage from sequences in the C-terminsal portion of the
Gag polyprotein produces the nucleocapsid (NC) region. NC contains approximately
70 aminso acids and has a molecular weight of 7 to 9kDa. This basic hydrophilic
protein binds genomic viral RNA in the nucleocapsid and may function to condense
the viral RNA genome for packaging into capsids during virion morphogenesis. NC
has a globular central domain consisting of the two cysteine-histidine motifs and
flanking basic residues. The first cysteine-histidine motif is essential for packaging and
shows that binding of zinc ions induces conformational changes in the NC, while the
second motif is dispensable. Because NC is an intrinsic component of the
nucleocapsid, this protein is thought to play a role in virion uncoating during entry
and may influence the reverse transcription process that takes place in a nucleoprotein
complex containing viral RNA as well as capsid proteins.
Cleavage of the gag-pol polyprotein p 160 by the viral protease produces the
viral enzymes plO (PR), p66/p5i (RT) (and RNase H), and p32 (IN). In HIV the gag
and pol genes overlap by 241 nucleotides and the pol gene is in a -1 reading frame
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with respect to gag. Expression of the pol gene is facilitated by a ribosomal ffameshift
which occurs at a low frequency and is directed by a short homopolymeric sequence
located in the overlap between the gag and pol open reading frames that allows a 'slip
back' of the ribosome into a -1 position. This results in the production of large
quantities of the gag gene products and relatively small quantities of the pol gene
products.
The mature form of PR is 99 aminso acids in length and displays a molecular
weight of lOkDa. The gag-pol polyprotein dimerizes in the infected cell, and the
mature PR is releases by an autocatalytic cleavage. The folly active PR then targets
other sites in the viral polyproteins; altogether four and seven cleavage sites are
recognised in the gag and gag-pol polyproteins. Site-specific mutagenesis
demonstrated that PR is required for replication. Also, this enzyme produces non¬
infectious particles containing uncleaved gag and gag-pol polyproteins.
PR produces reverse transcriptase and RNase H in two steps from the gag-pol
polyprotein during virus assembly. Firstly, p66 is cleaved and forms a homodimer.
Next, one unit of p66 in this homodimer is cleaved by PR near the C-terminsus to
yield a heterodimer composed of p51 and p66. Both the heterodimer and p66
homodimer display RT and RNase H activity. RT is an RNA-dependent DNA
polymerase which synthesises DNA from RNA as well as DNA templates and requires
an oligonucleotide primer. RNase H functions in reverse transcription by degrading
the RNA moiety of RNA/DNA hybrids and thereby uncovering the template for viral
DNA synthesis. RNase H also generates oligoribonucleotide primers for the reverse
transcription process. RT and RNase are indispensable for viral replication.
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The C-terminsus of the HIV gag-pol precursor polypeptide is proteolytically
processed by PR to produce the 32 kDa integrase (IN). An integrase domain near the
N-terminsus of HIV exhibits high sequence conservation with IN of other
retroviruses. This domain also contains pairs of cysteine and histidine residues that
adopt a similar structure to the metal-finger motif in several DNA-binding proteins.
Integrase is a viral enzyme possessing both DNA cleavage and joining activities. IN
mediates covalent linkage of linear double-stranded viral DNA into the host T-cell
genome.
The HTV-1 envelope glycoprotein is encoded by a bicistronic mRNA
containing the env open reading frame (ORF) just downstream of the vpu ORF. This
mRNA is synthesised at a late stage of viral replication and its expression is dependent
on the posttranscriptional function of the viral rev gene. The env genes of HIV and
SIV encode proteins of 850 to 880 aminso acids; extensive glycosylation of the Env
precursor polyprotein during synthesis produces gpl60 which is the major form of the
env gene product in infected cells. Oligopeptide mapping and aminso acid sequencing
reveal that gpl60 is cleaved to yield the N-terminsal subunit (gpl20), which is about
550 aminso acids long and the C-terminsal subunit (gp41), which is about 350 aminso
acids long, as mature envelope proteins. External viral gpl20 is responsible for
binding to the cellular receptors, while transmembrane gp41 anchors gpl20 through
noncovalent interactions and mediates membrane fusion with target T-cells (Veronese
et al, 1985). Noncovalent binding between gpl20 and gp41 produces the complex
gpl20/gp41 (Helseth et al., 1991) as well as the formation of tetramers on the cell
surface and the viral membrane (Popovic el al., 1983; Pinter et al., 1989).
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The external envelope glycoprotein, gpl20 is a highly glycosylated hydrophilic
protein positioned on the external surface of virion membranes as well as plasma
membranes. The aminso acid residues in both the N-terminsus and C-terminsus of
gpl20 are critical for maintaining the association of this subunit with gp41. HIV
gpl20 contains 24 potential sites for N-linked glycosylation, 13 of which are
conserved between isolates and 17 of these are modified with carbohydrate side
chains. Because of the extensive glycosylation of gpl20, few regions of the peptide
backbone of gpl20 protrude from the carbohydrate mass. Since, HIV gpl20 has 18
cysteine residues, which are highly conserved, disulphide bonds are presumed to play
more critical roles in the structure and function of this protein. A model for the gpl20
subunit shows nine intra-chain disulfide bonds which delineates gpl20 into several
functional regions including five conserved domains (C1-C5), five hyper-variable
domains (V1-V5) and a conformation-dependent domain that interacts with the CD4
receptor.
The transmembrane envelope glycoprotein (gp41) is hydrophobic and
traverses the lipid bilayer membranes of both virions and cells. Gp41 is classified as a
type 1 integral membrane protein. It contains four potential glycosylation sites and
three cysteine residues. The main functions ascribed to gp41 are fusion activity (Freed
et al., 1990), interaction with gpl20 (Bergeron et al., 1992; Chen et al., 1993),
anchoring of gpl20/gp41 to the membrane (Chen et al., 1994), involvement in
cytopathogenicity and participation in virion assembly (Bullough et al., 1994). About
20 aminso acids at the N-terminsus of gp41 are hydrophobic and define the fusion
peptide which is required for fusion of the virion membrane with the cell plasma
membrane during the entry step in viral replication. A second hydrophobic domain
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spans virion and cell membranes and thereby enables gp41 to serve as an anchor for
the Env gp heterodimer. The region between these two hydrophobic domains is
external to the membrane and contains a highly conserved sequence similar to the
leucine zipper motif implicated in protein/protein interactions of a variety of viral and
cellular proteins (Venable et al., 1989).
1.3.3 Regulatory genes of HTV-1
Tat is encoded by two exons. The first exon is located in the central region of
the viral genome between vpr and env. The second exon is located 3' of the env gene
and is of variable size, from 14-29 aminso acids. The tat gene is translated from early
multiply spliced transcripts and is considered to be an important factor in controlling
late events in viral replication. The tat gene increases rates of transcription from the
HIV-1 LTR (hence the name, transactivator of transcription). Tat allows RNA
polymerase II to traverse the length of the viral genome, thus dramatically increasing
levels of elongated transcripts. This effect of the tat gene is dependent on a viral cis-
acting RNA sequence, called the transactivation response element (TAR) which is
located precisely at the start of all viral transcripts. TAR extends from nucleotides +1
to +60 and forms a stable stem-loop structure. When the tat gene is present, it binds
to nascent RNA, represses the synthesis of short transcripts and modifies the
transcription complex allowing complete elongation of viral transcripts. The first exon
of the tat gene suffices for high levels of transactivation, the second exon mediates
cellular functions, such as lymphocyte activation (Lisziewicz et al., 1995; Ott et ah,
1997). While Tat has a modular structure, the RNA-binding domain of the tat gene
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cannot be separated from its activation domain for efficient interaction with TAR
(Wimmer et al., 1999).
Rev is also translated from early transcripts and is an important candidate in
controlling late events in viral replication. When viral transcripts from cells infected
with HIV-1 bearing mutations in Rev were analysed, a significant difference was
apparent when nuclear and cytoplasmic RNAs were analysed. All three mRNA (9 kb,
4 kb, and 2 kb) transcripts were present in the nucleus, but only 2kb transcripts were
observed in the cytoplasm. The appearance of 9kb and 4kb transcripts in the
cytoplasm was restored only after co-expression of rev in the same cells. Thus, rev
allows for the movement of unspliced and singly spliced transcripts from the nucleus
to the cytoplasm. Rev derives its name, the regulator ofviral gene expression, because
these late transcripts encode the structural and enzymatic proteins needed for virion
assembly.
Like tat, the rev gene is dependent on the presence of a cis-acting RNA
element. This sequence, the Rev response element (RRE) is between 240-and 351
nucleotides long and is located just 3' to the junction between the gpl20 and gp41
subunits of Env. Rev binds to the RRE, preventing the nuclear sequestration of
incompletely spliced viral transcripts. Since, Rev interacts with the nuclear export
pathway, these unspliced and singly-spliced transcripts are translocated to the
cytoplasm through the RRE.
The HIV regulatory protein Nef is a myristylated 27kDa protein expressed
early during virus infection from a multiply-spliced transcript. The nef gene of HIV-1
extends from the 3' end of env into the U3 domain of the 3' LTR. Initial studies
characterised Nef as a downregulator of viral gene expression but more recently Nef
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has been shown to down-modulate CD4 (Garcia et al1991). Expression of Nef in a
T-cell line appears to induce cell surface CD4 endocytosis which is dependent upon a
dileucine motif in the cytoplasmic tail of CD4 (Aiken et al., 1994). A second function
of Nef is to increase viral replication rates (Miller et al., 1994; Spina et al., 1994);
however this activity and its ability to down-modulate CD4 can be separated by
specific point mutations in Nef (Saksela et al., 1995). The mechanisms by which Nef
affects cell surface CD4 levels and viral replication rates remain unclear.
1.3.4 Accessory genes of HIV-1
Viral protein U (Vpu) is translated from a singly-spliced mRNA, is dependent
on rev function and is also produced late in infection. The vpu gene is located at the 5'
end of the env gene and is a viral integral membrane phosphoprotein that was
originally characterised as a 16kDa protein which increases viral particle release from
infected cells (Strebel et al., 1989). Subsequent studies demonstrated that expression
of vpu could decrease the half-life of CD4 in experiments on transfected HeLa
epithelial carcinoma cells (Willey et al., 1992). In this system, the effect of Vpu on the
stability of CD4 was dependent upon the presence of co-expressed gpl60 capable of
interaction with CD4. Although the mechanism of the effect of Vpu on CD4 is still
unclear, recent studies have demonstrated direct in vitro binding of Vpu to the
cytoplasmic tail of CD4 (Bour et al., 1995).
The viral infectivity factor (Vif) is located immediately downstream of the pol
gene. The vif gene is synthesised from an ORE encoding 193 aminso acids, has a
molecular weight of 23 to 27kDa and accumulates in the cytosol and cytoplasmic
membrane fractions of infected cells. The exact function of Vif is unclear but it has
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been shown to promote infectivity of cell-free virus since Vif-negative mutants were
shown to be 1000 times less infectious than virions with Vif. It has been suggested
that Vifplays an important role at the end-stage ofvirus replication although the exact
mechanism by which Vif affects viral infectivity is still unclear. The exact functional
domain of Vif has yet to be defined and additional studies are required to determinse
the early step of viral replication controlled by Vif and also whether Vif can modify
virion proteins and/or virion structure.
Vpr is a 15kDa virion-associated protein translated from a singly-spliced
mRNA, which is dependent on Rev function and thus accumulates late in infection. It
is encoded by a single exon and overlaps with the vif gene. Vpr is assembled into
virions and may play an important role in the early steps of the life cycle such as
nuclear localisation of the viral pre-integration complex. In mature virions, Vpr is
associated with the nucleocapsid and is as abundant as Gag-related proteins. Vpr may
also influence viral gene expression by altering the host T-cell regulatory mechanism,
which enhances viral replication. Vpr was also recently found to induce apoptosis. In
addition, it can induce arrest of cells in the G2 phase of the cell cycle causing
apoptosis in PBMCs, and fibroblasts (Bartz et al., 1996).
Vpx is 14 to 16kDa protein, translated from a singly spliced, Rev-dependent
transcript produced late in infection. Vpx has only been found in HIV-2 and SIV
isolates but not in HIV-1. In mature virions there are the same number of Vpx
molecules as there are molecules of the major Gag capsid protein. Mutagenesis
studies have not identified a clear phenotype for this gene. A strong sequence
homology exists between the viral protein Vpx of H3V-2 and Vpr of HIV-1 (Wu et
al., 1996). Vpx-negative isolates have been shown to infect primary lymphocytes with
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reduced efficiency. Other studies have also revealed that Vpx is needed for efficient
viral replication in PBMCs (Selig et al., 1999).
1.4 LIFE CYCLE OF HIV-1
The life cycle of HIV-1 infection requires infection of a human cell. Studies in
electron microscopy and X-ray crystallography reveal that direct fusion of the viral
and cell plasma membranes should be the principal pathway for virion entry which is
initiated by virion attachment (Ryu et al., 1990; Wang et al., 1990). A more complex
picture of retroviral interference has emerged from work on HIV-1 infection of CD4+
T-cells and monocytes/macrophages, for which infection is mediated by high-affinity
binding between viral gpl20 and cell surface CD4 (McDougal et al., 1986).
Establishment of productive infection is generally accompanied by the disappearance
of CD4 from the cell surface (Dalgliesh et al., 1984; Maddon et al., 1986; Stevenson
et al., 1988). Formation of complexes between CD4 and HIV env proteins occurs
intracellularly (Hoxie et al., 1986) and impairs CD4 maturation and transport to the
cell surface (Kawamura et al., 1989; Crise et al., 1990; Jabbar & Nayak 1990; Bour et
al., 1991; Butera et al., 1991). Other mechanisms of cell surface CD4
downmodulation involve non-env viral proteins that act at each of transcriptional,
translational and post-translational levels (Hoxie et al., 1986; Salmon et al., 1988;
Yuille et al., 1988; Garcia & Miller 1991; Willey et al., 1992,).
The life cycle can be summarised as follows: (1) HIV-1 attachment requires
binding of the virus to the surface of cells expressing a cellular receptor for HIV-1
















































Figure 1.3 Life Cycle ofHIV-1 (Modified from Stine, 2000).
Vims attachment involves the interaction of the gpl20 envelope glycoprotiens with
specific receptors - the CD4 glycoprotein and members of the chemokine receptor
family (Sattentau et al., 1991; Deng et al, 1996). (2) After attachment to the cell
surface, the vims is internalised and uncoated (Farnet & Haseltine et al, 1991). (3)
Following entry into the target cell, a double-stranded DNA copy of the F1IV RNA
genome is synthesised by the viral enzyme, reverse transcriptase (RT). (4) The newly
synthesised complementary viral DNA is incorporated into the nucleus while still
associated with viral Gag proteins and the viral integrase. (5) Integrase catalyses a
concerted cleavage and ligation reaction in which the viral DNA genome becomes
integrated into the host DNA (provirus). (5) A latent phase may follow viral
integration restricting the life cycle until the infected cell is activated allowing the
transcription of viral genomic RNA and mRNA. (6) Synthesis of virion proteins. The
virally encoded Rev protein plays an important role in determinsing the relative
amounts of spliced and unspliced HIV RNAs transported to the cytoplasm, for
translation or packaging into the nascent HIV particles. The actions of the various
regulatory factors determinse both the levels of HIV RNA synthesised and the
qualitative nature of those RNAs (7) Assembly and budding of virions (8) Processing
of capsid proteins (reviewed in Coffin, 1996, and Luciw, 1996).
1.4.1 Attachment
Like all vimses, retroviruses have a specific requirement for interaction with a
cell-surface receptor molecule for infection. The HIV-1 receptor complex essential for
vims entry consists of the CD4 molecule expressed on T-cells, macrophages, dendritic
cells and microglia, and a member of the seven-transmembrane chemokine receptor
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family, termed a co-receptor in the context of HIV and SIV infection. Early studies,
however, still hold true today: that HIV-1 attachment to T-cells correlates with CD4
expression (McDougal et al., 1986a; McDougal et al., 1986b), is gpl20-dependent
(Bahraoui et al., 1989; McDougal el al., 1986b) and might be the rate-limiting step in
viral entry into T-cells (Orloff GM et al., 1991). Due to difficulties involving assaying
virus-cell binding, HIV-1 attachment is still poorly understood. Virus binding has been
shown to be rapid, saturable and temperature-dependent in murine retroviruses. It was
also found to correlate qualitatively with infectivity, implying that specific receptor
usage is manifest at the attachment level. An indirect analysis of ectotropic murine
retrovirus attachment, in which virus infectivity was related to receptor expression,
showed that viral attachment is limited, in a cell type-specific manner, by factors other
than specific receptor expression level (Wang H et al., 1991). Similar restrictions may
apply to HIV-1 and related viruses. Thus, attachment specificity might determinse the
tropism of these viruses.
1.4.2 The CD4 receptor
One of the first discoveries in HIV research studies was that the first major
cellular receptor involved in virus-cell interactions was the CD4 molecule (Dalgleish
et al., 1984; Klazmann et al., 1984; Maddon et al., 1986). CD4 is a member of the
immunoglobulin superfamily and functions as a T-cell co-receptor that increases the
affinity of a helper T-cell for an antigen-presenting cell through its interactions with
major histocompatibility (MHC) class II molecules. It is present on most T-helper
cells, monocyte/macrophages, B cells, and specialised cells of the central nervous
system. Early experiments found that insertion of the CD4 gene into Hela cells made
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them permissive to productive infection and it was also shown that CD4 receptors
could be blocked by specific monoclonal antibodies, thereby preventing infection of
most T-cell types. The CD4 molecule has been implicated in signal transduction
pathways involved in T-cell activation (Barre-Sinoussi et al., 1883; Margolick et al.,
1987). CD4 is also crucial in the generation of many immunologic functions, such as
the activation of macrophages, induction of cytotoxic or suppressor T-cell functions,
secretion of growth or differentiation factors for lymphoid and hematopoietic cells
and induction of B-cell function. The CD4 molecule is a transmembrane glycoprotein
of 58kD and consists of an extracellular region of 370 aminso acids, a transmembrane
region of 25 aminso acids, and a cytoplasmic tail of 38 aminso acids at the C-terminsal
end (Janeway & Travers, 1996). The extracellular portion of CD4 is folded into four
distinct domains designated D1-D4. The N-terminsal D1 domain shares extensive
structural and sequence homology with the variable region of Ig light chains (Sullivan
et al., 1996). The other three domains are less closely related to Ig molecules at the
level of primary structure but fold similarly to Ig family domains, confirminsg that
CD4 is a member of the Ig-like superfamily (Moore & Ho et al., 1993).
1.4.3 HTV tropism and CD4+ cells.
Early reports that HtV-1 infection in vivo was restricted to the CD4+ subset
of T lymphocytes (Klatzmann et al., 1984a) were followed by studies which showed
that anti-CD4 mAb could block both infection of CD4+ target T-cells and subsequent
formation of syncytia (Klatzmann et al., 1984b; Dalgleish et al., 1984).
Immunoprecipitation with anti-gpl20 antibodies revealed complexes at the cell
surface between the HIV-1 envelope glyocprotein and a 58-kDA molecule identified
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as CD4 (McDougal et al., 1986). It was subsequently demonstrated that transfection
of CD4 cDNA into human cells led to expression of CD4 at the cell surface and
conferred susceptibility to HIV-1 (Maddon et al., 1986). Mouse cells which expressed
human CD4 could bring up gpl20 but were not infectable by HIV-1 (Maddon et al.,
1986), indicating that additional unidentified cellular factors, absent in cells of mouse
origin, are required for this process.
1.4.4 The envelope glycoprotein
The envelope glycoprotein regions on the surface of HIV particles bind to
CD4 receptors, located on the plasma membrane of CD4+ T lymphocytes,
monocytes, macrophages, and dendritic cells and thereby attach virions to cells. This
viral glycoprotein is responsible for the induction of syncytia in tissue culture cells and
is a major target for antiviral immune responses in the infected host. The env region of
HIV encodes 850-880 aminso acids; extensive glycosylation of the env precursor
polyprotein during synthesis produces gpl60 which is the major form of the env gene
product detected in infected cells (Moore & Ho. 1993; Levy. 1998). Intracelluar
cleavage of gpl60 yields the N-terminsal subunit (gpl20), which is about 550 aminso
acids long, and the C-terminsal subunit (gp41) which is about 350 aminso acids long
(Capon et al., 1991). Gpl20 is a highly glycosylated, hydrophilic protein positioned
on the external surface of virion membranes as well as plasma membranes of infected
cells (Schneider et al., 1986).
21
1.4.5 Binding site for gpl20 on CD4
Through extensive mutagenesis studies, the HIV-binding site has been mapped
to CD4 domain D1 (Ryu et al., 1990; Wang et al., 1990). Epitope mapping of CD4
substitution mutants with MAbs showed that a small region, containing aminso acids
41 to 52, was involved in gpl20 binding. Four charged residues (Lys-29, Lys-35, Lys-
46 and Arg-59) and one hydrophobic phenylalanine at position 43 were also essential
for gpl20 binding (Ashkenazi et al., 1990; Moebius et al., 1992). These five aminso
acids are predicted to form a hydrophobic pocket by folding phenylalanine residue, a
structure that may be involved in direct contact with gpl20 (Moebius et al, 1992).
1.4.6 Binding site for CD4 on gpl20
The HIV-1 gpl20 envelope protein has a complex secondary structure
stabilized by disulfide bonds between conserved cysteine residues. Extensive
variability is apparent in five discrete gpl20 domains termed V1-V5, as shown by
sequence comparison among various HIV-1 isolates (Shioda et al., 1991; Groenink et
al., 1992; Donaldson et al., 1994; Broder & Collman, 1997). Conserved aminso acid
sequences, termed C1-C5, separate these hypervariable regions (Willey et al., 1986;
Modrow et al., 1987; Myers et al., 1993). Several of these domains interact with
each other to form the complex secondary structure of gpl20. Consequently, probing
the CD4-binding site by aminso acid deletions and substitutions in gpl20 is often
impeded by the extensive structural changes caused by the mutations. Although the
N-terminsal part of gpl20 was originally thought to be involved in CD4 binding, it is
now accepted that the vast majority of residues important for CD4 binding are located
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in the C-terminsal half of gpl20, from the C2 to the C4 domains. They consist of
residues 256-299 in the C2 domain, residues 368 to 389 in the C3 domain and
residues 421 to 457 in the C4 domain. Additional residues in the C5 domain have
been reported to also contribute to the formation or stability of the CD4-binding site.
The C2 and C5 domains of gpl20 are poorly exposed at the surface of the molecule
and while they are important in the structure of the CD4 binding site they are not as
involved in the direct contact of CD4 unlike the C3 and C4 regions which have
proved to be of particular importance for interactions with CD4 (Olshevsky et al.,
1990; Pollard et al., 1991).
1.4.7 Post-binding events following CD4 and viral envelope glycoproteins
Following binding to CD4, HIV-1 enters the cell by a pH-independent
mechanism involving direct membrane fusion (Stein et al., 1987; McClure et al.,
1988). The fusogenic capacity of HIV-1 is located in the extracellular N-terminsal
sequences of gp41 proximal to the membrane-spanning region (Kowalski et al., 1987;
Freed et al., 1990). Association of gpl20 and gp41 appears to restrict the fusion
activity of gp41 by masking the amphipathic regions of the transmembrane
glycoprotein until the virus and cell membrane are in close apposition (Perez et al.,
1992). Both the C- and N-terminsal 30 residues of gpl20, located in the C1-C5
domains, are involved in these gp41 associations. These regions form a molecular
pocket that provides an anchor site for the cysteine loop present in the extracellular
part of gp41. The fusogenic domain of gp41 may be exposed once gpl20 associates
with CD4 to trigger a conformational change resulting in its dissociation from gp41.
In addition to the fusion activity provided by gp41, the V3 domain of gpl20 may be
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essential for the virus to come into close contact with the cell surface and for virus-
cell membrane fusion to occur (Hart et al., 1991; Sattentau et al., 1991). The role of
this envelope domain in viral infection is further supported by the highly neutralizing
activity of antibodies against the V3 loop (La Rosa et al., 1990; Robert-Guroff et al.,
1994).
1.4.8 Other receptors
The entry of HIV-1 into a cell is a multistep process. Env mediates binding of
virus to the cell surface through a high affinity interaction with CD4, the primary virus
receptor (Dalgleish et al., 1984; McDougal et al., 1986). However, it is the
subsequent interaction with the appropriate chemokine receptor that is thought to
trigger the final conformational changes in env, leading to fusion between the viral and
cellular membranes, allowing infection to proceed. HIV-1 variants can differ in their
cellular tropism (DeJong et al., 1992; Hwang et al., 1992): all variants are capable of
replicating in primary T-cells (Tersmette et al., 1988; Connor et al., 1994) but only
some can replicate in primary macrophages (Zhu et al., 1993; Van't Wout et al.,
1994) or in permanent T-cell lines (Schuitemaker et al., 1992). With the identification
of the HIV-1 co-receptors (Alkhatib et al., 1996; Bleul et al., 1996; Choe et al.,
1996; Deng el al., 1996; Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996;
Oberlin et al., 1996; Samson et al., 1996a), the basis for the observed variation in
HIV-1 cytotropism has been revealed. In addition to CD4, T-cell line adapted HIV-1
variants use the chemokine receptor CXC chemokine receptor CXCR4 as their co-
receptor, macrophage tropic HIV-1 variants use the CC chemokine receptors CCR5,
and primary SI HIV variants can use both (discussed in detail below).
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Chemokines are described as a large family of cytokines that have chemo-
attractant properties. They are small polypeptides that recruit leukocytes from the
circulation to sites of infection. Chemokines are secreted by many cell types. The
family can be divided into two major classes, a (also called CC) and P (also called
CXC), based on minsor differences in structure and function. Chemokines activate
cells by binding to specific cell-surface receptors that belong to a superfamily of
serpentine G-protein coupled receptors (Horuk et al., 1994; Powers and Wells,
1996). To date, eight CC and five CXC chemokine receptors have been identified,
(Table 1.2). Structural distinctions of the different branches of the superfamily have
been shown to parallel general distinctions in the biological activities of chemokines.
For example, most CXC chemokines are chemoattractants for neutrophils but not
monocytes, whereas CC chemokines generally attract monocytes and lymphocytes,
but not neutrophils Basophils and eosinophils are also affected predominsantly by CC
chemokines. The C chemokine appears thus far to be lymphocyte specific (Baggiolini
et al., 1994; Schall & Bacon, et al., 1994).
1.4.9 CCR5
HIV-1 uses two chemokine receptors as its principal co-receptors: CCR5 is
the chemokine used primarily during transmission and the asymptomatic phase of
infection (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al.,
1996; Dragic et al., 1996), whereas CXCR4 is generally used at later stages in the
infection (Berson et al., 1996; Feng et al., 1996). The CCR5 receptor is the major co-
receptor for macrophage-tropic non-synctium-inducing (NSI) isolates ofHIV-1 . Rare
strains are also able to use CCCR2b and CCR3 as co-receptors (Deng et al., 1996;
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Frade, 1997). Macrophage tropic NSI viruses are generally found within the first few
months of infection and persist throughout the course of infection (Asjo et al., 1986;
Groenink et al., 1991; Kuiken et al., 1992; McNearney et al., 1992; Roos et al.,
1992; Schuitemaker et al., 1991). CCR5 is a seven transmembrane-domain protein
containing four extracellular domains: an aminso-terminsal domain and three
extracellular loops. The replication of primary, NSI HIV-1 isolates in CD4+ T
lymphocytes is inhibited by p-chemokines, macrophage inflammatory protein la
(MlP-la), MIP-lp and regulated upon activation normal T-cell expressed and
secreted (RANTES), the natural ligands for CCR5. While RANTES, MlP-la and
MIP-ip block infection of lymphocytes, they fail to block infection of macrophages
or dendritic cells. It is not known how chemokines achieve their HIV suppressive
effects at the molecular level. Chemokine binding could simply antagonize the gpl20-
chemokine receptor interaction, preventing the fusion reaction (Deng et al., 1996).
Env-CCR5 interactions are conformationally complex, involving all four extracellular
domains of CCR5. There are two functionally redundant sites on CCR5: the N-
terminsal end and one of the extracellular loops. Viruses particularly well adapted for
CCR5 can often tolerate significant alterations in one of these sites. Interestingly,
dual-tropic viruses that also use CXCR4 are much less tolerant of changes in CCR5
(Doranz et al., 1996). Whether M- and dual-tropic viruses really use CCR5 in two
somewhat different ways will require the analysis of a larger number of viral strains.
Subsequent to the discovery of CCR5 as the co-receptor, Samson et al and
Liu et al described a polymorphism; a homozygous 32bp deletion in the CCR5 gene.
This mutant allele CCR5 was demonstrated to play a critical role in the establishment
of HIV-1 infection, because homozygosity for an allele encoding a fusion-defective
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CCR5, was present in ~1% of the Caucasian population, and was strongly associated
with resistance to HIV-1 infection (Dean et ah, 1996; Liu et ah, 1996; Samson et al.,
1996b). Although CCR5 A32 homozygotes have been found to be highly resistant to
HIV-1 infection, some individuals homozygous for the defective CCR5 gene do get
infected (Biti et al., 1997). Because of the rapid course of the disease in these patients
and the presence of SI variants at the earliest time that can be tested, it is most likely
that infection is established using CXCR4 as co-receptor.
1.4.10 CXCR4
As well as influencing HIV-1 tropism, chemokine receptors also appear to
determinse species specificity. Indeed, mouse cells expressing human CD4 cannot be
infected with HIV-1, whereas co-transfection with human CXCR4 renders these cells
susceptible (Berson et al., 1996; Feng et al., 1996). CXCR4 (previously known as
LESTR/Iusin) has been shown to mediate entry of the T-cell line-tropic (T-tropic)
form of HIV-1 but not macrophage tropic isolates. CXCR4 is a receptor for the CXC
chemokine stromal cell-derived factor 1 (SDF-1), which can inhibit CXCR4-
dependant HIV-1 infection and halt the formation of syncytia by blocking the co-
receptor. By contrast to CCR5, the N-terminsal domain of CXCR4 is considerably
less important for co-receptor function. Rather the first and second extracellular loops
of CXCR4, especially the second extracellular loop, are crucial determinsants for all
viral strains studied to date. Both the T and dual-tropic viruses appear to interact with
CXCR4 in a similar fashion.
The phenotypic switch from CCR5 use (R5 virus) to CCR5/CXCR4 (R5X4)
or CXCR4 use (X4) predicts the progression to AIDS, but the dynamics of this
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switch are not understood. Monomeric R5 gpl20 binds CCR5 poorly in the absence
of CD4, but competes well with macrophage inflammatory protein 1(3 ( MIP-1J3; a
natural chemokine ligand for CCR5) for CCR5 binding as a gpl20-soluble CD4
complex. Monomeric X4 gpl20 binds CXCR4 on certain cell types with detectable
affinity in the absence of CD4, suggesting that the CXCR4-binding surface on gpl20
is constitutively partially accessible.
Primary SI variants, which have the intrinsic capacity to replicate in permanent
T-cell lines, are able to use both CCR5 and CXCR4 as co-receptor (Simmons et al.,
1996). Both CCR5 and CCR3 can serve as co-receptors for HIV-1 on microglial cells
(He et al., 1997). The lack of T-cell line tropism of NSI variants is probably due to
the lack of CCR5 expression on these cells. The lack of macrophage tropism by SI
variants cannot be attributed to restriction by co-receptor availability as both CCR5
and CXCR4 are expressed on macrophages. Kozak and colleagues showed that the
limiting factor in macrophage infection by SI variants is not co-receptor expression
but CD4 expression. SI variants have a lower affinity for CD4 compared with NSI
variants, and these variants may require much higher levels of CD4 expression to
enter cells (Kozak et al., 1997).
The HIV-1 co-receptors CCR5 and CXCR4 on CD4+ T-cells are differentially
expressed on the surface of memory and naive cells. Specifically, CCR5, the co-
receptor for macrophage tropic viruses is largely restricted to memory cells while
CXCR4, the dominsant co-receptor for T-cell line tropic viruses is expressed on both
memory and naive cells, although more so on naive cells (Bleul et al., 1997; Spina et
al., 1997). It is unknown how this differential expression of the major HIV-1 co-
receptors correlates with the susceptibility of these subsets of cells to viruses of
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various phenotypes (CCR5-using versus CXCR4-using) in vivo (Ostrowski MA,
1999).
The isolation of X4 strains of HIV-1 is correlated with a decline in peripheral
CD4+ T-cell levels and the onset of clinical symptoms, and therefore X4 strains have
been considered more pathogenic than R5 strains. This difference in pathogenicity
may be due to differences in chemokine receptor usage and hence, target pool size in
vivo. The pattern of expression of chemokine receptors on T-cell subsets and their
regulation has important implications for AIDS pathogenesis.
CCR5 is expressed on 5 to 25% of peripheral cells, mostly CD4-CD45RA-
memory/effector cells, primary T-cells and granulocyte precursors (Alkhatib et al.,
1996; Deng et al., 1996) while CXCR4 is expressed on nearly all peripheral T-cells.
CXCR4 is thought to be widely distributed in human cells and tissues (Feng et al.,
1996) and has been detected in a number of CD4+ T-cell lines (Loetscher et al.,
1994). Monocytes, the other peripheral blood cell types infected by HIV-1, express
CXCR4 but do not appear to be infectable by X4 strains of HIV-1, perhaps due to a
post-entry block. Monocyte differentiation to macrophages in vitro results in CXCR4
down-regulation and CCR5 up-regulation allowing entry of R5 strains of HIV-1. Wu
et al also observed CCR5 on macrophage-like cells in sections of human lymph nodes
(Wu et al., 1996).
Individual isolates of HIV-1 display markedly distinct tropisms for infection of
primary macrophages as compared with CD4+ T-cell lines. The viral determinsants
for this cyto-tropism reside in the envelope glycoprotein, particularly in the gpl20
subunit containing the third hypervariable loop (V3) (Cheng Mayer et al., 1991;
Shioda et al., 1991; Westervelt et al., 1991; Chesebro et al., 1992). Exchange studies
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of genomic fragments from different isolates showed that the Env region was indeed
predominsantly responsible for differences in host range. For example, a 157bp
fragment including the V3 and V4 domains but not the CD4 binding site was
associated with the capacity to infect primary macrophages (Shioda et al., 1991).
Exchange of a 283bp domain, also including the V3 loop and only 2 of 11 aminso
acids in the CD4-binding domain, conferred macrophage tropism from the
macrophage-tropic variant ADA to the T-cell line adapted NL4-3 isolate (Westervelt
et al., 1991). The same genomic Env fragment was also identified as important for
synctium induction (Groenink et al., 1993). Exchange of part of the VI domain
together with the V2 and V3 domains conferred SI capacity to an NSI variant.
In addition to being more pathogenic in the periphery, X4 strains may be more
effective than R5 strains in decreasing the output of new T-cells by the thymus. The
predominsant population of CD4+CD8+ thymocytes expresses both CCR5 and
CXCR4 and likely serve as the main target of each strain. However, CXCR4 but not
CCR5 is expressed at high levels on immature CD4+CD8"CD3" intrathymic T-cell
progenitors (ITTPs). Proliferation and maturation of X4-virus-infected thymocytes
may contribute to the rapid spread of X4 through the thymus. However, Berkowitz et
al found that R5 strains of HIV-1 can also infect and destroy intrathymic cells. R5
strains initially infect stromal cells including macrophages in the thymic medulla but
after a short time infection spreads slowly throughout the thymocyte populations
(Berkowitz et al., 1998).
At least nine other chemokine receptors, or structurally related molecules,
have b^en described as supporting HIV-1 cwv-mediated membrane fusion or viral
entry in vitro. These include CCR2b, CCR3, CCR8, BOB/GPR15, Bonzo/STRL33,
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GPR1, US28, APJ, V28/CX3CR1 and MDC. The chemokine receptor CCR3 can be
used efficiently by a fraction ofHIV-1 isolates in vitro, provided the expression of this
protein in transfected cells is boosted (Alkhatib el al., 1996; Rucker el al., 1997;
Bazan et al, 1998; Ross et al., 1998). Several studies have compared co-receptor
usage by primary HIV-1 isolates of several genetic subtypes and in general, results
were similar, other than the occasional use of CCR3, the majority of isolates used
CCR5 and CXCR4 (Bjorndal et al., 1997; Connor et al., 1997). Another study looked
at the use of all other receptors and found that most NSI isolates could only use
CCR5. The SI isolates used primarily CXCR4, but some did employ V28, CCR8 and
APJ (Zhang et al., 1998).
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1.4.11 Interactions of chemokine receptors with hypervariable regions.
Cell tropism for HIV-1 is thought to be determinsed at the level of viral entry
by the interaction of the viral envelope proteins with certain types of co-receptors that
support either T-tropic and M-tropic HIV-1 infection. Generally, acquistion of basic
charges in the V3 loop correlates with CXCR4 use (Fouchier et al., 1992; Shioda et
al., 1992), perhaps because the regions of CXCR4 most important for co-receptor
function are far more acidic than the corresponding regions of CCR5 (Brelot et al.,
1997; Lu et al., 1997).
Studies of chimeric envelope glycoproteins demonstrated that the third
variable (V3) loop of gpl20 is a major determinsant of which chemokine receptor is
used (Cocchi et al., 1996; Deng et al., 1996). Speck et al (1997) recently
demonstrated that the specific aminso acids in the V3 loop of the envelope protein
that determinse cellular tropism also regulate chemokine co-receptor preference for
cell entry by the virus. Comparisons of variants with Q or E at position 25 in the V3
loop regulated the ability to use CXCR4 for cell entry. The use of CCR5 was
influenced by mutations at position 30 (Speck et al., 1997). It has been observed that
V3-deleted versions of gpl20 do not bind CCR5, even though CD4 binding occurs at
wild-type levels (Trkola et al., 1996). Anti-V3 neutralising antibodies may also
interfere with gpl20-CCR5 binding (Wu et al., 1996). These recent findings support
an involvement of the V3 loop in chemokine receptor binding. However, the
possibility of the involvement of other domains of gpl20, including the VI/V2
regions, cannot be excluded. Indeed, it has been speculated that subsequent to the
binding of the CD4 molecule, gpl20 changes its conformation and exposes the cryptic
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V3 loop together with the V1/V2 loop embedded in the gpl20 molecule (Sattentau et
al., 1991., Wyatt etal., 1995).
Alterations in VI and V2 sequence can alter viral tropism and co-receptor use
(Boyd etal., 1993; Groenink et al., 1993; Koito etal., 1994; Cho et al., 1998) as can
changes in the V3 loop (Hwang et al., 1991; Shioda et al., 1992; Cocchi et al., 1996;
Speck et al., 1997). Antigenic sites on gpl20 of HIV-1 that elicit strain-specific
neutralising antibodies include the V1/V2 loop as well as the V3 loop. (Goudsmit et
al., 1988; Matsushita et al., 1988; Palker et al., 1988; Fung etal., 1992; Davis et al.,
1993; McKeating et al., 1993;). Construction of chimeric proviruses from SI and NSI
molecular clones ofHIV-1 has demonstrated that the V1/V2 and V4 regions may also
be involved in SI capacity (Groenink et al., 1993; Fouchier et al., 1995). During the
transition from NSI to SI phenotype, the hypervariable V2 region is thought to
undergo increases both in length, mainly through insertion of potential N-linked
glycosylation sites, and charge (Groenink et al., 1993; Fouchier et al., 1995).
Also complex structural interactions between VI, V2 and V3 loops and
elements of CD4-binding site of gpl20 control entry of the virus into cells.
Stamatatos et al (1998) generated two mutant envelope proteins by making deletions
in the VI and V2 loops of a macrophage-tropic primary HIV-1 isolate SF162.
Comparison of the immunochemical structure of the wild-type and mutant monomeric
and virion associated gpl20 molecules revealed that the VI and V2 loop deletions
differentially altered the structure of the V3 loop, the CD4-binding site, and epitopes
within conserved regions of gpl20. Regardless of structural differences, both
mutated envelope proteins supported viral replication into peripheral blood
mononuclear cells to levels comparable to those of the wild-type virus but had no
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effect on co-receptor usage. It is likely that the structural changes resulting from the
introduced deletions in the VI and V2 loops affected the kinetics of the CD4-induced
gpl20 conformational changes that influenced the extent of gpl20-corecptor
interaction (Stamatatos etal., 1998).
1.4.12 CD4-lndependent Infection
Both HIV-1 and HIV-2 are capable of infecting CD4-negative cell lines. For
HIV-1 this has been demonstrated in vitro for cell lines of nervous system, fibroblast,
and liver origin (Chiodi et al., 1987; Dewhurst et al., 1987; Harouse el al., 1989;
Tatento et al., 1989; Choe et al., 1995). HIV infection of CD4-negative cell cultures
in vitro has been extensively reported, including CD4-negative glioma cell lines which
have been shown to be infectable (Cheng-Mayer et al., 1987). Infection of some
neuronal cell lines may have been mediated via a glycolipid, galactosyl ceramide
(Horouse et al., 1991), and sequences in either V3 or V4/V5 determinse this tropism
(Horouse et al., 1995). The relevance of CD4-independent entry in vivo and its
influence on pathogenesis are not yet clear. However there is evidence that CD4-
independent brain astrocytes in pediatric AIDS patients become infected by HIV-1 in
vivo (Saito et al., 1994). Infection of these astrocytes may occur through a CCR.5-
dependent mechanism (Berger et al., 1997; Berger et al., 1999), or through an
efficient gpl20/gp41 -independent route, such as phagocytosis of other infected cells
or by Fc receptor-mediated endocytosis of antibody-coated HIV virions as the HIV
virion has been found sequestered in intracellular vacuoles (Gendelman et al., 1989;
Abbas et al., 1999).
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It has been shown that efficient CD4-independent infection has occurred for
several HIV-2 isolates (Clapham et ah, 1992). The highly cytopathic nature of this
infection indicates that HIV-2 can utilise one or more alternative receptors
independently of CD4. The selection of the HIV-2 strain ROD/B (derived from the
prototype HIV-2 strain ROD/A) was shown to utilise the CXCR4 receptor to
efficiently enter CD4-negative target T-cells (Endres et al., 1996; Reeves et ah,
1997). A number of other HIV-2 strains, including some primary isolates, are also
able to infect T-cells which express CXCR4 or CCR5 but lack CD4. FIV infection of
CD4-negative cell cultures in vitro has been reported to occur via the CXCR4
receptor (Willet et ah, 1997; Poeschla et ah, 1998). In contrast, a significant number
of SIV isolates can use CCR5 as a primary receptor and can infect CCR5-positive,
CD4-negative primary cells such as rhesus brain capillary endothelial cells whereas
only low-level CD4-independent infection has been reported for a single R5 HIV-2
isolate (Chen et ah, 1998). The addition of CD4 in soluble or membrane-bound form
can enhance infection for most CD4-independent viruses, suggesting that CD4 is
required for optimal entry efficiency (Edinger et ah, 1999). Mutations located
immediately upstream of a proposed coiled coil domain in the transmembrane protein
and flanking the base of the V4 loop are crucial for the CD4-independent phenotype
of HIV-2. These mutations can reduce the amount of sCD4 required to trigger CD4-
independent T-cell-cell fusion, suggesting they lower the activation threshold for the
fusion process. A lower activation threshold of CD4-independent envelope proteins
may enable them to utilise other membrane molecules for entry which are not as
efficient as CD4 in triggering the conformational changes required for the membrane
fusion process (Reeves et ah, 1997).
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1.5 STEPS IN VIRAL REPLICATION
1.5.1 Fusion and entry
The mechanisms by which retroviruses enter cells is one of the most poorly
understood aspects of the virus life cycle. Enveloped viruses enter by either a pH-
dependent or pH-independent process (Stein et ah, 1987; McClure et ah, 1988). The
site of this fusion whether it is directly at the cell surface (pH-independent) or via
endocytosis (pH-dependent) varies among retroviruses. Some retroviruses do not
cause cell fusion, and infection by these is sensitive to high pH. Like many enveloped
viruses, these seem to be internalised via receptor-mediated endocytosis (RME) into
acidic endosomes, most likely provoked by the lower pH typical of endosomal
contents. Enveloped animal viruses such as HIV-1 penetrate cells in a pH independent
process (Stein et ah, 1987; McClure et ah, 1988), following direct fusion of the viral
envelope with the plasma membrane of the cell and not through the relatively acidic
conditions that are present following endocytosis.
It seems likely that the fusion process is mediated by a region of hydrophobic
aminso acids at the aminso terminsus of the smaller transmembrane TM (gp41) region
(Freed et ah, 1990; and can be modulated by the cytoplasmic domain (Ritter et ah,
1993; Owens et ah, 1994) and gpl20 (Bergeron et ah, 1992; Chen et ah, 1993).
Upon binding of HIV-1 to its receptor (the CD4 molecule), fusion of the viral and
cellular plasma membrane takes place. The interaction of the chemokine receptors
with gpl20-CD4 complex can promote changes in the envelope glycoprotein
complex. It has also been speculated that upon binding to sCD4 to gpl20,
conformational changes (important for fusion) occur by exposure of the cryptic V3
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loop together with V1/V2 loop embedded in the gpl20 molecule (Sattentau et al.,
1991; Wyatt et al., 1995; Stamatatos et al., 1998). Sakaida and colleagues also
showed that T-tropic HIV-1 derived V3 loop peptides bind to CXCR4 and inhibit T-
tropic HIV-1 infection (Sakaida et al., 1998). By analogy with the influenza
hemaglutinin, it has been suggested that the HIV gp41 ectodomian undergoes major
conformational changes during virus entry (Carr et al., 1997). The proposed result of
these changes is the insertion of the hydrophobic gp41 NH2-terminsus (the "fusion
peptide") into the membrane of the target T-cells. Mutagenic analysis (Freed et al.,
1996) and the recently determinsed crystal structures of HIV-1 gp41 ectodomain
fragments (Chan et al., 1997) are in accordance with this proposed model. The gp41
ectodomain structures reveal an extended, trimeric coiled coil that could potentially
bridge the viral and target T-cell membranes (Chan et al., 1997). Interactions of other
gp41 helical segments near the membrane-spanning region with the interhelical
grooves of the internal coiled coil are important for fusion-related conformational
changes in gp41.
Recent studies have shown that the V3 region ofgpl20 is involved in the early
step of virion-cell interaction indicating that the cell tropism is thought to be
determinsed at the level of viral entry by the interaction ofviral envelope proteins with
certain types of co-receptors that support T-tropic or M-tropic HIV-1 infection.
Binding experiments using mutant gpl20 molecules with a deletion at the V3 region
or anti-V3 loop neutralising antibody have strongly suggested that the V3 region is
crucial for interaction with CCR5 (Wu et al., 1996).
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1.5.2 Viral DNA synthesis by reverse transcription
After entry of the core into the cytoplasm, the process of reverse transcription
of the RNA genome into double-stranded DNA occurs (Figure 1.3). Reverse
transcriptase requires two strand-transfers (or "jumps") to convert the dimeric single
stranded viral RNA into a molecule of double stranded linear DNA. The viral RNA
genome is synthesised using a host DNA-dependent RNA polymerase (DNA-dep
RNA pol) and as a consequence contains cellular post-translational modifications,
namely the 5' end of the genome is capped (Gppp) and the 3' end has a poly A tail.
To enable efficient retroviral replication to occur there are three essential
requirements: (a) two copies of the viral single-stranded RNA genome (template), (b)
the host tRNA primer that is bound near the 5' end of the viral template (i.e. primer
binding site, PBS), and (c) the heterodimeric protein that has both RT and RNase H
activity.
The first step in reverse transcription occurs in the cytoplasm where DNA is
synthesised from the tRNA primer which is bound to the viral RNA template by using
the RNA-dependent DNA polymerase (RNA-dep-DNA-pol) activity of RT. The first
strand synthesis (negative (-) strand) is extended by RT to the 5' end of the viral RNA
genome; this is designated (-) strand strong stop DNA, which is a copy of the short
region consisting of R and U5 lying between the primer-binding site and the 5' end of
the genome. A second component of RT, RNase H degrades RNA in the DNA/RNA
hybrid and thereby exposes newly synthesised strong stop DNA sequences which are
complementary to the short repeat (R) at the 5' end of the viral genome. The newly
synthesised DNA region acts as a second primer binding site to the complementary R
at the 3' end of the genome. Initial strand-transfer, also known as the first "jump"
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takes place. Synthesis of the (-) strand is then continued along the viral RNA template
through U3 and into the viral genome using the RNA-dep-DNA-pol while RNase H
degrades the remainder of the RNA template. Synthesis of (+) strand begins at the
end of the (-) strand and continues through U5 and the tRNA primer. A second jump
occurs, as the tRNA primer is complementary to the 5'PBS, completing the synthesis
of the (+) DNA strand. Synthesis of the (+) strand can occur as an intermolecular or
an intramolecular event.
1.5.3 Integration of viral DNA
Integration of a double-stranded DNA copy of the viral RNA into the host T-
cell genome is a crucial step in a productive retroviral infection. Two regions of the
viral genome are required for integration: the long terminsal repeats (LTR) ends of
the viral DNA and the 3' region of the pol gene, which encoded the integrase protein.
After viral DNA synthesis, the linear DNA, the CA, the integrase enzyme (IN) and the
nucleocapsid (NC) protein enter the nucleus. Translocation of the preintegration
complex into the nucleus is known to be mediated by nuclear localisation signals in
the MA/Vpr proteins. Integrase cleaves the LTRs at conserved CA dinucleotides
within the U3 and U5 (3' processing reaction) and subsequently joins the recessed
viral ends to the 5' phosphates of a staggered double-strand cut in chromosomal
target DNA (strand transfer reaction). The integrase reaction leaves single-stranded
gaps and two mismatched nucleotides at each 5' terminsus. A cellular DNA repair
system fills in the resulting gap in the molecule, displacing the two mismatched bases
at the 5' end and ligating the remaining ends. The integrated HIV DNA genome is
known as the HIV provirus.
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1.5.4 Regulation of viral gene expression
Once the virus is integrated, it is treated as a normal cellular gene and the
polymerase enzymes (cellular polymerase II) that transcribe cellular genes begin to
produce viral RNA transcripts. Alternatively the virus may become transcriptionally
silent and enter a latent stage, but may be reactivated subsequently. Viral RNA
synthesis is complicated and involves several cellular proteins and viral regulators.
Replication is mediated via transcription of the integrated DNA form of the virus
(provirus) which behaves as a cellular gene with a promoter and transcriptional start
site located in the 5' long terminsal repeat (LTR), and a terminsation/polyadenylation
site located in the 3' LTR. The U3 domain of HIV-1 5' LTR contains basal promoter
elements, including a TATAA box for initiation by host T-cell RNA polymerase II,
and sites for binding the cellular transcription factor SP1. Initiation of viral RNA
synthesis occurs at the U3/R border of the 5'LTR. First of all, an initiation complex
for full-length viral RNA transcription is formed through interaction between HIV-1
Tat and nascent TAR RNA. Subsequently, an R-U5 segment is transcripted and
serves as the leader sequences for RNA elongation. The 5' ends of the transcripts are
post-transcriptionally capped with 7-methlyguanosine by cellular enzymes soon after
elongation initiates. HIV-1 RNA is synthesised by cellular RNA polymerase II and the
3' end of the viral transcript is terminsated at the border of R/U5 in the 3' LTR.
Signals in U3 region are recognised by cellular enzymes that add poly -A tails at the
3'-ends of viral transcript (Barre-Sinnoussi el al., 1996; Luciw et al., 1996). After
transport to the cytoplasm, a fraction of these full-length RNA copies is reserved as
the genomic RNA that is eventually assembled into progeny virions. The others serve
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as precursors for alternatively spliced mRNAs that are translated in the cytoplasm to
produce viral proteins (Barre-Sinoussi, 1996). High-level transcription from the
provirus is regulated by the viral protein Tat. As described previously, Tat is typical of
many transcriptional activators and includes an activation domain and a nucleic acid
binding domain. Tat function is dependent on a bulged RNA-stem-loop structure,
TAR (Tat activation region), that is present at the 5'-terminsus of all viral mRNAs.
Although HIV-1 transcription is mediated by cellular RNA polymerase II, Tat acts
mostly at the level of transcriptional elongation rather than at initiation itself, leading
to the synthesis of fully spliced mRNAs. When sufficient mRNAs are produced, rev
allows for the movement of the unspliced and singly spliced mRNA species from the
nucleus to the cytoplasm. These late transcripts encode the structural and enzymatic
proteins needed for virion assembly.
1.5.5 Virion assembly and release
The first event in virion assembly is the formation of the nucleoprotein
complexes composed of p55 Gag as well as the Gag-pol polyprotein (pi60) and
genomic viral RNA. Cleavage of the Gag-containing polyproteins during assembly is
mediated by the protease domain to produce a mature nucleocapsid composed of the
fully processed Gag (MA, CA, NC, p6, pi and p2) and Pol (PR, RT, RNase H, and
IN) as well as two molecules of the viral single-stranded RNA genome. The viral
glycoproteins are synthesised, glycosylated and processed by the endoplasmic
reticulum and Golgi apparatus. The glycoprotein is cleaved into a membrane spanning
and an extracellular region and associates to form dimers or trimers that migrate to
the plasma membrane. These oligomers of the Env glycoprotein are inserted into the
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cell plasma membrane, and the matrix domain of p55 is presumed to interact with the
cytoplasmic tail of Env gp41 during virion assembly (Arroyo et al., 1995). The viral
nucleocapsid complex extrudes or buds through the plasma membrane to produce a
virion with a nucleocapsid surrounded by a lipid bilayer membrane, which contains
oligomers ofEnv gp. Selected host proteins are also incorporated into mature virus
particles. Cell-to-cell spread ofHIV is enhanced by the ability to form multinucleated
giant T-cells, or syncytia. Syncytia are fragile and their formation enhances the
cytolytic activity of the virus (Lifson et al., 1986a; Lifson et al., 1986b; Lifson et al.,
1986c).
1.6 ORIGIN AND EVOLUTION
HIV-1 sequences pre-dating the recognition of AIDS may be crucial in
defining the time of origin and the subsequent evolution of these viruses in humans.
There are three principal groups of HIV-1: the main (M) group is responsible for the
global AIDS epidemic and comprises by far the majority of HIV-1 isolates; an outlier
(O) group is found in Cameroon, Gabon and Equatorial Guinea; and a new group (N)
was recently identified in two people in Cameroon (Simon et al., 1998). Group N is
the least widespread of all HIV-1 lineages.
More extensive sampling of HIV-1 in Africa and elsewhere has revealed much
greater diversity than previously recognised. Phylogenetic analyses of gag and env
gene sequences have revealed up to ten clusters of the main, M, group of HIV-1
(Myers et al., 1991; Louwagie et al., 1993). This has led to the development of a
subtype taxonomy (Louwagie et al., 1993), with designations A to J applied to the
phylogenetically clustered lineages (or clades). The subtypes can have complex
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patterns of subclusters, sometimes associated with the geographic origin of the virus.
The greatest diversity in terms of numbers of subgroups present is found in sub-
Saharan Africa, in particular western Central Africa, including Zaire (Democratic
Republic of Congo), Congo, Gabon, and neighbouring countries (Hu et al., 1996). In
East Africa, the D and A subgroups are most common, while in southern areas the C
group is more predominsant. The major epidemics in other continents are mostly
associated with a subset of these variants (Holmes et al., 1992) with the B subtype
characterising the epidemic in North America, Europe and Australia almost
exclusively. Although the O group of viruses have lower numbers of infections,
sequencing studies have revealed a startling level of diversity. Whereas most
subgroups of the M group represent many thousands or even millions of infected
individuals, most of the individual sequences from the O group are as different from
each other as are the subgroups of group M (Loussertajaka et al., 1995), possibly
signifying an older, or even independent origin for the O group epidemic (Gurtler et
al., 1996).
The natural reservoir for HIV-1 remains unclear, although it is highly likely
that known strains of HIV-1 have arisen in a similar fashion to HIV-2, namely
following cross species transmission. Phylogenetic analysis has shown a close
relationship between HIV-1 and SIV infecting chimpanzees (SIVcpz), which may
indicate the natural reservoir for HIV-1 is in fact the chimpanzee (Peeters et al.,
1992). Recently, Gao and colleagues provided new evidence which suggested that
HIV-1 came to humans from the chimpanzee, Pan troglodytes troglodytes, which
harbours a related simian immunodefiency virus, SIVcpz and lives in the same part of
central Africa where AIDS is thought to have arisen (Gao et al., 1998). There are also
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other chimpanzee subspecies infected with SIVcpz that are able to transmit their
viruses to humans (such inter-species transmissions of infectious disease are known as
zoonoses (Gao et al., 1998).
Four lines of evidence substantiate zoonotic transmission of primate
lentiviruses; (1) similarities in viral genome organisation, (2) phylogenetic relatedness,
(3) prevalence in the natural host and (4) geographic coincidence. Gao and
colleagues' evolutionary analysis of the M, N and O groups in comparison to SIVcp2
isolates indicates that these HIV-1 groups represent separate transfers from
chimpanzees to humans. Chimpanzees are commonly hunted for food, especially in
west equatorial Africa (Teleki et al, 1989), and as a consequence represent a ready
source for zoonotic transmissions. It was previously shown that several strains of
HIV-2 in West Africa were independently derived from SIVsm (sooty mangabey
[Cercocebus atys]) (Chen Z et al., 1997; Gao F et al, 1998). HTLV-1 also originated
from related simian viruses, including STLV-1 of chimpanzees. Other explanantions
for the origin ofHIV-1 groups M, N and O, such as viral diversification within human
populations or acquistion of virus from another primate species, are either inconsistent
with phylogenetics or implausible (Gao et al., 1998).
Since HIV-1 sequences first began to accumulate, researchers have been
interested in estimating the age of the epidemic and the rate of viral evolution (Smith
et al., 1988; Li et al., 1988; Gojobori et al., 1990; Gao et al., 1992; Louwagie et al.,
1993; Myers et al., 1995). Estimates of HIV-1 divergence rates are highly dependent
on the region of the genome under study (Leitner et al., 1996). Divergence rates also
have to allow for limitations such as recombination events and different evolutionary
rates in different lineages. For example, the V3 variable domain of the envelope
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protein is the most heavily sequenced region of the viral genome and an important
functional and immunogenic region. In the D subtype, the V3 loop is mutating
relatively rapidly, in the A and B subtypes it is mutating at a moderate pace, and in the
C subtype it is changing slowly. Early analyses of HIV sequences have suggested
dates for the separation of HIV-1 and HIV-2 from a common ancestor, which varied
from as little as 40 years (Smith et al., 1988) to as much as 1000 years (Gojobori et
al., 1990). The earliest sequence from a confirmed HIV-1 positive human sample was
obtained in west-central Africa in 1959 (Nahmias et al, 1986). Phylogenetic analysis
has placed this sequence close to the root of the major B and D subtypes, suggesting
that these groups diverged only a short time earlier. This suggests that the major
expansion/dispersion of HIV-1 M group occurred not long before 1959, perhaps 10
or 15 years earlier (Zhu et al., 1998). The date of the nonhuman primate lentivirus
precursor of HIV-1 is still unknown but it is an event which could have occurred
hundreds or thousands of years earlier. The dynamics of the epidemic have never been
regular, with the B subtype being the dominsant strain in the USA and Europe even
though it is almost unknown in Africa (Hu et al., 1996).
1.6.1 The natural history of HTV-1 infection
Infection with HIV-1 leads to a progressive impairment of cellular immune
function, characterised by a gradual decline in peripheral blood CD4+ T lymphocyte
levels which results in an increased susceptibility to a wide variety of opportunistic
viral, bacterial, protozoal and fungal infections, and also to certain malignancies. The
natural history of HIV-1 infection can be viewed as a progression of three distinct
clinical stages: an initial stage associated with primary infection (CDC Category A), a
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chronic stage resulting in a period of clinical but not virological latency (CDC
Category B) and finally, a crisis stage representing a period of profound
immunodeficiency manifest by the development of opportunistic infections and
neurological disorders (CDC Category C).
Initial infection with HIV may be followed by an acute disease syndrome
(Cooper et al., 1985), similar, in some respects, to infectious mononucleosis. During
this initial infection plasma HIV-1 titres increase manifested by high levels of viraemia
and high levels of HIV replication; viral p24 antigen can be easily detected (Goudsmit
et al., 1987) and virus can be readily isolated from the blood (Barre-Sinoussi el al.,
1983; Gallo et al., 1984; Coombs et al., 1989; Ho et al., 1989; Daar et al., 1991;
Saag et al., 1991; Rouzioux et al., 1992; Pan et al., 1993). This florid HIV replication
in vivo is likely to be associated with CD4 + T-cell death, although early in disease the
ability to produce new naive CD4+ cells allows for the maintenance of CD4+ cell
levels within the normal range. The memory subset of CD4+ lymphocytes appears to
be both readily infected in vitro, and more highly infected in vivo than naive CD4 cells
(Schnittman et al., 1990). A second consequence of initial viremic infection is an
apparent seeding of the lymph nodes with HIV, providing a continuing site of
persistent viral replication (Pantaleo et al., 1991; Saksela et al., 1993; Embretson et
al., 1993; Pantaleo et al., 1993). This acute stage of clinical infection is associated
with an acute seroconversion illness characterised by fever, malaise, rash and myalgia
(Ho et al, 1985). CD4 counts fall dramatically during this stage of infection, although
it is not clear whether this is a direct result of HIV cytopathicity or redistribution to
extravascular sites (Fahey et al., 1990; Ferbas et al., 1996; Bofill et al, 1996).
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Following the initial infection, HIV-infected individuals enter a stage of
clinical latency, the asymptomatic period, during which the number of CD4+ cells
remains within the normal range or slowly decreases over time (Ho et al., 1985; ).
Studies by Wei et al and Ho et al have showed that although this is a clinically latent
phase of HIV infection, it hides a very high rate of virus production (Ho et al., 1995;
Wei et al., 1995). The increase in viral replication in infected individuals is largely the
result of a dynamic process involving continuous rounds of de novo infection and
replication in host T-cells, with rapid turnover of both free virus and virus producing
cells. Recent evidence also suggests that significant replication persists in lymph node
follicles (Embretson et al., 1993) and other areas of lymphoid tissue (Graziosi et al.,
1993; Pantaleo et al., 1991; Pantaleo et al., 1993). Only low levels of plasma vireamia
(30 TCID 50 per ml) (Ho et al., 1989) is seen within this chronic stage of persistent
infection and few productively infected CD4+ cells are present in the peripheral blood
(1 in 10,000) (Harper et al., 1986).
During the asymptomatic phase of HIV infection, there may be selective
pressures favouring the emergence and persistence of non-syncytium inducing (NSI)
strains (Asjo et al., 1986; Tersmette et al., 1988; Schuitemaker et al., 1991). In the
face of an effective host immune response, a HIV strain that replicates slowly and can
persist in monocytes and macrophages may have a selective advantage over rapidly
replicating strains (Wolfs et al., 1992; Zhu et al., 1993).
The development of symptomatic HIV infection is a continuum of progressive
clinical states (Lane et al., 1983). Initial symptomatic disease may be characterised by
non-specific clinical presentations such as lymphadenopathy, diarrorhea, weight loss
and recurrent candidal infections. Progression to clinically defined AIDS is
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characterised by a dramatic loss of CD4+ lymphocytes and the development of
opportunistic infections, AIDS encephalopathy, or characteristic malignancies. HIV
can be isolated from as many as 1 in 100 peripheral blood mononuclear cells
(PBMCs) (Ho et al., 1989), and HIV DNA can be detected in up to 1% of CD4+ T-
cells in late stages of disease (Schnittman et al, 1990; Schnittman et al., 1989). The
course and pace of clinical progression are variable; epidemiological studies have
suggested that before the advent of effective anti-retroviral therapy 50% of HIV-
infected individuals developed full-blown AIDS by 8-11 years post-seroconversion
(Rutherford et at, 1991, Blattner et al, 1991).
1.6.2 HIV-1 Serological diagnosis
Detection of infection with HIV-1 or HIV-2 can be accomplished by several
techniques including the direct demonstration of virus (electron microscopy), virus
isolation by culture techniques, demonstration of a virus-specific antibody response,
and detection of viral antigen or the presence of the viral genome. Antibody tests
combining a screening assay and a confirmatory test have been the most widely used
techniques for establishing the presence of HIV infection. ELISAs are currently the
preferred initial screening techniques, utilising inactivated virus or synthetic peptides
as antigens. Some assays use recombinant HIV-1 proteins to env and gag products
while the synthesised peptides correspond to conserved regions of env and p24 core
proteins. Currently licensed ELISAs have a sensitivity and specificity of 98% to 99%.
Western blot techniques are the most widely utilised confirmation assays for ELISA-
reactive sera, although other methods such as fixed-cell immunofluorescence or RIPA
have also been used.
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HIV-1 may be isolated from peripheral blood leukocytes or genital secretions
and may occasionally be isolated from plasma or a variety of tissue sites (e.g. brain,
retina, bone marrow and lymph nodes). The virus is rarely isolated from saliva or
urine. Diagnosis of HIV-1 infection is not always possible based on the presence of
antibodies in the serum. For example, antibodies are not present in acute phase of
infection (serological window period) and can be lost in the advanced stages of
disease. Therefore diagnostic tests for either direct detection of the virus or its
components may be important in monitoring the disease when no antibody is present.
A relatively sensitive isolation technique is cocultivation of the test specimen with
uninfected mitogen stimulated peripheral blood mononuclear cells. After incubation
for several days to weeks, supernatant fluids are evaluated for reverse transcriptase
activity or for HIV p24 antigens. Although virus culture can provide conclusive
evidence for HIV-1 diagnosis, it is a costly, time consuminsg and labour intensive
method with the potential for exposure to high concentrations of infectious virus.
Detection of circulating HIV-1 p24 antigens by ELISA appears to be a useful
adjunctive test in certain situations. In the acute phase of infection, HIV p24 antigen is
often present in serum before antibodies are detected. As antibodies appear, p24
antigen becomes undetectable and remains so until the development of AIDS when
virus production increases dramatically. The low detection rate of p24 antigen in
serum from asymptomatic patients may be due to low levels of antigen production or
to the formation of immune complexes. Antigen assays, particularly those including
acid dissociation which disrupt p24 antibody-immune complexes, have been found to
be useful in improving the detection and quantitation of p24 antigen, allowing a more
accurate assessment of in vivo viral replication. They have also proved important in
50
monitoring the progress of individuals receiving antiviral drugs, as demonstrated
during trials of zidovudine and dideoxycytidine.
While HIV diagnosis remains serology-based (virus antibody/antigen),
molecular techniques are gaining in use owing to advances in molecular biology.
Traditional molecular approaches (Southern or dot-blot hybridisation and
autoradiography) have been largely superseded by amplification techniques often
using non-radioactive protocols. Amplification techniques, utilising PCR or other
methodologies are becominsg increasingly utilised for the detection of viral RNA and
cellular proviral DNA.
The branched DNA (bDNA) signal amplification assay (Urdea et al., 1993)
employs multiple DNA probes linked to an enzymatic system for visualisation of
captured target molecules by sequential oligonucleotide hybridisation, and is an
alternative to sequence amplification. The bDNA assay can employ a range of DNA
probes, which recognise a wide spectrum of HIV sequence variants. The enhanced
sensitivity (ES) modification of the prototype assay (Kern et al, 1996) is capable of
detecting as few as 400 copies per millilitre (copies per ml) of HIV-1 RNA in serum
or plasma by using preamplification molecules and a range of target probes. This
assay can suffer from inhibitory substances within the sample.
Detection of HIV proviral sequences in PBMCs by PCR remains the principal
method of diagnosing HIV infection by molecular techniques. This is particularly
relevant to HIV provirus detection where a potentially low peripheral load exists,
consisting of rare sequences in a complex mixture of human genomic sequences,
particularly in asymptomatic infection and neonatal infection where a molecular
diagnosis would be of most use.
In the majority of individuals infected with HIV-1 not receiving antiretroviral
treatment, HIV virion RNA is detectable in the cell-free fraction of peripheral blood
(Piatak et al., 1993; Mellors et al., 1996; Bruisten et at., 1997). The detection of HIV
RNA may also be particularly appropriate during the acute phase of infection, before
any other HIV markers become available. These assays included reverse transcriptase
PCR (RT-PCR), bDNA and nucleic acid-based sequence amplification (NASBA). The
presence of HIV-1 RNA in serum or plasma is readily detectable in these sensitive
assays, (i.e. they measure down to at least 500 copies of HIV RNA) in the majority of
individuals, and provides a clear diagnosis in the majority of cases.
HIV-1 replicates in lymph nodes and microglial cells, and the detection of HIV
provirus in tissues at central sites of the body may further confirm the presence of
HIV (Embretson et al., 1993; Pantaleo et al., 1993). While these are not front-line
diagnostic procedures, the possible clearance of detectable virus from peripheral sites
in HIV-infected individuals receiving potent combination antiretroviral therapy
indicates that it may soon be a requirement to detect virus at central sites of the body.
The application of PCR to diagnose vertical transmission events in the
perinatal and postnatal periods has several advantages over detection of virus-specific
antibodies which may take 18 months to yield an unequivocal result, owing to the
presence of passively acquired maternal antibodies. Transmission of HIV during
pregnancy may be diagnosed by HIV provirus detection in infants as early as 6 weeks.
Recent estimates of vims production are of the order of >109 virions per day,
and complete turnover of CD4+ cells occur in about 2 days (Ho et al., 1995; Wei et
al., 1995). This represents an enormous replicative activity and together with the
error-prone nature of the HIV reverse transcriptase, contributes to the tremendous
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diversity of HIV. This diversity surely leads to competition for survival, the main
driving force of Darwinian selection, and the consequent evolution of viruses that are
best adapted to their changing environment.
1.6.3 Prognosis of HIV-1
Prognostic markers have helped distinguish the progressors from
nonprogressors during the asymptomatic period. Decline of CD4+ T-cell counts is a
universal characteristic of people progressing to AIDS and may be the hallmark of
disease (Phillips et al., 1991). Among the other parameters that are useful in
predicting progression to disease are the high levels of (^-microglobulin, soluble IL-2
or TNF receptors, and soluble CD8 in the blood; high levels of neopterin in the urine;
low antibody titers to the p24 or p 17 Gag proteins in serum; high levels of p24 or
infectious virus in the blood; decreased dehydropiandrosterone levels in serum and the
decreased delayed-type hypersensitivity reaction (Levy, 1993). During the
asymptomatic phase of infection there appears to be an increase in CD8+ T-cells
suggesting that this population may also contribute to the limiting of HIV-1
replication during this phase (Giorgi et al., 1987; Lang et al., 1989).
Although the accelerated viral replication characteristic of HIV infection is
involved in the decline in CD4+ T-cells observed in disease progression (Ho et al.,
1995), factors not directly dependent on viral infection of target T-cells are also
important in this process. Antigen-induced cell death (AICD) in HIV infection is
mediated by at least two different components of the nerve growth factor/tumour
necrosis factor receptor family: TNF-(3 (Clerici et al., 1996) and APO-l/Fas (Kaisikis
et al, 1995). Indeed, lymphocytes of HIV-seropositive individuals express Fas in large
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quantities and are more prone to undergo programmed cell death upon ligation of this
receptor and the magnitude of anti-Fas-induced death is inversely correlated with
absolute CD4 cell counts (Debatin et al., 1994, Kaisikis et al, 1995., McCloskey et al,
1995). Serum concentrations of TNF-P and sAPO-l/Fas are predictors of disease
progression independent ofHIV viral load (Medrano et al., 1998).
Progression to HIV infection is characterised by complex dysregulation of Th
that can involve the T-cells and/or affect antigen presenting cells (APCs) (Lane et al,
1985., Smolen et al, 1985; Giorgi et al., 1987; Miedema et al., 1988; Clerici et al.,
1989). Th defects (analysed as the ability of Th lymphocytes to proliferate and secrete
IL-2) to soluble antigens appear early in disease. Soluble antigens are processed and
presented to CD4+ Th on the surface of autologous APCs in association with class II
molecules (Germain and Margulies, 1993). Thus, an alteration in the ability to
recognise soluble antigens is the most sensitive and accurate index of dysfunction of
CD4+ T lymphocytes. Because immune response to soluble antigens involves the
collaboration between two cell type, APCs and Th (Noelle and Shaw, 1991), the
primary defect could be due to an impaired ability of the APCs to process or present
antigenic peptides or to provide other accessory functions. Phytohemagglutinin
(PHA)-stimulated proliferation and IL-2 production become defective in HIV-
seropositive individuals in whom Th defects to soluble antigens and alloantigens are
already present. Because both CD4 and CD8 T-cells are stimulated by PHA and
because the ability of this T-cell mitogen to stimulate lymphocytes is only marginally
dependent on APCs, the inability to respond to mitogens is an index of a profound
impairment in Th function in HIV-infected patients (reviewed in Clerici et al., 1999).
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The CD4 T-cell count is an important and reliable prognostic factor in disease
progression and it can be used to monitor the effects of antiretroviral treatment. There
are many methods available to assess the CD4+ T-cell count: the absolute CD4+ T-
cell number in the blood, the percentage of CD4+ T-cells and the CD4+CD8+ T-cell
ratio.
If HIV-specific CTLs are important in the control of viral replication, it may
be expected that the presence or absence of such activity would have an influence on
disease progression. Carmichael et al have showed that CTL precursor (CTLp)
frequencies decline in parallel with the observed decline in CD4 counts as disease
progresses (Carmichael et al, 1993). An initial inversion of the CD4:CD8+ T-cell ratio
is another prominsent feature of HIV-1 infection although it is unclear as to whether
this inversion is due to a decrease in the number of CD4+ T-cells or augmentation of
CD8+ T-cells.
1.6.4 Classification system for HIV-1 infection (reviewed in Luciw, 1996).
Infection with HIV can lead to a range of clinical conditions, ranging from
asymptomatic infection to severe immunodeficiency and the acquisition of numerous
opportunistic infections and neoplasms. A number of classification systems for HIV-
related illnesses have been proposed. The Centers for Disease Control (CDC) have
constructed a system which classifies the manifestations of HIV-1 into three clinical
categories, A, B and C (Table 1.3) (Centers for Disease Control, 1993). These
categories respond to CD4+ T-lymphocyte counts per microliter of blood and guide
clinical and therapeutic actions in the management of HIV-infected adolescents and
adults.
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Table 1.3: 1993 revised classification system for HIV infection and expanded
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a PGL: Persistent generalised lymphadenopathy
bCD4 T-cell categories correspond to CD4 T lymphocytes per pi blood
1.6.4.1 Acute primary infection syndrome (Clinical Category A)
The CDC Category A group identifies patients who have recently undergone
seroconversion, shortly following initial infection, which may be accompanied by an
acute seroconversion illness, with clinical features such as a mononucleosis-like
illness, fever, rigors, malaise, lethargy, anorexia, nausea, diarrhoea, sore throat and a
truncal maculopapular, urticarial or vesicular rash. Neurologic signs and symptoms
often predominsate, including headaches, stiff neck, neuritis, irritability, and
depression. This illness may last from 2 to 3 weeks but usually result in clinical
recovery. Incubation periods ranging from a few days to 3 months have been
described and seroconversion usually occurs 1-10 weeks after the onset of acute
illness.
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1.6.4.2 Asymptomatic infection and persistent generalised lymphadenopathy
(Clinical Category A).
Category A also includes asymptomatic patients showing no signs or
symptoms of HIV-1 infection. This asymptomatic period may last from a few months
to many years before any signs of clinical disease become apparent. In adults, mean
incubation periods before development of disease has been estimated at 10 years in
the absence of therapy. The most useful and available single measurement of
prognosis appears to be the number or percent of CD4+ T lymphocytes in peripheral
blood. The CD4 count gives an indication of the degree of immunosuppression and
predicts the risk of developing AIDS. The ratio of CD4 to CD8 cells is also useful in
reflecting the changes between the critically important T-helper cell and the cytotoxic-
T suppressor cells. Plasma viral load measurements are also useful in predicting
disease progression and together with CD4 measurements, they have proved to be
very effective in determinsing an individual's response to therapy. Patients with
persistent generalised lymphadenopathy are also grouped in clinical Category A.
They are otherwise asymptomatic but have palpable lymphadenopathy (nodes >lcm)
at two or more extrainguinal sites. Lymphadenopathy by itself is not a good predictor
of disease progression.
1.6.4.3 Symptomatic HIV infection (Clinical Categories B and C)
The CDC Category B group consists of symptomatic conditions in an HIV-
infected individual that are not included among conditions listed in clinical Category
C. Some of these conditions may include oral hairy leukoplakia, herpes zoster,
oropharyngeal candidiasis and listeriosis. After a variable period of asymptomatic
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HIV seropositivity, a variety of symptoms may herald deterioration. Category C may
consists of symptoms such as chronic fevers, night sweats, diarrhoea, weight loss,
herpes zoster, oral thrush or hairy leukoplakia. These symptoms may occur
individually, simultaneously, or sequentially. The term AIDS-related complex (ARC)
is used when two or more symptoms or two or more laboratory findings are indicative
of immune dysfunction. Once the diagnosis of AIDS is made, survival is often less
than 2 years, although considerable variability exists, depending on factors such as age
and therapy (Hirsch et al., 1993).
1.7 EPIDEMIOLOGY (reviewed in UNAIDS/WHO 1998 and 1999 and references
within).
After 15 years of study, much has been learned about the magnitude and
distribution of AIDS and HIV-1 infection. Infection with HIV-1, HIV-2 or in some
cases coinfection with both viruses is now widely accepted to be causally associated
with the subsequent progression to severe immunodeficiency and acquired immune
deficiency syndrome (AIDS). Type 1 HIV is recognised as the agent of the global
AIDS pandemic, with HIV-2 mostly confined to the countries of West (DeCock et
al., 1993). The global pandemic of HIV infection comprises many separate epidemics
in different geographic areas and is influenced by many factors including the time of
introduction of the virus, population density and diverse cultural and social variables.
Estimates by the Joint United Nations Programme on HIV/AIDS (UNAIDS)
and the World Health Organisation (WHO), indicated that at the end of 1999, some
33.6 million men, woman and children were infected with HIV and that 12 million
people around the globe had already lost their lives to the disease. With 16,000 new
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infections daily, the proportion of people living with HIV is set to grow even further.
HIV/AIDS is one of the top ten killers worldwide, and may soon overtake well
established causes of death such as diarrhoeal diseases. The overwhelminsg majority
of people with HIV (95%) live in the developing world. It is clear that infection rates
are rising rapidly in much of Asia, Eastern Europe and southern Africa.
Sub-Saharan Africa continues to bear the brunt of HIV and AIDS, with close
to 70% of the global total of HIV-positive individuals. Life expectancy at birth in
southern Africa, which rose from 44 years in the early 1950s to 59 in the early 1990s,
is set to drop to 45 between 2005 and 2010. Heterosexual transmission is the main
mode of transmission among African adults. New information suggests that between
12 and 13 African women are infected for every 10 African men. Female prevalence is
higher due to the greater efficiency of male-to-female sexual transmission. HIV has
also caused huge increases in death rates among young adults. This age factor makes
AIDS uniquely threatening to children quite apart from the risk of vertical
transmission. By the end of 1999, the epidemic had left behind a cumulative total of
11.7 million ATDS orphans.
HIV was a relative latecomer to Asia, but its spread has been swift, with over
4 million now thought to be infected (Quinn, 1996). Thailand was the first Asian
country in which HIV was recorded. Transmission was generally concentrated in
groups such as drug users and sex workers whose behaviour was known to put them
at risk. (Morris et al, 1996). Although no Asian country has reached anything like the
prevalence in sub-Saharan Africa, by 1997 HIV was well established across the
continent. The countries of South-East Asia, with the exception of Indonesia, the
Phillipines and Laos, are comparatively hard hit, as is India. While prevalence remains
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low in China, it was estimated at the end of 1996 that the number of people living
with HIV/AIDS was over 200,000. Two major epidemics are underway in China; the
first among increasing numbers of injecting drug users (Wu et al, 1996) and the
other newer epidemic, surfacing among heterosexuals, especially along the prosperous
eastern region where prostitution is widespread. Thailand has recently shown a
decrease in the number of new infections among sex workers and their clients. This is
due to sustained efforts towards prevention aimed at increasing condom usage among
heterosexuals and AIDS-awareness.
In Eastern Europe, HIV infection was not recognised until much later than in
the USA or Africa. However, the pattern of consistently low prevalence began to
change in 1995 in several of the countries of the former Soviet Union, Belarus,
Moldova, the Russian Federation and Ukraine with new infections increasing six-fold
in the past three years. Most of these new infections are related to intravenous drug
users (IDUs) and their partners. In the Ukraine, 44 people from a survey of the whole
population tested positive for HIV in 1994, roughly the same as in 1992 and 1993.
Rut the number of diagnoses increased 30-fold in 1995 and exploded to over 12,000
in 1996. Now, just over four years later, more than 110,000 people are estimated to
be infected. Injecting drug use gave the Eastern European and central Asian region
the world's steepest HIV curve in 1999 (UNAIDSAVHO, 1999).
In 1997 it was estimated that 30,000 new infections occurred among Western
Europeans. New infections are concentrated among IDUs in the southern countries of
the continent, particularly Greece and Portugal. In Europe as a whole, the number of
cases attributable to homosexual transmission decreased significantly from 62% to
36% between 1985 and 1992 (Quinn, 1996). The opposite trend for IDU has been
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reported with an increase from 16 to 40% in recent years (UNAIDS7WHO).
Similarly, transmission through heterosexual contact also increased. In Western
Europe, the number of new AIDS cases decreased 38% between 1995 and 1997. This
downturn is due to the new antiretroviral drug therapies, which postpone the
development of AIDS and prolong the life of individuals living with HIV.
HIV infection amongst individuals in the Americas has been estimated at three
million, with over one million in North America and two million in Latin America and
the Carribean. There is a trend in these countries for a marked decline of HIV-1
among the heterosexual population (Heverkos el al., 1995). In some disadvantaged
sections of society in the USA, there is an increase in the number of AIDS cases.
Among African -Americans, new AIDS cases rose by 19% among heterosexual men
and 12% among heterosexual women in 1996. This is mainly due to unsuccessful
prevention efforts in the minsority communities.
1.7.1 Transmission of HIV-1
HIV-1 transmission can be divided into four main groups depending on the
mode of transmission (1) Sexually active individuals (homosexual and heterosexual),
(2) intravenous drug users (IDUs) and their sexual partners (3) transfusion of infected
blood products and (4) transmission from mother to infant. African-Americans and
Hispanics are disproportionally represented in the HIV-1 positive population. Health
care workers who may also come into contact with contaminsated blood or blood
products are also at increased risk of infection.
Transmission through sexual contact accounts for 75 to 85 percent of the
nearly 40 million worldwide infections with HIV that have occurred so far (Mann &
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Tarantola et al., 1998). HIV-1 is transmitted by both homosexual and heterosexual
contact, and, as with other sexually transmitted infections, the likelihood of infections
is related to the number of partners as well as to different sexual practices (Luciw,
1996). In the United States, anal intercourse between men has been the most common
mode of transmission, whereas in Africa, the Caribbean, and Asia, heterosexual
vaginal intercourse appears the dominsant mode of transmission. In both homosexual
and heterosexual intercourse the receptive partner appears more at risk of infection
than the insertive partner (Rodrigues et al, 1995). HIV-1 can be isolated from both
semen and female genital secretions, and in both it appears to be largely cell
associated. In cervical biopsies, HIV antigens are detectable in inflammatory cells, and
genital ulcer disease has been associated with an enhanced risk of acquisition or
transmission.
The primary risk of HIV transmission via blood is through intravenous drug
abuse. HIV is transmitted among injecting drug users through the use of
contaminsated needles and other equipment. Risk factors include frequency of needle
sharing, frequency of injections, use of "shooting galleries", and prevalence of HIV
infection in the area. There is also an increased risk of transmission to sexual partners
of intravenous drug users (Ronald et al., 1993). Similarly, frequent drug abuse is
associated with other high-risk behaviours such as sexual promiscuity. For example,
prostitution is frequently motivated by the cost of drug addiction (Celentano et al.,
1994).
Before 1985, individuals receiving blood transfusions or organ transplants, and
haemophiliacs receiving clotting factors from pooled blood were at high risk of HIV
infection. Screening of the blood supply has practically eliminsated transfusion-related
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transmission of HIV. Haemophiliac recipients of pooled clotting factors are protected
further by appropriate handling of the factor (prolonged heating) to inactivate the
virus. A small number of health care workers have contracted HIV infection from
accidental needle sticks, cuts, or exposure of broken skin to contaminsated blood. To
date, there has only been one case where a health care worker has infected patients.
This involved the transmission of HIV from a dentist to a number of patients (Ou et
al., 1992). Prospective studies of needle stick recipients indicate that fewer than 1%
of those exposed to HIV-positive blood experience seroconversion. Tattoo needles,
acupuncture and other invasive body piercing instruments that may have come into
contact with contaminsated blood are other potential vectors ofHIV transmission.
Most HIV-1 infections of children result from mother-to-infant transmission,
which has been shown to occur in utero (intrauterine or transplacental), at the time of
delivery through exposure to an infected genital tract (perinatal) or postnatally, as a
consequence of breast feeding (Mofenson, 1998; Peckham et al., 1995). The rate of
perinatal transmission has ranged from 13 to 40%, with the highest rates being
reported in Africa where rates of breast-feeding are highest and the severity of
maternal HIV disease has been greatest.
A number of potential routes have been shown not be important in the
transmission of HIV, including non-sexual personal contact such as touching and
hugging, exposure to saliva, coughing, sneezing, insects, water, food or utensils,
toilets, swimminsg pools and public baths.
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1.8 IMMUNE RESPONSE IN HIV-1 INFECTION
After a burst of virus production during primary infection by HIV-1, the
plasma viral load declines, which may indicate either a diminsishing pool of
susceptible cells or an effective immune response. Subsequently, HIV-1 undergoes
antigenic drift, especially in epitopes that lead to generation of neutralising antibodies,
bind selective co-receptors, or participate in cytotoxicity which indicates a continous
and effective immune response by the human host. It is not known exactly which
components of the immune system are necessary for protection from natural infection.
The immune system must elicit effector T-cell responses to eliminsate virally infected
cells, and produce antibody responses to neutralize cell-free virus. Despite the
devasting effects of HIV-1 on host immunity, infected individuals develop both
humoral and cell-mediated responses against HIV-associated antigens. These include
virus-specific neutralizing antibodies, antibody-dependant T-cellular cytotoxicity
(ADCC), cytotoxic T lymphocytes (CTL), natural killer (NK) cells, and complement-
dependent lysis (Pantaleo et al., 1995). In most patients, antibodies develop within 4-
6 weeks post infection. They are detected by an enzyme-linked immunosorbent assay
(ELISA) and their specificity for envelope, gpl20 (env), pl7 (core) and p24 (matrix)
from the gag protein and p53 and p64 from the polymerase (pol) proteins can be
confirmed by Western blotting. Antibodies against env persist throughout infection
while antibodies against gag decline during advanced infection. Antibodies to the
transmembrane glycoprotein, gp41, are often not detected until several weeks later.
Virtually all neutralising activity in the sera of infected individuals is directed against
these proteins and particularly against regions of gpl20. Within 2-3 months of
primary HIV infection, neutralising antibodies develop that typically recognise
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Figure 1.4 The V3 Loop (modified from Fields Virology, 1996).
epitopes on the V3 loop (Figure 1.4), an exposed 38-aminso acid segment of the viral
envelope protein, gpl20. Unfortunately, the aminso acid sequence of the V3 loop
differs between HIV strains; thus V3-specific antibodies that neutralise one virus
strain often fail against others. Some investigators have noted a correlation between
progressive disease and low neutralising antibody titers in serum (Ho et al., 1985),
whereas others have not (Groopman JE et al, 1987., Robert-Guroff M et al, 1987,).
The V3 hypervariable region has been found to be the principal neutralising domain in
HIV-1 infection. V3 neutralising antibodies can prevent HIV-1 entering target T-cells,
although they do not necessarily abrogate binding to the cell via the gpl20-CD4
interaction. The V3 loop can present both linear and conformational determinsants for
antibody recognition. Later in infection, other neutralising antibodies develop and
recognise the CD4-binding site located in the carboxy-terminsal region of gpl20. This
CD4-binding region appears to be a complex folded epitope that is relatively
conserved between different virus strains: antibodies that are directed against the
CD4-binding region can neutralise a broad range of HIV strains. Neutralising
antibodies directed against VI and V2 hypervariable regions of gpl20 have also been
detected. As with the V3 loop, linear and conformational determinsants appear to be
involved.
1.8.1 Humoral responses to HTV-1 infection
HIV-specific humoral responses can be detected readily during primary
infection, but are mostly comprised of low-avidity Env-specific IgG antibodies that
possess little or no neutralising activity. In fact, emergence of significant neutralising
titers does not generally take place before transition to chronic HIV infection. Delays
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in antibody response might be due to the dysfunstion and depletion of CD4+ Th cells
which in turn interfere with the T-cell-B-cell interaction, altering the antibody
response such as avidity maturation and neutralizing activity (Soudeyns et al., 1999).
The principal neutralisation mechanism for HIV-1 involves coating the virus by
antibody obstructs the close approach of virion and target T-cell, thereby effectively
inhibiting virus-cell attachment. The HIV envelope is the major target for humoral
antibody responses. Six regions of the viral envelope are involved in HIV-1
neutralisation. These have been localised to the envelope gpl20 and the external
portion of gp41. It was originally documented that the principal neutralising domain
(PND), was the central portion of the third variable region (V3 loop; aa308-322),
located in the N-terminsal portion of the gpl20. More recently however, it has
become increasingly clear that the V3 loop of HIV-1 primary isolates is not an
important target for neutralising antibodies generated by infection or by candidate
HIV vaccines.
Although V3 is a variable region, the PND is a linear epitope conserved
among many strains or differing only slightly in aminso acid structure. Recent studies
concerning the molecular events driving HIV-1 neutralisation suggest that the
dominsant mechanism may be simpler than originally thought: occupation by antibody
of a minsimum number of binding sites on the envelope glycoproteins may be the
principal factor determinsing neutralisation, implying that antibody affinity and
concentration are more important criteria than epitope specificity. The V3 loop is not
a significant epitope for primary virus neutralisation; any neutralisation achieved by
V3-directed antibodies, however, appears to be mediated by inhibition of virion
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attachment, not later stages of the fusion process (Spenlehauer et al., 1998;
Stamatatos et al., 1995). The V3 loop can have both neutralising and non-neutralising
epitopes, since sera with high-titer antibody to V3 peptides do not always neutralise
the homologous HIV-1 strain (Kostrikis et al., 1996; Moore et al., 1998). The lesser
role of the V3 loop in primary virus neutralisation appears to be a consequence of its
decreased accessibility in the mature oligomeric envelope of primary isolates, leading
to a lower affinity to this region. Work with escape mutants has indicated that sites
within and outside the V3 loop can be involved in efficient antibody neutralisation
(Yoshiyama et al., 1994). The V3 region can be both a linear and conformational
determinsant for antibody recognition. In this regard, glycosylated forms of the HIV-1
envelope can be better recognised than nonglycosylated proteins by immune sera
(Moore et al., 1996; Wyatt et at, 1998). Another major neutralising region on gpl20
is the CD4-binding domain. Antibodies that cross-neutralise a large number of
different strains, including those with different V3 regions, are directed against this
region. The determinsant is generally conformation dependent. Finally, the V2 region
is also another neutralising region of gpl20 (Yoshiyama et al., 1994). Similar to the
V3 loop, both linear and conformational determinsants are involved in this region
which is also recognised by antibodies to both glycosylated and non-glycoylated
regions. The clinical relevance of these neutralising antibodies remains uncertain since
AIDS patients often elicit antibodies that enhance rather than neutralise infection by
the virus found in the patient. The virus changes under immunologic responses to
escape neutralisation (Burns et al., 1993; Wei et al., 1995; Nyambi et al., 1997).
Thus, the induction of neutralising antibodies would appear to be most beneficial early
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in the course of HIV infection and to have less influence in later (Wei et al., 1995;
Lathey etal., 1997).
Antibodies that bind effectively to HIV-1 envelope glycoprotein on virions or
infected cells may either inactivate or enhance viral infectivity through Fc-mediated
effector mechanisms. These include: antibody-dependent T-cell-mediated cytotoxicity
(Evans et al., 1989; Koup et al., 1989; Ljunggren et al., 1987; Ljunggren et al., 1988;
Ljunggren et al., 1989), antibody-dependent complement-mediated virolysis (Wahren
et al., 1987), and antibody-dependent enhancement of infection (Takeda el al., 1988;
Homsy et al., 1989; Laurence et al., 1990; Reisinger et al., 1990; Robinson et al.,
1990; Tremblay et al., 1990).
1.8.1.1 Antibody dependent T-cell mediated cytotoxicity
Antibody-dependent T-cell-mediated cytotoxicity (ADCC) directed against
HIV-1 infected cells has been demonstrated by a number of investigators. Such
activity appears to reside in IgG fractions and is directed predominsantly against
epitopes on gpl20 and gp41 (Evans et al., 1989; Koup et al., 1989; Ljunggren et al.,
1987; Ljunggren et al., 1988; Ljunggren et al., 1989). Antibody-antigen-coated cells
are recognised by effector NK cells bearing the Fc receptors or by other monocytes
and killed by a cytotoxic mechanism, most probably cytokine mediated (Yagita et al.,
1992). Only certain epitopes on HIV envelope proteins induce this response, since not
all anti-Env antibodies produce this activity and they can be distinguished from
neutralising antibodies (Bottiger et al., 1988). A detrimental effect of ADCC could be
the release by cell destruction of large quantities of infectious particles with
subsequent spread in the host. Antibodies active in ADCC are present in substantial
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titers during the course of infection (Evans et al., 1989) but eventually decline with
progression of disease. The extent of effector-cell activity is the important parameter
influencing the ability of the ADCC process (Brenner et al., 1991; Szelc, et al., 1992;
Tyler etal., 1990).
1.8.1.2 Antibody-dependent complement mediated virolysis
Antibody bound to HIV-1 virions activates complement in human plasma.
HIV-1, however, carries complement-regulatory molecules, which are acquired from
the host T-cell membrane during budding, or recruited from plasma by attachment to
HIV-1 envelope glycoproteins. These regulatory molecules promote the resistance of
virions to virolysis by inhibiting full activation of the complement cascade (Wahren et
al., 1988). Primary isolates of HIV-1 have been found to be more resistant than
TCLA viruses to complement-mediated virolysis (Spear et al., 1990; Saifuddin et al.,
1995; Sullivan et al., 1996). The reistance of primary isolates to virolysis was found
to directly correlate with the poor exposure of antibody binding sites on the primary
virus envelope (Takefman et al., 1998).
1.8.1.3 Antibody-dependent enhancement of infection
Binding of neutralising antibody does not always result in a decrease of virus
infectivity. The clinical importance of antibody dependent enhancement (ADE) in still
relatively unknown, but its association with disease suggest that it has a role in
pathogenesis. Both Fc receptor mediated (FcR-ADE) and complement-mediated
(C'ADE) antibody dependent enhancement of infectivity have been described for
HIV-1 (Robinson et al., 1988; Takeda et al., 1988; Homsy et al., 1989; Laurence et
69
al., 1990; Reisinger et al., 1990; Tremblay et al., 1990). It has been shown that FcR-
ADE is CD4 dependent; it acts through stabilisation of the virus-cell interaction rather
than via Fc receptor-mediated internalisation of HIV-1 (Connor et al., 1991).
Complement receptor 2 (CD21) can mediate CADE, either by acting as a receptor
for FIIV-1 opsonised with antibody and complement, or by increasing virus binding to
the cell due to an interaction of CD21 with opsonised virus (Boyer et al., 1991).
1.8.2 CELL MEDIATED IMMUNE RESPONSES TO HIV-1 INFECTION
1.8.2.1 CTL Response
Cellular responses in HIV-infected individuals were first described more than
10 years ago. High frequencies of cytotoxic T-lymphocytes (CTLs) have been
detected in peripheral blood and a general loss of CTLs has been observed with
disease progression (Skolnick et al., 1993). These cells recognise virus-infected cells
by a direct interaction with the T-cell receptor (TCR) of the CTL and a viral peptide
presented by MHC class I molecules on the surface of the infected cell (Goulder et
al., 1999). In vitro models using cloned CTLs have shown that they can dramatically
inhibit HIV replication and under idealised conditions can clear infectious virus from
cultures (Yang et ah, 1996). In such circumstances, inhibition of viral replication can
be cytolytic and non-cytolytic (Yang et al., 1997). CTLs react with env, gag, and pol
regulatory gene products. .Efrv-specific CTL reactivity is seen in nearly all infected
individuals while Gag and Pol reactivity appears less constant. CD8+ cells have been
shown to inhibit HIV-1 replication in CD4 cells in vitro. Immune reconstitution and
CTL depletion studies indicate that HIV replication and the level of viraemia are
controlled by HIV-specific CTLs (Brodie et ah, 1999; Jin et al., 1999) and the
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correlation of strong, HIV-specific responses mediated by CD4+ T-cells with viral
load indicates that Th cells may also play an important role in immune control of HIV-
1 (Rosenburg et al, 1997). Because neutralising antibody responses do not appear
until several weeks after viraemia has subsided; it is possible that CTL responses are
the only mechanism involved in viral clearance during primary HIV infection.
CTLs have also been reported in persistently uninfected people who have been
exposed to HIV or in transiently infected individuals, suggesting that these persons
may have generated a protective CTL response. Studies of long-term non-progressors
infected with HIV-1 suggest that low viral load is associated with apparently effective
neutralizing and CD8+ lymphocytes responses. (Pantaleo et al., 1995). CD8+ T-cells
seen in peripheral blood in chronic infection has been shown to represent clonally
expanded, antigen specific CTLs (Tan et al., 1998) and CTLs can be readily
demonstrated in peripheral blood, lymph node, skin and semen of infected persons
(Bachelez et al., 1998; Quayle et al., 1998). It is only recently that the contribution of
these responses to immune control of HIV has been widely appreciated. Advances in
the development of more sensitive and quantitative assays (Altman et al., 1996) have
provided the first link between CTLs and control of viraemia (Ogg et al., 1998).
Natural killer (NK) cells can also display cytotoxic reactivity against HIV-1 gpl20
(Tyler et al., 1989; Szelc et al., 1992). NK cells recognise and kill virally infected cells
in a non-MHC-directed manner. In HIV infection NK cells are found to have
decreased function, particularly as individuals progress towards disease.
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1.8.2.2 T-helper cell response
Studies by Clerici have suggested that specific subsets of CD4+ T-helper cells
are instrumental in determinsing the extent of cell-mediated and humoral immune
responses (Clerici et al., 1993). One T-helper cell subset (Thl) produces interferon-y
and IL-2 which increase cellular immunity while the other subset (Th2) produces IL-4
and EL-10 which enhance antibody production. The interaction of the Thl and Th2
cell subsets is competitive and over-expression of cytokines by one cell type can
suppress the activity of the other. A predominsance of Th2 cells could be responsible
for the decrease in Thl activity. This would be reflected by a high antibody
production in the absence of a strong CD8+ cell response. IL-2 produced by Thl
cells increases CD8+ cell anti-viral activity, whereas IL-10 produced by Th2 blocks
this activity (Levy et al., 1993). How well HIV-specific CD4+ T-cell responses can be
restored in chronic infection has yet to be determinsed. Moreover, the greater the
pretreatment CD4+ T-cell loss, the more difficult it may be to fully recover a
functional T-cell repertoire. Thl responses are found primarily in healthy,
asymptomatic individuals and in high-risk individuals who do not show evidence of
HIV infection. It has been suggested that this type of response helps induce cell-
mediated immunity. It has also been suggested that virus-specific T-helper cell
responses are critical to the maintenance of CTL function. In the absence of ongoing
helper cell function, CTL responses decline and there is a lack of control of viremia
during the chronic phase of infection (Goulder et al., 1999). Rosenburg et al revealed
that a unique subset of long-term non-progressors could control viremia in the
absence of antiviral therapy indicating that HIV can induce robust T-helper cell
responses in some individuals. In this small subset of persons controlling viremia, both
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strong CTL responses as well as strong Gag-specific T-helper cell responses are
detected, consistent with the murine data which indicates a need for T-helper cell
responses in order to maintain control of viremia (Rosenbug et al., 1997). Other
studies have indicated an association between strong T-helper cell responses and
strong CTL responses (Kalams et al., 1998), indicating that these two arms of the
cellular immune response are coordinately linked, and providing support for the
hypothesis that T-helper cells may mediate their antiviral effect through facilitation of
CTL responses.
1.8.2.3 Natural killer cells
Cytotoxic reactivity against HIV-1 gpl20 can also be displayed by non-T-
effector cells phenotypically resembling those with natural killer (NK) activity (Tyler
et al., 1989; Szelc et al., 1992). NK cells recognise and kill virally-infected cells in a
non-MHC-directed manner. In HIV infection, this cell type has found to have
decreased function, particularly as infected individuals progress to disease. NK cells
most probably play the important role in ADCC (Szelc et al., 1992);
polymorphonuclear leukocytes could aslo be involved. CD 16+ NK cells carrying the
anti-gpl20 antibodies can be detected in the blood (Tyler et al., 1989).
1.8.2.4 Monocytes
Monocytes-macrophages are crucial in the phagocytosis and eliminsation of
foreign organisms, the presentation of antigen to lymphocytes and the secretion of
regulatory cytokines. Hence, infection of these cell types would be expected to result
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in a panoply of immunologic abnormalities and these have been amply demonstrated
in AIDS patients.
It is not clear what host responses are important in protection against HIV-1
infection or disease, and it is also not clear whether such a protective response can be
elicited. Overall, HIV-1 has evolved to express an envelope structure of minsimal
antigenicity and immunogenicity in its oligomeric form, a strategy which enables it to
evade humoral immunity. The virus has also an ability to rapidly escape any minsimal
neutralising antibody response that does develop (Burns et al., 1993; Wei et al., 1995;
Nyambi et al., 1997). Furthermore, it may spread through a cell-to-cell route against
which antibody is relatively inefficient. Neutralising antibody effective against this
challenge virus can protect against infection but may not affect the course of an
established infection. Neutralising antibodies may play a role in the critical early phase
of infection, since by reducing the viral inoculum, they may buy cell-mediated
immunity time to mature and to clear cells that do become infected.
1.9 ANTI-RETROVIRAL TREATMENT FOR HIV-1 INFECTION.
The need for highly active antiretroviral therapy regimens (HAART) is
highlighted by the lack of an effective anti-HIV vaccine in the foreseeable future and
the limited possibility of altering human behaviour to control the HIV pandemic
(Luciw et al., 1996). HIV poses several difficult challenges for the development of
effective antiviral therapies. Firstly, proviruses have a chance of remaining latent
within the cell (Chun et al., 1997; Finzi et al., 1997; Wong et al., 1997; Finzi et al.,
1999; Zhang et al., 1999). Although anti-HIV drugs inhibit replicating virus and
reduce viral load in infected individuals, proviruses within quiescent T-cells will not be
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affected. Secondly, HIV is disseminsated in T-lymphocytes and
monocyte/macrophages throughout the body, including the CNS. Delivery of the
antiviral agent to all target T-cells is difficult to achieve. Thirdly, reverse transcription
is a process that does not incorporate proof-reading to eliminsate misincorporated
nucleotides; therefore variant genomes including antiviral resistant strains are readily
generated (D'Aquila et al, 1995; Welles et al., 1996).
In individuals with HIV-1 infection, recent antiretroviral drug combinations
have proven remarkably successful at suppressing virus production and reducing
lymphoid tissue viral reservoirs to levels near or below detection levels. To
understand how to interpret changes in plasma HIV RNA and other viral parameters
after the institution of antiretroviral therapy it is important to know exactly how the
drugs act. The two main classes of antiretroviral drugs, reverse transcriptase inhibitors
and protease inhibitors, both prevent infection of new cells. For reverse transcriptase
inhibitors the viral RNA is unable to reverse transcribe fully into DNA and hence the
virus is unable to infect the cell (Larder & Kemp, 1989; Larder et al., 1991; Kellam et
ah, 1992; 1994). Protease inhibitors (Pis) prevent infected cells from producing
replication-competent virions and hence new infection of cells is prevented owing to
the lack of infectious particles (Kozal et al., 1996). There are currently 15
antiretroviral agents approved for the treatment of HIV infection (table 1.4). These
drugs may be used alone, or as components of double or triple therapy.
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Table 1.4 Current Antiretroviral therapy
Drug Therapy













The first treatment available was Zidovudine (ZVD/AZT), a nucleoside
reverse transcriptase inhibitor (Yarchoan et al., 1986). It acts as a competitor for
nucleotides used by the polymerase and is a potent chain terminsator of viral DNA
synthesis. In 1990 two studies showed that zidovudine delayed the progression to
severe AIDS related complex (ARC) and AIDS in patients with early symptomatic
disease and in those who were symptomless (Fischi et al, 1990., Volberding et al,
1990). A number of early studies suggested that early adminsistration was more
effective in slowing progression to disease (Yarchoan et al., 1986; Graham et al.,
1992; Cooper et al., 1993; Fauci et al., 1993; Volberding et al., 1995). However, the
Concorde study found that no important clinical benefit was observed in symptomless
patients when immediate and deferred treatment policies were compared (i.e. starting
AZT after randomisation, or delaying it until the onset of symptomatic disease or a
CD4 count at which the onset of symptomatic disease was imminsent) (Concorde
coordinating committee 1994).
The beneficial effects of AZT may persist for months to years, but eventually
failures occur, in part related to the development of viral resistance. The rapid
turnover of the virus population, which has a half-life of 1-2 days, coupled with the
high rate of HIV-1 mutation, provides the ideal machinery for producing drug-
resistant variants (Ho et al., 1995; Perelson et al., 1996; Wei et al., 1995). The
advantages of AZT monotherapy have been limited with the emergence of drug-
resistant strains, especially after prolonged therapy, and this associated with mutations
arising at four positions in HIV RT (Boucher et al., 1992). Other nucleosides that
have shown promise in HIV-1 infection are didanosine (ddl), zalcitabine (ddC),
lamivudine (3TC) and stavudine (d4T). They are all less effective than AZT as initial
therapy for advanced infection but are useful as alternatives for patients who have
failed or are intolerant of AZT.
A number of studies have been carried out to investigate the therapeutic
potential of combination therapies using two and three combined drug regimens
(Caliendo et al., 1994). In the first trial, patients were randomised to receive either
AZT alone, AZT plus didanosine or AZT plus zalcitabine (Delta Coordinating
Committee, 1996). Combination therapy was shown to improve survival over
monotherapy while also significantly delaying progression to AIDS or death. A similar
double blind trial comparing the combination of three drugs (AZT, saquinavir,
zalcitabine) was found to result in a considerably more favourable outcome than with
combinations of AZT and saquinavir or AZT and zalcitabine (Collier et al., 1996).
Katlama and Staszewski also showed that the effects of double nucleoside
combinations on viral load were superior in the short term to those seen with
monotherapy (Katlama et al., 1996; Staszewski et al., 1996). Other phase II clinical
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trials are also showing the superior effects of triple combination regimens including PI
inhibitors or NNRTIs over double and monotherapy arms in terms of change of CD4
counts and viral load over 24-52 weeks (Gulick et al., 1997).
Combination therapy with one or more nucleoside analogue drugs may
produce additive or synergistic effects; have activity in different T-cell populations;
reduce the emergence of resistance; decrease viral fitness; decrease toxicity by the use
of lower doses of drugs with non-overlapping toxicity profiles; and perhaps
advantageously exploit pharmacokinetic interactions (Knox et al., 1996; Larder.,
1994). It has become apparent from recent studies that HIV-1 has the capacity to
mutate in order to become resistant to antiretroviral agents. Monotherapy with
nucleoside analogues or non-nucleoside reverse transcriptase (RT) inhibitors
(NNRTIs) has, without exception, resulted in the emergence of drug-resistant virus.
This may only take a matter of weeks with NNRTIs or months to years in the case of
AZT, ddl and ddC (Larder et al., 1989a; Larder et al., 1989b; Boucher et al., 1992;
Boucher et al., 1993; Tisdale et al.,1993; Schinazi etal., 1993).
The limited success of nucleoside inhibitors (ddl, ddC, AZT and d4T) in the
treatment of HIV infection led to the development of drugs that use an alternative
target. Inhibitors of HIV-encoded protease, combined with nucleoside analogues with
antiretroviral activity, cause profound and sustained suppression of viral replication,
reduce morbidity, and prolong life in patients with HIV infection. Recent guidelines
recommend that initial treatment of all HIV-infected patients include the
adminsistration of an HIV protease inhibitor. HIV protease inhibitors prevent
cleavage of Gag and Gag-Pol protein precursors in acutely and chronically infected
cells, arresting maturation and thereby blocking the infectivity of nascent virions.
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Protease inhibitors have no effect on cells already harbouring integrated proviral
DNA. Protease inhibitors (Pis) have become the first-line antiviral agents for the
control of HIV-1 infection and are widely used in HAART regimens. The four
approved HIV-protease inhibitors are based on aminso acid sequences recognised and
cleaved in HIV proteins, indinavir, nelfinavir, ritonavir and saquinavir. In three large
clinical trials, protease inhibitors with nucleoside analogues slowed the progression of
disease and improved survival (Cameron et al., 1999; Hammer et al., 1996; Mclaren
etal., 1996).
A number of aminso acid mutations in the protease protein are associated with
the emergence of resistant clinical isolates (Schinazi el al., 1997). Single or primary
mutations do not lead, in the main, to high levels of resistance, but subsequent
secondary mutations may arise in order to restore viral replicative fitness (Roberts et
al, 1998). Furthermore, resistance may arise not only to the protease inhibitors being
given but also to other protease inhibitors (Condra et al., 1995). No firm
recommendations are presently possible for patients who fail Pi-containing regimens.
Treatment failure has been defined in virological terms as the inability to
completely suppress viral replication. Once multidrug resistance is present, regaining
control of vireamia becomes difficult because no effective 'salvage' strategy has been
devised. The factors leading to this type of failure are straightforward: poor adherence
to HAART, prior exposure to antiretroviral drugs in mono- or bi-therapy, the
sequential addition of drugs to a failing regimen, the phenomenon of 'quasispecies'
(the simultaneous presence in a patient of a swarm of viral variants), and the extent of
cross-resistance among antiviral drugs used . More recently, the transmission of
viruses resistant to inhibitors of both RT and protease have been reported (Hecht et
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al., 1998., Boden et al., 1998). The optimal initial treatment strategy to avoid the
emergence of drug resistance is the use of a maximally suppressive antiviral regimen.
Most physicians now begin therapy with a triple combination consisting of two
nucleosides and either a PI or an NNRTI. However, it cannot be assumed that this is
applicable to all infected individuals. Those individuals with more advanced disease
may need to be treated with four or even five drug combination regimens to attempt
maximum suppression of virus replication. Once a course of treatment is initiated, it is
essential to monitor the response by following general health, the CD4 count, the
plasma viral load and the emergence of resistant viral strains. Viral eradication is not
achievable with current strategies (Wong et al., 1997), and the shift in treatment
paradigm to one of long-term suppression has led to the challenge of ensuring
continuous treatment benefit and avoiding failure (Carpenter et al., 1997).
1.10 MOLECULAR EVOLUTION
The complex evolutionary process of HIV-1 is marked by a high level of
genetic variation. RNA viruses show high mutation rates. Because of this high
mutation rate and high rates of replication, the rates of RNA genome evolution can be
more than a million-fold greater than the rates of the DNA genome of their hosts
(Holland et al., 1982). Molecular evolution involves the reconstruction of the
evolutionary history of genes and organisms, also known as molecular phylogeny,
inferred from molecular data.
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1.10.1 Genetic distance estimation
The evolutionary distance between a pair of sequences is usually measured by
the number of nucleotide or aminso acid substitutions between them. The mutation
rate of a virus can be defined as the probability that during a single replication of the
virus genome a particular nucleotide position is altered through substitution, deletion,
insertion or recombination. There are many methods for estimating evolutionary
distances, and these vary in their accuracy and in the extent to which they have been
applied to different viruses (Jukes-Cantor, Tajima-Nei, Kimura 2-parameter model,
etc). In this study the Jukes-Cantor method was used (Gojobori et al, 1986; Nei et al,
1987). Like the other methods it is relatively simple and frequently used by molecular
evolutionists.
The Jukes-Cantor method was developed under the assumption that the rate
of nucleotide substitution is the same for all pairs of four nucleotides A, T, C and G,
and it gives a maximum likelihood estimate of the number of nucleotide substitutions
between two sequences (Jukes-Cantor, 1969). Nucleotide substitutions in coding
genes can be subdivided into two classes, i.e., synonymous (ds) and nonsynonymous
substitutions (dn). Synonymous (or silent) substitutions are the nucleotide
substitutions that do not result in aminso acid changes, whereas nonsynonymous
substitutions are those that change aminso acids. HIV-1 envelope genes are highly
variable between and often within individuals. Part of this variability is thought to be
the result of immune-mediated positive selection for sequence diversity. To measure
positive selection it has become customary in HIV research to calculate the ratio of
the proportions of synonymous and nonsynonymous substitutions per potential
synonymous and nonsynonymous site, respectively. The Jukes-Cantor one parameter
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distance method can be used to calculate distances for synonymous and
nonsynonymous substitution as this parameter does not take into account differences
in the frequency of transitions (purine to purine, pyrimidine to pyrimidine
substitutions) or transversions (purine to pyrimidine). Unlike the Jukes-Cantor model,
the Kimura two-parameter model takes into account the rate of transitional and
transversional substitutions per site.
1.10.2 Nucleotide substitution
The rate of nucleotide substitution is assumed to be the same for all nucleotide
sites but this assumption rarely holds true, and the rate varies from site to site. It can
be calculated by dividing the pairwise distance calculated for any two sequences with
twice the time of divergence between the two sequences. The divergence time is
assumed to be the same for the two sequences considered. The rate of
nonsynonymous substitution may be extremely variable among genes as the majority
of nonsynonymous substitutions are subject to purifying selection from external
factors such as host immune response. Consequently, nonsynonymous substitutions
which improve protein function may be selected resulting in a greater rate of
nonsynonymous to synonymous substitution. Reciprocally, nonsynonymous
substitutions resulting in a deleterious effect on protein function will be eliminsated by
selection, reducing the rate of nonsynonymous substitution. However, synonymous
substitutions do not cause changes in aminso acids and will not be subject to purifying
selection. These substitutions are thought to reflect the underlying mutational rate




Genetic distance is represented in a phylogenetic tree as a branch length and is
an estimate of how many mutational events actually occurred between two sequences.
Phylogenetic methods use different ways to estimate the genetic distance between
sequences and to organise a set of sequences into a hierarchy of ever more distantly
related sequences. There is a general trend toward greater evolutionary distances
between viral sequences over time. However, estimates of HIV-1 divergence rates are
dependent on the region of the genome under study. Different alignments of the same
sequences can yield different divergence rates and depend on the evolutionary model
used to calculate the genetic distances. Phylogenetic trees can be rooted or unrooted.
A rooted tree indicates the direction of evolution, and the root is the common
ancestor of all the operational taxonomic units (OTUs) studied. An unrooted tree
specifies the relationship among the OTUs but does not define the evolutionary path.
In practice, the majority of tree-making methods produce unrooted trees. However, in
order to root an unrooted tree an outgroup can be added which is evolutionarily
related to the OTUs under study, having diverged from the other OYUs prior to their
divergence from on another.
There are numerous methods for constructing phylogenetic trees from
molecular data and they can be classified into distance methods and discrete character
methods (maximum parsimony). In distance methods, a pairwise evolutionary distance
(pairwise distance) is computed for all pairs of taxa (e.g nucleotide sequences) to be
studied and a phylogenetic tree in constructed by certain principles and algorithms. In
the construction of phylogenetic trees, the principle of minsimum evolution or
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maximum parsimony is often used. Character methods involve data with discrete
character states such as nucleotide states in DNA sequences). The standard algorithim
of the tree-making methods based on this principle is to examinse all possible
topologies (branching patterns) or a certain number of topologies that are likely to be
close to the true tree and to choose one that shows the smallest amount of total
evolutionary change as the final tree.
Recent computer simulations (Nei et al, 1991) have shown that one of the
most efficient distance methods in recovering the correct topology is the neighbour-
joining method proposed by Saitou and Nei (1987). This neighbour-joining (NJ)
method produces a unique final tree under the principle of minsimum evolution
(Saitou and Nei, 1987). The method involves finding pairs of operational taxonomeric
units (OTUs [=neighbours]) that minsimise the total branch length at each stage of
clustering OTUs. The branch length as well as the tree topology can quickly be
obtained using this method. In the neighbour-joining method the smallest value of the
sum of all branches is not calculated for all the topologies. Instead, the examinsation
of different topologies is embedded in the algorithim, so that only one final tree is
produced. This method produces an unrooted tree, and usually requires an outgroup
to find the root.
Another distance method is the unweighted pair-group method with arithmetic
means (UPGMA). This method employs a sequential clustering alogrithm. Clustering
of OTUs starts with the two OTUs with the smallest distance, and more distantly
related OTUs are gradually added to the cluster. The two OTUs that are most similar
among all the OTUs are identified and subsequently treated as a new single OTU.
New distances between this composite OTU and other OTUs are calculated similarly,
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until only two OTUs are left. This method assumes a constant rate of evolution and
hence a rooted tree is produced.
1.10.3.2 Statistical significance of tree topologies
There are two different types of methods available for testing the reliability of
a tree obtained. These are the maximum likelihood method (Felsenstein, 1988) and the
bootstrap test (Felenstein, 1989). The maximum likelihood method examinses the
reliability of every interior branch of the tree. This method can be very time
consuminsg and is generally limited to small data sets. The bootstrap test involves
randomly resampling the data from which the tree was constructed, producing a new
tree with the resampled data. This process is repeated several hundred times and the
frequency at which particular branches are observed in the newly constructed trees is
calculated giving a probability to each branch in the original tree. This statistical




The aims of this study were to investigate further the dynamics of HIV
replication and the functional significance of CD8+ T lymphocyte infection in vivo.
Resolving the mechanism of HIV infection in CD8+ T lymphocytes is relevant to
evaluating the contributory effect of infection of this cell type on immunodeficiency.
In this study we examinsed the frequency of infection and the relation of virus load in
the naive and memory subsets of CD4+ and CD8+ T lymphocytes in vivo. Changes in
virus distribution were also investigated in the cells from individuals receiving
antiretroviral therapy. This study also aimed to characterise genetically HIV-1 variants
obtained from the naive and memory CD4+ and CD8 T lymphocytes, assess whether
separate populations existed, the degree of compartmentalisation and whether such
differences reflected variation in biological properties. Finally, immunocytochemical
techniques and in-situ PCR were used to detect the presence of HIV-1 DNA in CD4+
and CD8+ T lymphocytes in vitro and in vivo.
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CHAPTER TWO: MATERIALS AND METHODS
2.1 SAMPLES AND CLINICAL DETAILS OF STUDY PATIENTS
20-30ml samples of whole blood were collected in ethylenediaminsetetraacetic
acid (EDTA) blood tubes (Sarstedt, Leicester, UK) from 16 seropositive individuals. The
individuals in this study group were attending the Genito-Urinary Medicine clinic (The
Royal Infirmary, Edinburgh) and the Western General Hospital in Edinburgh. CD4
counts, viral load information and risk groups from all patients were available (please
refer to Chapter 3, table 3.1 for this information). Risk factors for infection included
intravemous drug use and sexual contact with an HIV-positive individual. Seven
individuals were receiving anti-retroviral therapy during the course of this study.
CD4, CD8 and total lymphocyte counts were available for all the samples studied.
CD4 counts ranged from 15 to 850 CD4 lymphocytes per p.1. Four individuals had CD4
counts associated with late stage disease (CD4< 200/p.l), whereas the other 12 had no
symptoms and a CD4 count above 200/p.l. Of the individuals with CD4 counts less than
200/pl, 2 had an AIDS defining illness. Absolute CD8 counts ranged from 280 to more
than 2500/p.l.
2.2 BIOLOGICAL RISKS OF WORKING WITH HIV-1.
With no cure or vaccine for HIV, prevention of infection is of paramount
importance. Universal precautions are a set of infection control practices, developed by
the Centers for Disease Control and Prevention (CDC), in order for all health care
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workers, teachers and other persons who may become exposed to blood-borne pathogens
to appropriately utilise barrier protection (gloves, gowns, masks, eyewear etc.) for
anticipated contact with blood and certain body fluids of all patients. HIV-1 is a blood
borne virus and transmission of HIV infection may occur via contact with any body fluids
of an infected individual which might contain virus particles or infected cells, such as
cerobrospinal fluid, peritoneal, pleural, pericardial fluids, semen, vaginal secretions, breast
milk and blood. Unfixed tissues, organs and any other body parts from HIV positive
patients are also included in this high-risk categorisation.
HIV-1 has been classified as a dangerous pathogen of the hazard group 3. All
work with live HIV-1 must be carried out within a specifically designed Containment
Laboratory. It is recommended that the growth and manipulation of HIV in research
laboratories must be carried out in Containment Level 3 facilities. Needle stick and
scalpel blade injuries with contaminsated blood are the major route of all laboratory based
infections. Special care must therefore be taken when dealing with all needles, blades,
scissors and syringes. Universal safety measures include wearing double gloves, a plastic
apron over a specific coat, and a disposable plastic cuffs being worn at all times. Chain
mail gloves between two layers of rubber gloves should be worn when handling cutting of
fresh tissues. A face shield is also required to protect the eyes and mouth from splashes.
All work involving blood tissue and body fluids from HIV-1 positive individuals, must be
undertaken in a Containment Level 3 laboratory using a Class 1 microbiological safety
cabinet. Unfixed high-risk specimens must not be exposed outside the Class 1 safety
cabinet. All work surfaces must be disinfected regularly with either 70% ethanol, 0.5%
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Nonidet, 0.5% Sodium hypochlorite or 1:1 ethanol/acetone. Regular autoclaving should
be enforced to decontaminsate experimental waste such as gowns, gloves and remaining
tissue residues, blood clots and small pieces of equipment. Fumigation is regularly carried
out for decontaminsating working spaces and larger pieces of equipment.
2.3 DETERMINATION OF INDIVIDUAL ABSOLUTE CELL COUNTS
Absolute cell counts were determinsed by flow cytometry in the HIV
Immmunology laboratory, The Royal Infirmary, Edinburgh. An Ortho Trio patient
summary report (Ortho-Clinical Diagnostics, Herts, UK) was produced illustrating the
CD3-positive T-cells, CD4-positive T-cells, CD8-positive T-cells, CD19-positive B cells,
CD16-positive, CD3-negative natural killer cells as cells per microlitre of whole blood.
The numbers of CD4 and CD8 memory and naive cells were determinsed using a panel of
antibodies against CD4, CD8, CD45RA (naive cells) and CD45RO (memory cells).
(FACS analysis was carried out by Helen Cerutti).
2.4 ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC).
Blood samples were diluted with an equal volume of Phospate buffered saline
(PBS) (GIBCO BRL, Paisley, UK) and peripheral blood mononuclear cells (PBMC) were
isolated by density centrifugation over a Ficoll-Hypaque gradient (Nycoprep, Nycomed).
10 mis of diluted whole blood were carefully layered over 3 mis of Nycoprep and
centrifuged at 2000rpm in Sorvall H-1000B for 30 mins with no brake. The denser red
blood cells pelleted while the less dense PBMCs and platelets remained on top of the
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Ficoll-Hypaque gradient. Plasma was collected at the top layer and stored in liquid
nitrogen for further use. The PBMC'c were collected and washed twice in 1 x PBS for 10
mins at 1400rpm in Sorvall H-1000B with the brake on. This ensured full removal of
leftover platelets and any remaining Ficoll-Hypaque gradient. Using a haemocytometer
and Trypan Blue exclusion all viable cells were counted. All PBMC's were then used for
subsequent T-cell separation protocols. There are two general approaches to magnetic
cell sorting: positive selection and depletion. Positive selection implies that the wanted
cells are labelled and isolated directly as the magnetic positive fraction. Depletion
involves labelling the unwanted cells thus eliminsating them from the desired fraction. In
this project a combination of depletion and positive selection was used. PBMC's were
initially separated into CD4+ and CD8+ lymphocytes by negative selection and then
further enriched by positive selection into the naive and memory subsets using the MACS
system (Miltenyi Biotec, Bergish-Gladbach, Germany).
2.4.1 Negative selection (depletion).
In this project a CD4+ T-cell Isolation Kit and a CD8+ T-cell Isolation kit were
used to obtain the CD4+ and CD8+ T-cells. The T-cell Isolation kits are individual
magnetic labeling systems for the isolation of untouched T-cells from peripheral blood. T-
helper cells, dendritic cells, monocytes, granulocytes, B cells, platelets, early erythroid
precursor cells and natural killer cells are labelled using a cocktail of hapten-modified
antibodies. All cells except the targetted CD4+ T-cells or the CD8+ T-cells are
magnetically labelled using Microbeads. Excellent recoveries of highly pure CD4+ cells
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and CD8+ cells are achieved by retaining the magnetically labelled non-CD4+ and non-
CD8+ cells on a depletion column while the non-labelled cells pass through. Both labelled
and non-labelled fractions can be completely recovered.
2.4.2 Positive selection.
The enriched CD4+ and CD8+ cells were positively selected to obtain the
CD45RA+ (Naive) and CD45RO+ (Memory) cells. The enriched fractions of CD4+ cells
and the CD8+ cells were directly labelled with antibody specific for CD45RO (anti-
CD45RO) cells. Microbeads were then added to the antibody labelled cells and they
were passed through a column. When the column was removed from the magnetic field,
the magnetically retained CD45RO+ cells are eluted. The depleted fraction was labelled
with anti-CD45RA and again the Microbeads were added to the antibody labelled cells.
When the column was removed from the magnetic field the CD45RA+ cells were eluted.
Cytotoxic T-cells and T-helper cells were isolated separately by incubating with a
cocktail of monoclonal antibodies directed against CD4 or CD8 (depending on which
subset is being isolated), CDllb, CD16, CD19, CD36 and CD56 (20pl per 107 cells)
followed by incubating on ice for 15 mins. Next, the antibody labelled cells were washed
and resuspended (lxlO7 cells/80p.l incubation buffer; PBS/2% inactivated foetal calf
serum (FCS)/5mM EDTA). Magnetic beads (20pl per lxl07 cells; Miltenyi Biotec) were
added to the cells and they were incubated for a further 15 mins on ice. After a final wash
the cells were resuspended in 500pJ incubation buffer. In order to remove the
magnetically labelled non-CD4+ and non-CD8+ cells, enrichment was performed with
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pre-washed BS+ depletion columns (capacity: lxl08 cells) and the VarioMACS magnet.
The magnetically labelled non-CD4+ and non-CD8+ cells were retained in the column
whilst the CD4+/CD8+ cells were washed through with 15ml of incubation buffer.
The CD4+ and CD8+ enriched T-cell fractions were then further selected for
CD45RA+ (Naive) and CD45RO+ (Memory) cells using directly labelled microbeads
(Miltenyi Biotec). CD4+ and CD8+ cells were stained with CD45RA and CD45RO
microbeads (20|il /lxl07 positive cells) for 15 mins at 4°C. After one washing step, cells
were resuspended in incubation buffer (400 pl/lxlO7 cells) and enrichment was performed
with a pre-washed MS+ positive selection column (capacity: lxlO7 cells) The positively
selected cells (RA+ /RO+) retained in the column were eluted by removing the column
from the magnet and washing with 1ml of incubation buffer.
Each isolated cell fraction was divided in two and frozen in liquid nitrogen. One
part was snap frozen as a cell pellet for DNA extractions while the other was resuspended
in 0.5 mis of freezing medium containing 90% RPMI and 10% DMSO (dimethyl
sulfoxide). This aliquot was frozen slowly over ice-cold ethanol (100%) and then stored
in liquid nitrogen. 1ml aliquots of plasma from each sample were also stored in liquid
nitrogen. In order to show that the cell separation procedure did not interfere with the
polymerase chain reaction (PCR), all separations were carried out in parallel with
PBMC's isolated from bufly coat leucocytes derived from HIV-negative blood (Regional
Blood Transfusion Service, Edinburgh).
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2.5 ANALYSIS OF THE PURITY OF ISOLATED SUBSETS BY FLOW
CYTOMETRY
The purity of the separated cell subsets was assessed from five HIV-1 negative
controls and one HIV-1 positive sample. Flow cytometry was carried out under the
supervision of Dr. Sarah Howie, Dept. of Pathology, University of Edinburgh. The
following combinations of monoclonal antibodies were used on lOOpl aliquots
(minsimum of lxl05 cells ) of each of the isolated cell suspensions; CD4+CD45RA+,
CD4+CD45RO+, CD8+CD45RA+ and CD8+CD45RO+ (lOpl per lxlO5 cells; 30mins at
4°C); (a) fluorescein conjugated (FITC) CD8, phycoerytherin (PE) CD3 and CyChrome
(Cy5-PE) CD4; (b) FITC CD45RA, PE CD45RO; (c) FITC rabbit anti mouse CD45RA,
PE CD45RO, Cy5 CD4; (d) FITC anti mouse CD45RO, PE-CD45RA, Cy5 CD4; (e)
FITC rabbit anti mouse CD45RA, PE CD45RO, Cy5 CD8; (f) FITC anti mouse
CD45RO, PE-CD45RA, Cy5 CD8 (DAKO, Glostrup, Denmark). Next, cells were
washed twice in PBS with 2% FCS to remove any unbound antibody and fixed in 200ul
2% formalin for FACS analysis. The purity of the isolated CD4+CD45RA+,
CD4+CD45RO+, CD8+CD45RA+ and CD8+CD45RO+ cell populations was assessed
by FACS (Fluorescent Activated Cell Sorter) on a Coulter Epics Elite after gating on live
lymphocytes based on a standard light scatter histogram.
2.6 EXTRACTION OF DNA FROM CELL SUBSETS
DNA was extracted from PBMC or specific subsets of PBMC's by incubating the
cells at 37°C for 20 mins with 400pl of lysis buffer (0.11M sodium chloride, 55mM Tris
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pH8, l.lmM EDTA pH8, lmg/mL proteinase K, 0.55% sodium dodecyl sulphate (BDH
laboratory Supplies, Poole, UK) and 40pl p.g/mL poly A). The lysed cells were then
shaken vigorously for 5 mins with 450pl of water saturated with phenol (Rathburn
Biochemicals, Walkerburn, UK) and spun for 5 mins at 15,000rpm (14000xg) (Heraeus
benchtop centrifuge). The upper aqueous layer was transferred to a fresh Eppendorf
containing 450^1 of chloroform/iso-amyl alcohol (50:1) (BDH laboratory supplies). The
centrifugation step was repeated and the extracted DNA contained within the upper
aqueous layer was then mixed with 0.1 volume of 3M sodium acetate (pH5.2) (Sigma)
and 800pl of ethanol (-20°C) (Rathburn Biochemicals). After thorough mixing the DNA
was left to precipitate overnight at -20°C and then centrifiiged for 20mins at 15,000rpm
in Sorvall H - 1000B. After washing once with 80% (v/v) ethanol the DNA was left to
dry at 42°C for 15mins. The nucleic acid was re-dissolved in 25pl nuclease-free water
and left for lOmins before using in any further reaction to ensure the entire pellet is
dissolved.
2.6.1 PCR Quantification
HIV virus and cDNA were quantified by a limiting dilution nested PCR
(Simmonds et al 1990). The first and second round PCR were firstly subjected to a
thermal cycle of 18 seconds at 94°C to allow denaturation of the dsDNA, 21 seconds at
50°C to allow the primers to anneal to the ssDNA, and 72°C for 1.5 mins to allow strand
extension. Each template strand was allowed 25 cycles of amplification. At the end of the
last cycle samples were heated to 72°C for 6 mins to allow terminsation of uncompleted
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strands. The initial (primary) PCR was carried out in a 50pi volume, containing DNA in
an adjusted volume of lpl, 5pl of 10 x PCR buffer (50mM KCI, lOmM Tris-HCL, pH
9.0, Triton X-100 and 1.5mM MgCl2), 30pM each of dGTP, dATP, dTTP and dCTP,
0.25pl of sense primer (approximately 20pM), 0.25pl of antisense primer (approximately
20pM), 42pl of pyrogen-free water and lpl of Taq polymerase (lpl is equal to 5 units).
The second, nested PCR was carried out in a 20pl volume, for each sample, containing
lpl of primary PCR product, 2pi of 10 x PCR buffer, 0.2pls of dNTP's, 0.1 pi of sense
primer (approximately x 8 pM), 0.1 pi of antisense primer (approximately x 8 pM),
15.6pl of pyrogen-free water and 0.4 units of Taq polymerase (Promega). Prior to
transfer to the thermal cycler each sample was covered with a drop of minseral oil to
prevent loss of sample due to evaporation. Quantification was performed using primers
spanning the V1/V2 and V3 region. The nucleotide sequences of the primers and the
position of the 5' base in the HXB2 genome (Myers et al 1993) are given in table 2.2.
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Table 2.2: Primer sequences
Primer Sequence (5'-3') Position of 5' base
V1/V2 5'- ATTGTACTGTGCTGACAT T-3' (-6944)
V1/V2 5'- CAATAATGTATGGGAATT GG-3' (-6857)
V1/V2 5'- GA TCAAAGCCTAAAGCCATG-3' (+6560)
V1/V2 5'- GAGGATATAATCAGTTTATGG-3' (+3539)
V3 5' - TACAATGTACACATGGAATT-3' (+6957)
V3 5'- TGGCAGTCTAGCAGAAGAAG-3' (+7009)
V3 5'- CTGGGTCCCCTCCTGAGG-3' (-7331)
V3 5' - ATTACAGTAGAAAATTCCCC-3' (-7381)
After preliminsary quantifications using serial ten fold dilutions of DNA and
subsequently (using V3 primers), on two-fold dilutions in triplicate around the end-point,
between 8 and 10 replicates were then carried out at the end-point in order to accurately
determinse the virus load. The end point was taken as the lowest dilution with at least one
positive replicate. All separations, extractions and amplifications were carried out with
parallel samples of PBMC's isolated from buffy coat leukocytes derived from HIV-
negative blood to serve as negative controls.
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2.6.2 Visualization of amplified PCR products
Amplified PCR products were visualized on 2% Agarose gels containing ethidium
bromide. Ethidium bromide is an intercalating agent which exhibits fluorescence under
UV light, allowing any positive PCR products to be detected as fluorescent bands. The
gel was run for 10-15mins at 150V and analysed under UV light.
2.7 CLONING OF THE PCR PRODUCTS
Amplified DNA was ligated into a plasmid vector prior to nucleotide sequencing
using 50ng of the pGEM-T Vector System (Promega, UK). 20pl of PCR product and
3Weiss units/pl of T4 DNA ligase (Promega). After overnight incubation at 4°C, the
ligation product was used to transform JM109 competent T-cells (Promega) and plated
on L-Agar plates (200gg/ml Ampicillin). Cloned PCR products were analysed by PCR
amplification of the cloned insert using primers complementary to the plasmid sequences
flanking the polylinker, which were also used for the sequencing of the cloned inserts.
Next, the plasmid DNA was denatured by incubating with 1/10 volume of 2M sodium
hydroxide/2mM EDTA at 37°C for 30 mins. DNA was precipitated by adding 1/10
volume of 3M sodium acetate/2 volumes of ethanol and incubating at -20°C overnight.
DNA was collected by pelleting at 13K for 10 mins.
98
2.8 DNA SEQUENCING OF PCR PRODUCT
2.8.1 Solid-phase sequencing
Dideoxynucleotide sequencing was carried out using the Sequenase Version 2.0
DNA sequencing kit (United States Biochemical) with Sequenase Version 2.0 T7 DNA
polymerase (Amersham). For each template strand of ssDNA a single annealing reaction
was used to allow the primer strand to bind to the ssDNA. For each template, 2pl of the
appropriate primer, 2pi of 5x Sequenase reaction buffer, 1 pi of dimethylsulfoxide
(DMSO) and 5 pi of the cloned DNA were pipetted into an Eppendorf tube and placed in
a heating block. The PCR parameters were one cycle at 65°C for five mins after which
the mixture was allowed to cool slowly to room temperature over the next 30 mins.
During this time 2.2pl of the appropriate dideoxy terminsation mixture were added to a
microtitre plate containing wells labelled G, A, T, and C for each sample. This was then
incubated at 37°C in a water bath. To each annealed template-primer the following
extension (labelling) mix was added: 2pl of diluted labelling mix (1/20), lpl of
Dithiothreitol (DTT, 0.1M), 0.5pl of [a-l5S] dATP and 2pl Sequenase polymerase (1:8,
approximately 3.25 units). After thorough mixing, 3.5pl of the annealing reaction and
extension mix was added to the corresponding wells containing the terminsation mix and
incubated for approximately 5 mins at 37°C . Next, 4pl of stop solution (95% formamide,
20mM EDTA, 0.05% Bromophenol blue, and 0.05% xylene cyanol FF) was added to
each terminsation reaction stopping the terminsation reaction. The plate was heated to
95°C for denaturation prior to loading on a 6% acrylamide gel. The gel mix was made up
of the following: 21g urea (AnalaR), 6 mis of sequagel XR concentrate, 5mls lOx TBE
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(0.089 M Tris, 0.089 M Boric acid, 0.02 M EDTA), 0.05g ammonium persulphate
(Sigma) and 20pl TeMed (Sigma). The gel mix was then dissolved in a final volume of
50mls with distilled water. The gel was poured between clean glass plates and left to
polymerise for 1 hour. The gel was then pre-run at 70 volts for 10 mins using lx TBE as
the electrophoresis buffer after which it was run for 1-2 hrs at 75 volts allowing
approximately 300 bases to be read. The gel was then fixed, dried and developed on
BioMAX film overnight after which the bands were analysed.
2.8.2 Cycle sequencing
Direct sequencing of PCR products uses double-stranded product directly as a
template for sequence analysis of either strand. Cycle sequencing involves repeated cycles
of thermal denaturation, primer annealing and polymerization to produce a greater
amount ofproduct in a DNA sequencing reaction. Internal primers used in the preceeding
PCR were used to initiate the sequencing reaction. This amplification employs a single
primer so the amount of product DNA increases linearly with the number of cycles. The
first step in sequencing PCR products consists of treating the PCR sample with a
combination of lpl of shrimp phosphatase and lp.1 exonuclease per sample. This mixture
is incubated at 37°C first, followed by 15mins at 80°C. This process removes
phosphatases from the ends of PCR products and forms blunt ends before the sequencing
process starts. Preparation of the terminsation mix involves adding 2pl of the nucleotide
dGTP master mix to 0.5pl of each a-33p ddNTP (G, A, T, or C - one of each per
sequence). Four tubes are labelled ('G', 'A', 'T' and 'C') and 2.5pl of each terminsation
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mix was added. 4.5pl of the reaction mix (2pl of reaction buffer, 3(il of DNA, 0.5pl of
primer, 12.5pl ofH20 and 2pi of Thermo Sequenase polymerase) was transferred to each
terminsation tube ('G', 'A', 'T' and 'C'), mixed well and covered with 10pi of oil. The
cycling program parameters involved denaturating at 94°C for 30 sees, 55°C annealing
for 30 sees and an extension temperature of 72°C for 1 mins. This was repeated for 30
cycles. Next, 6pl of each terminsation reaction was transfered to a fresh tube containing
4pl of stop solution. Samples were then heated to 95°C for 2mins and loaded
immediately on to a sequencing gel. Gels were run, fixed and developed on BioMAX film
overnight.
2.8.3 Extraction of plasma RNA
RNAases are difficult to inactivate and only minsute amounts are sufficient to
destroy RNA. Therefore, it was necessary to create a Ribonuclease-ffee environment.
This was achieved by using proper microbiological aseptic techniques, latex gloves,
sterile reagents, plastics and utensils. The laboratory area used was first treated with
RNAase away (Molecular Bio-Products Inc, San Diego, U.S.A). In order to avoid co-
purification of DNA, plasma samples were filtered with a 0.2pM filter before use. RNA
was extracted from three patient plasma samples using the Qiagen RNA extraction kit
according to the manufactuers instructions (Qiagen, UK). Buffer solutions were prepared
and used in accordance with the volume of plasma RNA being extracted.
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2.8.4 RT-PCR
RT-PCR is a technique which couples reverse transcription (RT) of an RNA
template with PCR amplification. RT-PCR is a sensitive and versatile method which can
be used to determinse the presence of a transcript, to estimate expression levels and to
clone cDNA products. RNA was detected by the Access RT-PCR System (Promega)
which was designed to incorporate RT and PCR in one amplification in one reaction step.
The reaction mix was prepared as follows: lx AMV/T/z (Thermns flavus) buffer, 0.2mM
of each dNTP (dATP, dCTP, dGTP and dCTP), ImM outer sense and anti-sense primers,
ImM MgSC>4, O.lU/pl AMV-RT, 0.1U/pl Tfi DNA polymerase and lOpl RNA. This was
made up to a final volume of 50pi with nuclease-free water. Positive control RNA,
primers and a negative control were also supplied. The Tfi polymerase is a thermostable
DNA polymerase from Thermus flavus. The RT-PCR reaction conditions are shown in
Table 2.3.






























lpl of primary product was used in a secondary reaction and the product was visualised
on a 2% Agarose gel stained with ethidium bromide. See section 2.x (Gel Visualisation).
2.9 IMMUNOSTAINING TECHNIQUES
Cell medium was prepared using sterile instruments and a sterile still air cabinet. It
was prepared as follows: 100 mis of RPMI 1640 (GIBCO BRL), 10 mis of heat
inactivated FCS (GIBCO BRL), 1% streptomycin (GIBCO BRL), 1% pencillin (GIBCO
BRL), 1% L-glutaminse (GIBCO BRL), 300pl phytohaemaglutinin (Murex, Dartford,
UK) and lOOpl interleukin-2 (IL-2) (MRC, NIBSC). PBMC's were isolated by Ficoll-
Hypaque centrifugation as described earlier from a HIV-1 negative whole blood pack
supplied by the Regional Blood Transfusion service. The cells were washed and
resuspended in complete RPMI (lml/106 cells). After incubation for 72 hours at 37°C in a
plastic cell culture flask, the cells were passaged and more medium was added to the new
flasks of cells.
Viral SI and NSI isolates came from two patient isolates (23 and 36 - SI and NSI
respectively). These isolates were originally cultured in the PBMC's for three days and
the viral supernatant was stored in 5ml aliquots in the -70°C freezer. Once defrosted
these 5ml aliquots of SI and NSI isolates were placed in individual 10ml culture flasks
containing 5mls of fresh PBMC'S. They were subsequently grown up at 37°C for 3-5
days. These procedures were carried out in a Category 3 area with a sterile still air flow
cabinet, plastic pipettes and autoclaved tips.
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2.9.1 Monoclonal ABC procedure
Slides of infected and uninfected cells were prepared once the presence of cells
and syncytia were viewed in the culture flasks. Once syncytia had formed, 5ml aliquots
from each flask (uninfected control cells, SI and NSI infected) were taken out and
washed twice with lOmls of lx PBS. They were centrifuged for 5 minsutes at 2000rpm in
Sorvall H-1000B with the brake on. The pellet was then resuspended in 2ml of lx PBS.
Next, 20pl suspensions of liquid were spotted on to each well of a 12 well multispot
microscopic slide (Hendley-Essex). The slides were dried in the Category 3 cabinet and
once dry they were immersed in ice-cold acetone (Merck, BDH) to permeabilize the cell
membranes. The slides were then rinsed and washed in Tris Buffered Saline (TBS)
(AnalaR) to remove any excess acetone. They were then blocked for any non-specific
staining with normal serum. The normal serum used in each experiment was determinsed
by the species of the secondary antibody e.g. if the secondary antibody was rabbit anti-
mouse, normal rabbit serum was used. CD4 and CD8 monoclonal antibodies were
supplied by SAPU and were incubated on the slides for 30 minsutes at 37°C.
After washing the slides twice in lx TBS they were then incubated in a
Biotinylated secondary antibody (rabbit anti-mouse, DAKO) for 30 minsutes at 37°C so
that it would bind to the primary antibody. At this stage the AB (Avidin-Biotin) Complex
(DAKO) was prepared according to the manufacturer's protocol. Next, the antibody was
rinsed off and the slide was washed twice in lx TBS. Excess buffer was washed off and
the AB Complex was applied to the slide for 30 mins at 37°C.
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The fast red/fast blue complex (Sigma, UK) was prepared using powdered forms
of fast red, fast blue with Napthol AS MX phospate (Sigma, UK) and N,N
dimethylformamide (Sigma, UK) and Tris buffer (pH 8.2) (AnalaR). The slides were
incubated with this complex for 30 minsutes at 37°C and then rinsed in water, dried,
mounted (with 50% PBS in glycerol) and viewed under the light microscope. Double
label stains were prepared on the same wells of the slide by simply subjecting the cells to
a different monoclonal antibody and a different colour complex, for example; CD4
monoclonal with fast red and CD8 with fast blue on a single well or CD8 monoclonal
with a p24 monoclonal (Dupont) in conjunction with either Diaminsobenzidine or FITC
(Sigma, UK). Triple label incubations were tried with a p24 monoclonal antibody using
the same monoclonal ABC procedure.
2.10 IN-SITU PCR
Brain, lymph nodes and spleen tissue sections were obtained at autopsy between
24 and 48 h after death from individuals with HIV-1 who had died of AIDS related
conditions. These organs were fixed in 10% formalin for 2-3 weeks, sliced for
examinsation and selected tissue blocks were then processed in a tissue-tek VIP (Miles
Scientific) before paraffin embedding. Five prn sections of frontal lobe tissue were floated
onto aminso alkylsilane-coated in situ PCR glass slides (Perkin Elmer) and incubated at
55-60 °C for 36-48 h. The presence of HIV-1 in the selected tissues was confirmed by
tube PCR using primers to the gag region ofHIV-1, GE1 and GE2, which were also used
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in the in situ PCR, and by immunohistochemistry for HIV-1 p24 antigen. Control tissue
was taken from lymph node and spleen uninfected with HIV-1.
2.10.1 Pretreatments of tissue sections.
The sections were deparaffinised in xylene for 30 mins at 37 °C and then two
further xylene treatments of 10 mins each at room temperature. Tissue sections were
placed in 100% ethanol for 10 mins and then rehydrated through 75, 50 and 25% ethanol
(5 mins each) to fresh molecular grade water (Sigma) for 5 mins. Next, sections were
incubated in 0.02 M HCL for 10 mins and then rinsed in PBS. The slides were then
immersed in 0.01% Triton X-100 (Boehringer Mannheim) preheated to 40 °C for 90s and
then washed in PBS. The slides were transferred to a humidified chamber and treated
with 10 pg/ml proteinase K (GibcoBrl) in 0.1 M HCL pH 7.5, 5 mM EDTA for 10 mins
at 55 and 37 °C for 20 mins. The tissue sections were then placed in a staining rack in a
plastic container containing 500 ml of 0.01 M citric acid buffer ph 6.0 and microwave
irradiated at full power in a 600 W microwave oven for 10 mins. The slides were
removed from the oven and incubated in 20% acetic acid at 4 °C for 15 s and then rinsed
in water for 2 x 5 mins and in PBS for 5 mins. Tissue sections were fixed in
paraformaldehyde made in PBS for 5 mins and then rinsed in PBS for 2 x 5 mins and
water for 5 mins. The slides were then dehydrated through graded alcohols 25, 50 and
75% for 2 mins each and then stored in 100% ethanol until required for in situ PCR.
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2.10.2 In-situ PCR
In-situ PCR was performed using a solution that contained 100 pmol of each
HIV-1 Gag primer GE1 5'GAAGGAGCCACCCCACAAGATT; and GE2
5'TAGGTGGATTATTTGTCATCCA which hybridised to positions 1317-1337 and
1553-1554 of the HX13 2 prototype sequence (Oswell DNA), 1.2 pi of a 1:10 dilution of
50 nmol stock of Biotin-16-dUTP (Boehringer Mannheim), and the following reagents
which are part of the GeneAmp in situ PCR core kit (Perkin Elmer), 200 pM of each
dNTP, 10 x PCR buffer, 4.5 mM MgC12, and 10 units of AmpliTaq DNA polymerase, IS.
The tissue sections were removed from 100% ethanol and allowed to air dry
completely. A slide was placed on the assembly tool (Perkin Elmer) preheated to 70 °C to
facilitate a hot start and 50 pi of reaction mix was enclosed onto the section with a clip
and a silicon rubber disc. The slide was then placed in the in-situ PCR machine (Perkin
Elmer) and held at 70 °C until all slides were in place. The in-situ PCR was performed
using the following conditions, 94 °C for 2 mins 30s and 55 °C for 1 mins 30 s for 1
cycle, 94 °C for 55 s and 55 °C for 45 s, for 30 cycles. Controls included reactions
without primers to demonstrate that DNA repair was not creating false positives, a
reaction containing just one HIV-1 gag primer (GE1) and an irrelevant primer to
demonstrate that a prins type amplification was not evident, a reaction without TAQ
polymerase and a reaction without Biotin dUTP. A positive control for in-situ
amplification with b-globin primers 5' ACACAACTGTGTTCACTAGC and 5'
CAACTTCATCCACGTTCACC was also carried out.
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2.10.2 Post in situ PCR treatment
The slides were removed from the in situ PCR machine and washed in 2 x saline
sodium citrate (SSC) for 2 mins and in PBS for 2 mins. The sections were then post-fixed
in fresh 4% paraformaldehyde made in PBS for 5 mins and then washed in PBS for 3 x 5
mins.
2.10.3 Detection of in situ PCR product by tyramide signal amplification (TSA).
The tissue sections were washed in water for 2 mins and endogenous peroxidase
was quenched by treatment with 3 % aqueous H2O2 (BDH) for 10 mins. The slides were
then washed in water for 2 mins and in TBS buffer for 2 mins before being attached to
disposable immunostaining chambers (Shandon) and then placed in a SEQUENZA
immunostainer (Shandon). The sections were washed for 3 x 5 mins with TNT buffer (0.1
M Tris-HCL pH 7.5, 0.15 M NaCl, 0.05% Tween-20) and then incubated in 300pl of
TNB buffer (0.01 M Tris-HCL pH 7.5, 0.15 M NaCl, 0.5% DuPont blocking reagent) for
30 mins. One hundred pi of StreptAvidin-HRP diluted 1:500 in TNB buffer was applied
and the sections were incubated for 30 mins at room temperature. The sections were then
washed in TNT buffer for 3 x 5 mins and lOOpl in Biotinyl tyramide (diluted 1:50 in
amplification buffer) was added and the tissues were incubated for 10 mins at room
temperature. The slides were washed in TNT buffer for 3 x 5 mins and lOOpl of
streptAvidin-HRP or streptAvidin-Texas red (diluted 1:500 in TNB buffer) was applied
and incubated for 30 mins at room temperature. The sections were washed in TNT buffer
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for 3 x 5 mins. Chromogenic substrate (diaminsobenzidine; Vector) was then applied to
each section and monitored between 3 and 5 mins until the colour fully developed.
2.10.4 Diffusion of in situ PCR amplicons.
To ensure that the positive in situ PCR signal was not due to diffusion of
amplified DNA to an uninfected cell, the post in situ PCR amplification solution was run
on a 2 % agarose gel with molecular weight markers and stained with ethidium bromide.
An aliquot of the post in situ PCR solution was also subjected to nested PCR using
primers Gil 5'TGCTAAACACAGTGGGGGGA; and GI2
5'CCTGAAGGGTACTAGTAGTT which hybridised to positions 1346-1365 and 1521-
1540 of the HX13 2 prototype sequence.
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CHAPTER THREE: INTRODUCTION
3.1 MECHANSIMS OF CD4 T-CELL LOSS
The progression of human immunodeficiency type 1 (HIV-1) infection is clearly
associated with an increase in the viral load in plasma and a progressive depletion of
CD4+ T-cells. One explanation for this depletion is the exhaustion of T-cell turnover,
which must occur at a very high rate to replace the CD4+ lymphocytes permanently
destroyed during HIV infection. The mechanisms for T-cell depletion during HIV
infection are more complex than originally thought. The depletion observed in the blood
compartment may result from a combination of cell destruction in lymph nodes and
inflamed tissues or it could be due to a failure of T-cell regeneration in primary lymphoid
organs such as the thymus (Chene et al., 1999). Some observations have suggested that
HIV-1 infection causes major destruction to this organ and is also associated with a
profound disorganisation of the epithelial network (Rosenzweig et al., 1993). This
deterioration was also confirmed by the inability to restore thymopoiesis in infected
thymuses from SCID-hu mice treated with HAART (Wilthers-Ward et al., 1997). It has
been suggested that age-related involution may also affect the ability of the thymus to
reconstitute T-cells expressing CD4 cell-surface antigens that are lost during HIV
infection (Pantaleo et al., 1993). Antiretroviral therapies reverse the loss of naive cells to
an extent through expansion of pre-existing cells and thymic production of new cells.
However, this recovery is poor and it has been suggested to be the result of severely
impaired T -cell progenitors (Hengel et al., 1999).
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Theories about the causes of the observed loss of CD4 cells range from direct
destruction or dysfunction by cytopathic infection with HIV-1 to apoptosis resulting from
defects in antigen presentation (Levy et al., 1993). Apoptotic cell death of CD4 + T-cells
occurs through the activation of a complex cell-intrinsic suicide program. Apoptosis plays
a major role during development, homeostasis and in many disease including cancer,
AIDS and the neurodegenerative disorders (Stellar et al., 1995). HIV can cause direct
cytopathic events in activated CD4+ T-cells in culture, either in single cells or by
synctium induction. The cytopathic effect of HIV in CD4 T-cell cultures, manifested by
ballooning of cells and formation of syncytia, was shown to be associated with apoptosis.
Syncytia are giant multi-nucleated cells and may include as many as 500 CD4 expressing
cells. These syncytia produce virus for a short time after which they die. By incorporating
non-infected cells into syncytia, a single gpl60 expressing cell can eliminsate many
uninfected CD4 cells. This apoptosis event is a late process occurring when cells are
actively involved in the synthesis of viral proteins (Laurentcrawford et al., 1993; Weiss,
1993).
3.2 REASONS AND MECHANISMS FOR HIV-INDUCED CELL KILLING
HIV-1 can be generally grouped into three clinical phases (i) the acute infection
period, which in some ways presents similarly to a mononucleosis-like syndrome: (ii) an
asymptomatic period of variable duration where initial bursts in viremia fall dramactically,
often as much as 10-100 fold: (iii) the period of clinical disease during which multiple
opportunistic infections and neoplasms are manifested. Recent estimates of virus
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production are of the order of >109 virions per day, and complete turnover of CD4+ cells
occurs in about 2 days (Bonhoeffer et al., 1995; Ho et al., 1995; Wei et al., 1995).
Uninfected individuals show a mean level of 1100 CD4 T-cells/pl whole blood, while
individuals with AIDS can sometimes have CD4 T-cell counts less than 1/pl.. This
represents an enormous replicative capacity and, together with the error prone reverse
transcriptase, contributes to the tremendous diversity of HIV. This diversity surely leads
to competition for survival, the main driving force of Darwinian selection, and the
consequent evolution of viruses that are best adapted to their changing environment. The
success of HIV in establishing chronic disease and in promoting a slow but progressive
deterioration of the different components of the immune response is somewhat difficult to
explain. Potent virus-specific cell-mediated and humoral immune responses can already be
detected during the early days of primary HIV infection, and can persist for years without
either preventing the establishment of chronic infection or blocking HIV disease
progression (Soudeyns et al., 1999).
During mucosal infection, HIV primarily targets Langerhans cells (LCs) and or
tissue macrophages (Zaitseva et al., 1997). As part of the physical process of antigen
processing and presentation, LC's carrying HTV migrate towards the T-cell areas of
lymphoid tissue. Hence, macrophage tropic (R5) and T-cell tropic (X4) strains of HIV
are directly carried to the site where immune responses are generated. Importantly, R5
and X4 viral envelope can mediate biologically relevant transmembrane signals to CD4
T-cells. In the case of R5 envelope, this interaction results in activation and chemotaxis of
these cells. The active recruitment of susceptible target T-cells to the site of initial virus
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localisation certainly leads to rapid spreading and amplification of HIV infection. As well
as the rapid spreading of the virus, the strategies of establishing chronic infection are
already operative, with the formation of a pool of latently infected CD4 T-cells
containing replication-competent HIV proviral DNA. This enables HIV to establish viral
latency before the appearance of an HIV-specific immune response in the host.
Furthermore, these latently infected CD4 T-cells constitute a stable viral reservoir in
which HIV remains sheltered from the effects of host immune response and anti-retroviral
therapy (Chun et al., 1997; Chun et al., 1998). HIV-specific CD4+ T-cell proliferative
responses are rapidly lost during primary HIV infection, as a result of direct and/or
indirect virus induced cytopathology. These include accumulation of nonintegrated
circular DNA copies of the genome, increased permeability of the plasma membrane, and
synctium formation. Preservation of virus-specific CD4+ responses have been shown to
be dependent upon the time of initiation of anti-retroviral therapy at the time of primary
infection (Rosenburg et al., 1997). Although viral load increases with disease
progression, direct killing of CD4+ lymphocytes by HIV most probably cannot account
for the magnitude of the loss of these cells during the course ofHIV infection.
Other cell types of the hematopoietic system are also susceptible to infection by
the virus, particularly macrophages although they produce low levels of HIV and
sequester virus in intracellular vacuoles. Stem cells, monocytes, B-lymphocytes,
megakaryocytes, natural killer (NK) cells, eosinophils, thymic epithelial cells and dendritic
cells are all the other hematopoietic cells known to be infected (reviewed in Levy, 1998).
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3.3 T-LYMPHOCYTE RESPONSES IN HIV-1 INFECTION.
Several observations have associated cell death with direct toxicity from the virus
or viral envelope proteins (Levy et ah, 1993). Ayyavoo et al and Zauli et al showed that
several HIV gene products could induce or modulate T-cell apoptosis through
dysregulation of intracellular signalling pathways, leading to depletion and functional
impairment of CD4+ and CD8+ T-cells (Ayyavoo et ah, 1997; Zauli et ah, 1999). These
apoptotic pathways could be mediated either directly by virus replication as a
consequence of viral gene expression, or indirectly through priminsg of uninfected cells to
apoptosis when triggered by different agents. Tat, a viral transcriptional factor, was
shown to affect transcription of genes involved in cell survival. In recent studies, Tat
alone was insufficient to induce apoptosis but it appeared to sensitize cells to apoptosis
by triggering a second signal, such as CD95 or T-cell receptor (TCR) signalling (Li et ah,
1995). The Vpr gene was also recently found to induce apoptosis (WithersWard et ah,
1997). Vpr is required for productive infection of non-dividing cells and it was shown to
induce arrest of cells in the G2 phase of the cell cycle (Bartz et ah, 1996). Following the
arrest of cells in the G2, Vpr induces apoptosis in human T-cells, peripheral blood
lymphocytes and fibroblasts. In addition to these pathways, a complementary cytopathic
effect is provided by the immune system, since infected cells may be killed by HIV-
specific CTLs or antibody-dependent T-cell-mediated cytotoxicity (ADCC) (Gougeon et
ah, 1996).
A phenotypic study of apoptotic cells on a large cohort of HIV-positive patients
revealed that not only T-cells but all mononuclear cells, including B cells, natural killer
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cells, granulocytes and monocytes, have an increased fragility upon short-term culture
(Gougeon et al., 1996). Recent analyses of lymph nodes from patients demonstrated that
apoptosis occurred in vivo and was detected not only in CD4 but also in CD8, B cells and
dendritic cells (Amendola et al., 1996).
Moreover, the cell fusion that often leads to cell death has been associated with
gpl20. The ability of HIV to kill the target T-cell correlates with the amount of CD4
expressed by the cell. The gpl20 binds tightly to CD4, can prevent its cell surface
expression and immunological function and promotes cell-cell fusion leading to cell lysis.
Addition of gpl20 to peripheral blood mononuclear cells (PBMC) or cultured brain cells
caused cell killing in a dose-dependant manner. Changes in the N-linked glycosylation
sequences of gpl20 produce a cytopathic variant. Only a small proportion of circulating
T-cells actively express HIV in vivo, indicating that the killing of single infected cells is
unlikely to account solely for the profound immunodeficiency associated with this
disease. Therefore, HIV may indirectly alter the immunological competence of
noninfected CD4+ T-cells. In this context, gpl20 and MHC II compete for a distinct but
overlapping binding site on CD4. In addition, the CD4 and MHC II interaction is
considerably weaker than CD4 and gpl20. It is thus likely that gpl20 can displace MHC
II interactions with CD4. Binding of soluble gpl20 on the surface of noninfected CD4+
cells can thus render them unable to participate in immunological responses against a
variety of pathogens, including HTV-1. Binding of purified gpl20 to CD4+ T-cells can
not only deliver intracellular signals that inhibit subsequent T-cell proliferation but it can
also transduce inhibitory signals that lead to T-cell anergy characterised by resistence to
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subsequent T-cell activation. The ability of gpl20 to induce CD4 internalization may
involve mechanisms whereby noninfected T-cells which have cell-surface CD4-gpl20
complexes are targetted for destruction by cytotoxic cells (Bour et al., 1995).
Regulation of cell survival and death is essential for T-cell homeostasis during
precursor cell development and terminsation of an immune response in the periphery. The
blind homeostatis hypothesis states that only T-cell levels, regardless of CD4 or CD8
phenotype are regulated in the peripheral blood and peripheral lymphoid tissues.
According to this hypothesis, as CD4+ T-cell numbers decrease, peripheral CD8+ T-cell
numbers increase. This homeostatic mechanism is maintained for long periods after HIV-
1 infection is established but is lost in the last two years preceeding AIDS (Margolick et
al., 1996). The observed depletion of T-cells may result from a combination of trapping
of these cells in lymph nodes and inflamed tissues, as well as a failure of mature T-cell
regeneration in primary lymphoid organs and in particular, the thymus (Chene et al.,
1999). T-cell development can occur via extrathymic pathways but generation of the
mature T-cell repertoire that is required for immune system function is dependent on tf^e
thymus. HIV infection is accompanied by a decrease in thymic function. T-cell
progenitors in the thymus or peripheral pools may be infected with HIV and therefore fail
to proliferate and replenish the mature T-helper cell population.
3.3.1 Failure of CTLs
It is generally held that a progressive decline in HIV-specific cytolytic activity
occurs in parallel with the development of HIV-related disease, so that it is rare to be able
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to demonstrate HIV-specific CTLs in patients with fullblown AIDS. Such decline may be
due to a general impairment of CD8+ cell cytolytic activity through lack of CD4+ T-cell
help.
Another possible cause of progressive infection is the specific or nonspecific loss
of CTLs over time. Even with a vigorous virus-specific CD8 response there is still the
persistence of HIV viremia, and high levels of CTL activity to HIV peptides does not
prevent the development of disease. In acute infection, CTL responses have been linked
to the development of viral sequence variation within the targetted epitope; disease
progression has also been observed coincident with the emergence of CTL-escape
variants in vivo (Borrow et al., 1997; Richard et al., 1993). The possibility that CTL
function may also be impaired in vivo may help to reconcile observations that class I
restricted CTL clones can persist at high precursor frequencies in adults for many years
without achieving immunologic control (Kalams et al., 1994; Moss et al., 1995). HIV-1
Tat and Nef proteins have also been shown to downregulate HLA class I expression, and
thus allowed the virus to escape T-cell recognition (Collins et al., 1998; Weissman et al.,
1998). The loss of immune function may contribute to the rapid fall in lymphocytes
observed as an individual approaches AIDS (CD4< 200/pl).
Additional mechanisms for CD8+ cell impairment and deletion have been
proposed: antigen presentation on B cells has been described to have the potential for
direct tolerization of CTL responses and macrophages seem to be responsible for the
induction of apoptosis of CD8+ cells by triggering TNF receptor II signalling after
interaction with HIV gpl20 (Brander et al., 1999).
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3.3.2 Effects of HIV-1 infection on CD8 T-cell function
Despite the broad spectrum of HIV-1 targets, the mechanisms by which the virus
interacts with and affects CD8 T-cells as well as the pattern of infection (latent vs
productive) have yet to be established. CD8+ T-cell infection has been previosuly
described for several in vitro and in vivo in animal models (Stanley et al., 1993). While
CD4 lymphocytes are considered to be the principal target HIV-1 (refer to section 1.4.2 a
number of more recent studies have shown the in vivo infection of other lymphoid cell
types including CD8 T lymphocytes (DeMaria A et al., 1994; Flamand et al., 1998;
Livingstone et al., 1996; Mercure et al., 1993; Yang et al., 1998). CD8+ T-cells are a
major immunological defence against HIV-1 infection. In most individuals, HIV mediates
a strong specific cytotoxic activity that eliminsates productively infected cells. This
response also blocks intracellular viral replication in CD4+ cells by production and
secretion of a number of soluble inhibitory factors such as macrophage inflammatory
protein (MIP) -la, MIP-ip, RANTES, IL-16 and as yet other unidentifiable factors
(Haynes et al., 1996; McMichael et al., 1998). During the course of infection, there is a
gradual loss of CD4+ cells; after an initial increase in the number of cytotoxic T-cells, the
CD8+ cell number similarly falls during disease progression (Levy et al., 1993). The
observed decline in both the number of CD8+ cells and specific HIV cytotoxic activity
coincides with an increase in viral load and may ultimately be a contributory factor to the
eventual collapse of the immune system and the development of AIDS.
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The clinical significance and ability of HIV-1 to infect peripheral blood
mononuclear cells other that CD4 T lymphocytes in vivo is controversial. Livingstone et
al, previously reported that CD8+ cells accounted for the majority of the proviral load
amongst PBMC's of individuals with advanced HIV-related disease. One of the factors
contributing to the high frequency of CD8-positive lymphocytes occurring only in late-
stage disease is the loss of CD4 T-cell population from the circulation. On the other hand,
a substantial increase in CD8 T-cell infection on disease progression may possibly be
related to the phenomenon by which HIV-1 spreads to non-lymphoid tissues during the
later stage of disease with loss of immune control (Livingstone et al., 1996). The exact
mechanisms leading to CD8 T-cell dysfunction and depletion are still unclear. CD8 T-
cell function may be indirectly influenced by a defective HIV-1 specific CD4 T-helper
response that is necessary for the maturation and function of cytotoxic T-cells. It has also
been demonstrated that CD8+ T-cells are subject to apoptotic events. After antigenic
stimulation some CD8+ T-cells develop a state of unresponsiveness and eventual death
which is mediated via apoptosis (Lewis et al., 1994). Herbein et al showed that apoptosis
of CD8+ T-cells was mediated by macrophages through the interaction of gpl20 with the
chemokine receptor CXCR4. SI HIV strains can be recovered in almost half of HIV-
infected individuals, usually in the late course of infection and these are associated with
accelerated disease progression. Therefore, SI/X4 viruses appear to exert their
deleterious effect on the immune system not only by direct cytopathic effects on CD4+ T-
cells, but also by indirect killing of CD8+ T-cells (Herbein et al., 1998).
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The peripheral interaction between CD4 and CD8 cells occurring in vivo as part
of the immune response may allow direct transmission of infection to the CD8
lymphocytes. Alternatively, it is possible that damage or deficiency to the thymus may
also contribute. HIV-1 may infect and destroy both intrathymic T progenitor cells (CD3"
CD4+CD8"), double positive thymocytes (CD3+CD4+CD8+) (McCune et al., 1991; Su
et al., 1995) and mature CD3hlCD8+ thymocytes (Lee et al., 1997). The targetting of
such progenitor cells would impair the production of both CD4+ and CD8+ naive cells.
Using the SCID-hu mouse which characterises thymic abnormalities after HIV infection,
Lee et al found that HIV-1 can infect a population of mature CD3hlCD8+ thymocytes
wherein viral mRNA transcription occurs (Lee et al., 1997). Recent studies have offered
an alternative explanation as to why CD8 cells may become infected. They suggest that
infection is mediated through the CD4 molecule whose gene is expressed following
activation through the T-cell receptor (TCR) complex. HIV DNA sequences could be
detected in uncultured and sorted mature CD3+ CD8+ T-cells from HIV+ individuals.
Additionally, activated neonatal CD8+ cells were shown to express chemokine co-
receptors and to be infectable by M-tropic HIV-1 isolates. These results suggest a new
mechanism by which HIV could attack the immune system and may help to explain the
CD8+ T-cell defects in AIDS patients (Flamand et al., 1998; Su et al., 1995; Yang et al.,
1998).
In addition to CD4+ and CD8+ HIV-specific T-cells, HIV might interfere with
other cell types such as monocytes/macrophages and dendritic cells whose function is
critical for the generation of immune responses. These specialized antigen-presenting cells
(APCs) are central to the induction of humoral and cell-mediated immune responses.
Interference with APC function might be the result either of quantitative depletion by
direct cytopathogenicity or suboptimal formation of MHC-antigenic peptide complexes.
Another major component of the cellular immunity are NK cells which recognise and kill
target T-cells in a non-MHC-directed manner. Impaired activity and a decline in NK cell
numbers is one of the many immunological defects seen in AIDS patients. Indeed it has
been demonstrated that HIV-1 tat released by infected cells can inhibit NK cell cytolytic
function by acting on the intracellular signalling pathways of infected cells.
3.3.3 In vivo and in vitro infection of naive and memory cells.
CD4+ and CD8+ T-cells are characteristically made up of two functionally
different phenotypes, the naive (CD45RA+) and memory (CD45RO+ ) cells. Naive cells
are those T-cells that have not been exposed to stimulatory signals before. Functionally
the naive cell subset has a lower cytokine response after mitogenic stimulation. They
express low levels of adhesion molecules and when activated, they differentiate into
effector/memory cells and express the RO isoform of CD45. Memory cells are generated
after exposure to an antigen and have much broader cytokine expression profiles and
express higher levels of adhesion molecules. After activation and in the absence of future
immune stimulation they shrink in size and become inactive "resting" cells, capable of
surviving for long periods in the lymphoid population (Sanders et al., 1988). CD4 and
CD8 naive lymphocytes are lost preferentially as total CD4 counts fall (Rabin et al.,
1995; Roederer et al., 1995). Stimulation of these cells may lead to HIV-infection. As the
121
naive cell subset disappears the host becomes less able to control opportunistic infections
and new virus variants. Naive cells and their loss will inevitably lead to a reduction in the
number of circulating T lymphocytes.
During HIV disease progression, naive T-cells of the CD4+ and CD8+ subsets
seem to be preferentially lost compared with cells of the memory phenotype. A decrease
in thymic production of new T-cells would also decrease the diversity of the T-cell
receptor, because a smaller number of T-cell receptor clones would be produced, further
contributing to immune dysfunction (Roederer et al., 1995). Naive T-cells are
phenotypically defined as coexpressing CD45RA and CD62L. Early depletion of thymus-
derived naive (CD45RA+ CD62L+) CD4+ and CD8+ T-cells is a fundamental feature of
HIV-1 infection (Rabin et al., 1995; Roederer et al., 1995; Roederer et al., 1997). Since
these cells are resistant to productive infection by HIV-1 (Roederer et al., 1995;
Schnittman et al., 1990; Woods et al., 1997), it is unlikely that they are being destroyed
by direct viral infection. It is possible that they are not being produced-that is, that thymic
failure is a primary pathologic lesion in HIV-1 disease. Although there is substantial
evidence that HIV-1 infection per se does not trigger T-cell activation, the virus may
preferentially target a subset of T-cells that are easily activated subsequently. Such a sub-
population of memory cells may be 4 to 10 times more susceptible to HIV infection in
vitro than are naive T-cells. This may be related to the selective depletion of memory T-
cells in patients. Infected memory cells have been shown to contain integrated provirus,
suggesting that their state of activation provided the necessary requirements for
establishment of productive infection (Bour et al., 1995). Ostrowski et al demonstrated
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that both memory and CD45RA+/CD62L+ naive CD4+ T-cells are infected in HIV-1
infected individuals. HIV-1 provirus could be detected in the memory and naive subsets
from 11 HIV-1 infected individuals; in addition replication competent HIV-1 provirus
could be isolated from these cells upon stimulation in tissue cultures (Ostrowski et al.,
1999).
To investigate the mechanism of CD8 depletion further we determinsed the
distribution of infected cells in the naive and memory cell subsets of CD4 and CD8
lymphocytes in 16 HIV+ individuals using a combination of monoclonal antibody cell
separation techniques. HIV proviral sequences within these cell populations was
quantified by limiting dilution nested PCR. HIV preferentially infected the naive subset of
CD8 lymphocytes along with the naive and memory populations of CD4+ cells. The
preferential distribution of HIV in the naive subset of CD8 lymphocytes has implications
for the mechanism of CD8 lymphocyte infection, and these hypotheses are discussed.
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3.4 RESULTS
3.4.1 Cell separation and FACS analysis.
Analysis of HIV infection of CD4 and CD8 lymphocytes was carried out on
samples from 16 HIV seropositive individuals (HIV-1 subtype B) attending the
Genitourinary Medicine clinic and the Regional Infectious Diseases unit at the Western
General Hosptial, Edinburgh. CD4 cell counts ranged from 10-850/p.l blood. Four
individuals had CD4 cell counts of less than 200 and 12 had CD4 counts greater than
200. Risk groups included intravenous drug users (IVDU), and homosexual and
heterosexual conduct. The general characteristics of the 16 subjects included in this study
together with their plasma virus measurements at the time of study entry are listed in table
3.1.
3.4.1.1 Experimental design.
CD4 and CD8+ T naive and memory cell subsets were isolated from samples
using a combination of magnetic bead depletion and flow cytometric analytical
techniques. Magnetic cell separations involved were carried out using a VarioMACS and
a MinsiMACS magnetic system (Miltenyi Biotec) either by negative or positive selection.
To isolate the naive and memory subsets of CD4 and CD8 lymphocytes, the negative
selection procedure was used initially to isolate the CD4+ T-cells and CD8+ T-cells. This
isolation technique involved using direct CD4+ and CD8+ T-cell isolation kits and a
VarioMACS magnet, which allowed for selection of up to lxl 08 cells. The CD4' and
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CD8+ T-cells were then positively selected for the naive and memory subsets by a direct
labeling technique involving CD45RA and CD45RO MACS microbeads and a
minsiMACS magnet which selected for a maximum of lxl07 cells. The minsiMACS and
varioMACS proved to be very efficient at isolating specific cell subsets while the beads
allowed direct FACS (Fluorescent Activated Cell Sorter- Coulter EPICS machine)
analysis of the selected cell subsets.
3.4.1.2 Purity of isolated cell subsets.
The purity of the isolated CD4+CD45RA, CD4+CD45RO+, CD8 CD45RAr and
CD8+CD45RO+ cell populations was assessed by FACS. Directly conjugated fluorescent
antibodies were used to check the purity of the depleted cell fractions from five HIV-
negative individuals and one FHV-1 positive individual (table 3.2). Samples from the
HIV-1 negative individuals showed that the purity of CD4+ naive T-cells was 91.7% with
only 1.3% contaminsating CD8+ cells. The purity of the sample from the HIV-positive
individual was similar (95.1% CD4+ naive cells, 1.6% contaminsating CD8+ cells).
Equivalent results were also observed with the CD4+ memory cells with less than 1%
contaminsating CD8 cells in both the negative and positive control samples. The mean
purity of the CD8+ naive T-cells in the HIV-1 negative individuals was 83.3% with 1.7%
contaminsating CD4+ cells, while in the HIV-1 positive individual, CD8+ naive cells were
92.8% pure with only 0.4% eontaminsating CD4+ T-cells. Median values for the naive
and memory cell subsets of CD4+ and CD8+ T lymphocytes \yere CD4CD45RA4 95.6%;






















































































































Satisfactory FACS analysis and PCR testing could not be carried out on the same
samples due to the limitations in the sizes of blood samples available from the study
group patients. However, estimated levels of CD4 contaminsation in the CD8
lymphocytes were calculated using the mean purity FACS data from control samples
(Table 3.2) and were found to range between 1% and 12% of the total proviral load in
the CD8 naive cell subset. This level was insufficient to account for the detection of HTV-
1 proviral sequences in the isolated CD8, CD45RA+ lymphocytes in six patients. In one
patient (p8) however, it is likely that CD4 contaminsation could account for the
sequences detected in the naive CD8 lymphocytes, although a very low level proviral load
was detected in this subset.
3.4.2 Quantitation of HIV proviral sequences in lymphocyte subsets.
Once the purity of the separated cell subsets was determinsed nucleic acid was
extracted and proviral DNA was quantified in each cell type by limiting dilution and
nested PCR (Simmonds et al., 1990). The quantitation was performed using primers
corresponding to the VI/V2 and V3 region. A nested PCR approach was used because
this method can detect one single molecule of target DNA, and allow quantitation by
dilution of DNA to an end-point (refer to section 2.6.1). The PCR product was visualized
on a 2% agarose gel containing ethidium bromide.
HIV sequences in DNA from each of the purified lymphocyte subsets of the 16
study subjects was quantified, and expressed as proviral copies per million cells. All
separations, extractions and amplifications were carried out with parallel samples of
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mononuclear cells isolated from buffy coat leucocytes derived from HIV-1 negative
blood, which serve as negative controls. HIV-1 DNA could be detected in CD4 T
lymphocytes and CD8 T lymphocytes but was never detected in any negative controls.
The virus load in the naive and memory subsets of CD4 and CD8 cells from 16
HIV-1 positive individuals, and their frequency in total T lymphocytes, was used to
calculate the proportion of virus in each subset isolated (Table 3.4). Using cell counts
from each sample and the number of copies of provirus detected it was possible to
express the results as proviral copies per million cells. HIV-1 proviral DNA was detected
in all the individuals studied, 4 with CD4 counts less than 200 and 12 with CD4 counts
greater than 200. CD4 lymphocytes were infected at all stages of disease progression.
Infection was detected in the CD4 naive and CD4 memory subsets of all patients
(between 55 and 4307 provirus copies per 106 cells) except in the CD4 memory subset of
patient 15.
HIV DNA was also detected in 9 samples of separated CD8+CD45RA+ and in 3
CD8+CD45RO+ subsets from 10 of the 16 individuals. The contribution of
contaminsating CD4 lymphocytes to the measured virus loads was small or insignificant
in 10 of these samples (Table 3.1) and these were considered to represent infection of
CD8 lymphocytes. In eight individuals, HIV preferentially infected the naive subset of
CD8 T lymphoctes, with proviral frequencies ranging from 25 to 1444 provirus copies
per 106 cells. There was a tendency for higher frequencies of infected CD8 , CD45RA+
cells to be found in individuals with lower CD4 counts, although this difference did not
reach statistical significance (p = 0.286). Frequencies of HIV-infected CD8 lymphocytes
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did not correlate with disease status, risk group, antiviral therapy or total CD4
lymphocyte counts. There was no correlation between frequency of infection of CD8 cells
with either CD4 subset.
The frequency of infection and proportion of virus load contributed by naive and
memory subsets of CD4 lymphocytes varied with absolute CD4 count. CD4 naive
lymphocytes contributed the majority of infected cells in those with high CD4 counts (r =
0.703, p = 0.02), while memory cells were predominantly infected in individuals with
low CD4 counts (r = -0.450, p = 0.08). These results are also illustrated on a bar graph
(figure 3.1).
The absolute cell counts for each cell fraction and the frequencies of infection
were combined to determinse the contribution of HIV-1 DNA from each cell subset to
the proviral load in total T lymphocytes. The contribution of each cell subset to the
overall proviral load in T lymphocytes (% total load in T lymphocytes) were also
illustrated on a bar graph with individual patients plotted along the X-axis in ascending
order according to their CD4 count (cells/pl).
In order to investigate the percentage distribution of memory and naive CD4 and
CD8 lymphocytes, PBMCs from 11 individuals were stained with monoclonal antibodies
directed against CD4, CD8, CD45RA and CD45RO. These values were plotted against
CD4 counts (figure 3.2-pie charts). In these pie charts, the CD4 and CD8 naive and
memory cells are shown as percentages of the total lymphocytes present in each
individual. In individuals with CD4 counts of greater than 350cells per pi, the majority of
CD4 and CD8 lymphocytes expressed the naive cell marker CD45RA. However as CD4
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Figure 3.1 The relative distribution ofCD4 and CD8 naive and memory T
lymphocytes isolated by VarioMACS to proviral load in total T lymphocytes.
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Figure 3.2. Percentage distribution of naive and memory cells with disease
progression.
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counts fall to 200-350 cells per p.1, there is a modest decline in the number of naive cells
with the memory cell subsets becominsg the major cell population in both the CD4 and
CD8 lymphocytes.
3.4.3 Effect of antiviral therapy on CD4 and CD8 lymphocyte infection.
In order to investigate the turnover of the infected cell populations during the
period of HAART treatment, where virus replication is suppressed, the frequency of
infected (proviral DNA positive) cells was analysed. CD4 and CD8 naive and memory
lymphocyte subsets were separated from pre- and sequential post-treatment samples
collected from five individuals receiving combination antiviral treatment, and analysed for
proviral sequences (Table 3.5). Treated individuals showed rises in circulating CD4
counts, and reductions in circulating viraemia. Despite the effectiveness of the antiviral
therapy as indicated by the clearance of plasma RNA, the distribution and frequency of
infected cells in each of the subsets remained relatively stable, in all cases remaining
within a ± one logio range of the levels detected in the initial samples. Infection of CD8
lymphocytes remained detectable in the three individuals (p9, plO and pi4) whose first
samples were positive (figure 3.3a, figure 3.3b & figure 3.3c), while the two individuals
(pi and pi2) with negative CD8 lymphocytes in the pre-treatment samples remained
negative during treatment (figure 3.3d and figure 3.3e). There was evidence for a decline
in the frequency of infected CD4+, CD45RA+ and CD45RO+ lymphocytes over the course
of treatment (r = -0.428; p = 0.098 and r = 0.545; p = 0.029 respectively) with half-lives
of infected cells approximately 6 months, in agreement with previous studies (Ibanez,
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TABLE 3.5
INFECTION OF LYMPHOCYTE SUBSETS OF STUDY SUBJECTS
RECEIVING COMBINATION ANTIVIRAL THERAPY.




Patient Therapy* (days) Count LoadJ RA RO+ RA RO+
pOl Prelf 0 10 14,000 98 834 Neg. Neg.
+ 27 150 1,700 34 239 Neg. Neg.
p09 Prel 0 283 750,000 575 2321 40 Neg.
+ 48 - 3,000 72 1807 215 Neg
plO Prel 0 301 81,540 - - - -
+ 49 - Neg. 1307 464 622 Neg.
+ 62 466 Neg. 533 533 697 Neg.
+ 100 - Neg. 878 364 1049 Neg.
+ 115 - ± 667 577 2764 Neg.
+ 154 428 ± 1498 1390 489 Neg.
Stop 360 349 16,000 734 2884 435 Neg.
pl2 Prel 0 329 64,680 55 115 Neg. Neg.
+ 14 477 Neg. 15 188 Neg. Neg.
+ 41 540 Neg. 19 119 Neg. Neg.
+ 100 442 Neg. 9 48 Neg. Neg.
+ 340 207 Neg. 18 56 Neg. Neg.
p!4 Prel 0 360 Neg. 533 980 11 Neg.
+ 27 418 Neg. 158 1307 203 Neg.
+ 153 465 Neg. 351 183 144 Neg
* Combination treatment over study period; Pre: Sample collected pre-treatment, Stop:
Treatment stopped because of side effects,
f Time since start of treatment
X Circulating plasma virus load (genome equivalents ofRNA /ml); Neg.: <400 geq. /ml
Samples tested and recorded on Table 3.1
Figure 3.3 (a) and Figure 3.3(b). Percentage of HIV proviral load per T
lymphocyte cell number in the CD4 and CD8 naive and memory cell subsets of P09
and P14.
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Figure 3.3 (c).Percentage of HIV proviral load per T lymphocyte cell number in the
different cell subsets ofP10.
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Figure 3.3 (c) and Figure 3.3(d). Percentage of HIV proviral load per T
lymphocyte cell number in the CD4 and CD8 naive and memory cell subsets of P01
and PI 1.
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1999; vanHarritelen, 1997; Izopet, 1998; Bruistein, l&fy. A similar decrease in the
frequencies of ihfected CD8 , CD45RA+ cells was hot observed, although fewer
observations were made (r = 0.070; p = 0.870).
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3.5 DISCUSSION
To investigate the mechanism and functional significance of infection of CD8
lymphocytes by human immunodeficiency vims type 1 (HIV-1) in vivo, the frequency
of infection in the naive (CD45RA+) and memory (CD45RO+) CD4 and CD8
lymphocytes was carried out in 16 HIV-1 positive individuals during different stages
of disease progression. This study shows that it is the CD45RA subset of CD8
lymphocytes that is predominsantly infected with HIV-1 in vivo, in contrast to the
distribution of proviral sequences in the RO and RA subsets of CD4 lymphocytes.
Frequencies of infected CD8 cells in this study were comparable to those previously
reported in a similar cross-sectional study of CD4 and CD8 lymphocytes (Livingstone
et ah, 1996), although the correlation between CD8 infection with disease
progression (or CD4 lymphocyte count) was not apparent from this study group.
The current study used microscopic magnetic beads for cell separation, and
this allowed a direct assessment of the purity and degree of CD4 or CD8 lymphocyte
contaminsation of isolated cells. Investigations were also carried out into whether
cross-contaminsation could produce false-positive results as contaminsating CD4+
lymphocytes in purified CD8 T lymphocytes may potentially contribute to the
observed proviral load. From FACS analysis, the mean contaminsation by CD4 cells
in CD8 lymphocytes separated was calculated (Table3.2). Using the mean
contaminsation level per subset in conjunction with the proviral loads detected per
sample, the mean frequency of proviral sequences detected in CD8 lymphocytes that
originate from contaminsating CD4 lymphocytes were estimated. In only 3-4 samples,
where proviral load in CD8 lymphocytes was in any case very low, could CD4
contaminsation account for the sequences detected. Previous estimates of the
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contribution of contaminsating cells to the detection of HIV-1 in CD8 lymphocytes
have come to similar conclusions (Livingstone et al., 1996). Furthermore, there was
no correlation between frequencies of infected CD4 lymphocytes and detection of
proviral sequences in either the CD8, CD45RA+ or RO populations (Table 3). For
example, the sample with the highest frequency of infected CD4 lymphocytes (p4)
contained undetectable frequencies of infected CD8 lymphocytes; similarly the sample
with the highest CD8 proviral load contained relative low frequencies of infection of
both subsets of CD4 cells. Thirdly, although there was considerable inter-subject
variability in the detection of CD8 lymphocyte infection, longitudinal sampling of the
same individual over time revealed remarkable stability in proviral loads in each of the
lymphocyte subsets. For example, pre-treatment samples from pi and pl2 contained
undetectable frequencies of infected CD8 lymphocytes, while samples subsequently
remained negative. The remaining individuals with infected CD8 lymphocytes pre-
treatment, remained PCR-positive subsequently. The consistency of provirus
detection in the lymphocyte subset argues against sporadic contaminsation by CD4
lymphocytes as a reason for our observations.
As negative selection was used in this study to separate CD4 and CD8
lymphocytes, there is a possibility that purified CD8 T lymphocytes may contain null
(CD4-, CD8-) cells. While acknowledging this fact, it was not possible to carry out
positive selection of CD4 and CD8 T lymphocytes prior to separating naive and
memory cells as positive selection affects the activation status of the cells, and
consequently the isoform expressed on the cell surface. Since completing this thesis
however, further work was carried out (McBreen el al, 2000, manuscript attached)
on a new group of 7 individuals in which CD4 and CD8 T lymphocytes were
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positively selected from PBMCs. Purified CD8 lymphocytes in this way showed a
range of proviral loads (Table 3.3, attached manuscript) similar to those found in CD8
lymphocytes isolated by negative selection. Having established that HIV proviral
sequences can be detected in CD8-positive lymphocytes, it is unlikely that the results
obtained from the negative selection procedure used here were the result of null cells.
In this study, expression of the RA and RO isoforms of CD45 was used to
select between two functionally different subsets of T lymphocytes (naive and
memory /effector respectively) in the peripheral circulation. Separate identification of
HIV-1 infection in naive and memory/effector cells provides information on the time
of infection of T-cells relative to maturation and activation, which in turn provides
indirect information on the likely mechanisms underlying infection. While expression
of CD45RA and CD45RO has been the most commonly used method for separating
naive and memory/effector cells, expression of other markers in combination with
CD45 has been used to more strictly define functionally distinct subsets. Markers of
cellular activation such as CD38 expression and down-regulation of CD27 and CD28
have been used to identify effector from memory and naive CD8 lymphocytes
(Burgisser et al., 1999; Giorgi et al., 1994; Hamann et al., 1997; Ho et al., 1993; Ogg
et al., 1999). Expression of CD62L in combination with CD45RA has been used to
define purer populations of naive CD4 cells, as there is evidence that a proportion of
memory CD4 cells of HIV-positive individuals express CD45RA (Roederer et al.,
1997; Ostrowski et al, 1999). Whether abnormal expression of CD45RA on the CD8
lymphocytes of HIV-positive lymphocytes also occurs has not been determinsed.
Recently it has been reported that the isoform of CD45 expressed on memory cells
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may ultimately revert to RA, potentially producing a subset of CD45RA+ cells
functionally distinct from the naive phenotype (Bell et al., 1998).
While it is possible that a proportion of the CD45RA+ CD4 and CD8
populations analysed in our study may have originally been memory cells, the
predominsance of HIV-1 infection in the CD8 CD45RA+ subset argues empirically
that the main target CD8 lymphocyte is the naive subpopulation. For example, it is
unlikely that the infected CD8 cells detected are memory revertants as it would be
likely that a similar frequency of non-revertant CD45RO+ lymphocytes would also be
infected.
Infection of naive cells has been documented extensively in CD4 lymphocytes
(Ostrowski et a/, 1999; Schnittman et al., 1990; Sleasman et al., 1996), and is
confirmed in the current study although in contrast to our findings, frequencies of
infected CD45RA+ have been reported to be lower than in the CD45RO+
effector/memory population. The latter cells are considered to be the main
contributors to the pool of infected lymphocytes in vivo, where cellular activation on
antigenic stimulation produces cells susceptible to infection and destruction by HIV-1
(Stevenson et al, 1990; Chun etal, 1997; Farnet et al., 1997; Zack et al., 1990; Zack
et al., 1992). In contrast, productive infection of naive CD4 lymphocytes in vitro by
laboratory isolates of HIV-1 is demonstrably inefficient, most likely through lack of
T-cell activation necessary for efficient reverse transcription and integration of the
HIV genome after entry (Stevenson et al, 1990; Chun et al., 1997; Farnet et al., 1997;
Roederer et al., 1997; Spina et al., 1997; Zack et al., 1990; Zack et al., 1992) and
because they do not express the CCR5 chemokine co-receptor required for the entry
of primary (non-syncytium inducing) variants (Bleul et al., 1997; Mo et al., 1998).
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Hypotheses developed to account for the infection of naive CD4 lymphocytes may
also be relevant for the infection of naive CD8 lymphocytes in vivo reported here.
3.5.1 Loss of na'ive CD8 T-cells
The preferential loss of naive CD8 cells has important consequences for the
development of immune responses in HIV infected individuals. As naive subsets
disappear the host becomes less able to control opportunistic infections and new virus
variants. As yet it is not fully understood why CD8 naive cells are selectively
depleted. Destruction of cells destined to become CD8 lymphocytes may be a major
factor in the decline in CD8 lymphocyte frequencies and function on disease
progression, and contribute directly to the observed immunodeficiency in AIDS.
Preferential distribution of HIV-1 in naive CD8 lymphocytes suggests that infection
occurred early in T lymphocyte maturation, perhaps during maturation in the thymus.
Kitchen and colleagues found that infection of an immature CD8+/CD4+ thymocyte
further differentiated into a CD87CD4" cell and resulted in CD8+ thymocytes that
expressed HIV-1 (Kitchen et al., 1997). Infection of such progenitor cells would
impair the production of both CD4 ' and CD8+ naive T-cells. Damage to or deficiency
of the thymus might also contribute. There are several potential mechanisms for the
infection of CD8 lymphocytes, although most would not predict the preferential
distribution of infection in the naive subset. Peripheral CD8 lymphocytes express low
levels of CD4 on mitogenic and antigenic stimulation in vitro, and it has been
hypothesised that this allows productive infection of CD8 lymphocytes in vivo to
occur (Flamand et al., 1998; Kitchen et al., 1998; Yang et al., 1998).
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These findings suggested that when CD8 cells are stimulated out of their
quiescent state, as they would be when responding to antigenic stimulation, they make
CD4 (Flamand et al., 1998; Kitchen et al., 1998). In HIV-infected individuals,
cytotoxic T-cells recruited to kill HIV-infected cells would, as a consequence of
specific antigenic activation, express the CD4 antigen and become targets for HIV
infection (Flamand et al., 1998). It is not known how frequently CD8+ T-cells express
CD4 in vivo, although it has been speculated that this phenomenon may occur more
often in lymphoid tissue, where costimulation occurs. The requirement for cellular
activation suggests that the CD45RO+ population would be the main reservoir of
infected CD8 lymphocytes.
The overall decline of naive and memory T-cells in infected individuals has
been influenced by the rates of production of each population, the frequency of
infection of each population, the susceptibility of each population to the cytopathic
effects of infection, and the suspectibility of each population to the indirect effects of
cell killing mechanisms.
3.5.2 Hypotheses for CD8 T lymphocyte infection.
The interaction between CD4 and CD8 T-cells in the periphery as part of the
immune response may perhaps transmit infection to CD8 T-cells in vivo. In the later
stages of disease, the architecture of the lymph node collapses and these organs lose
their ability to trap the virus. The spillover from the lymphoid organs may to some
extent explain the increase in viral burden as disease progresses.
The failure of the lymphohematopoietic system during HIV progression may
be due to a primary pathogenic event rather than simply T-cell destruction and
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exhaustion. Either the bone marrow or the thymus is rendered dysfunctional during
HIV-1 disease, resulting in low rates of replenishment of mature T-cells, which would
ultimately result in immune system collapse. This would cause an overall decrease in
the number of naive T-cells, a distorted level of CD8+ T-cell populations and a
restricted TCR repertoire (reviewed in Hellerstein et al., 1997). Donaldson and
colleagues found that HIV could spread to non-lymphoid tissues during the later stage
ofHIV disease (Donaldson et al, 1994). These findings may possibly be related to the
observed increase in CD8 T-cell infection upon disease progression (Livingstone et al,
1996). On the other hand, a defective HIV-1 specific CD4 T-helper response may
indirectly influence normal CD8 T-cell function. CD8 T-cell depletion has been also
been attributed to apoptotic and anergic events (Herbein et al., 1998; Lewis et al.,
1993).
The thymus represents a major target for HIV-1 infection in vivo and
destruction of thymopoietic areas is observed on autopsy examinsation of AIDS
cases. Functional HIV proviruses have been found in thymocytes lacking surface CD4
expression. Neither HIV-mediated CD4 downregulation nor CD4-independent
infection contributed to the localisation of HIV in cells lacking the primary virus
receptor. Instead, infection of a CD4-positive precursor cell (CD4positive/CD8
positive) with subsequent differentiation into a mature CD4-negative phenotype
resulted in productively infected CD4-negative cells (Kitchen et al., 1997). HIV-1
infection of CD4+, CD8+ immature thymocytes destined to become CD8 lymphocytes
during thymic maturation (Kitchen et al., 1997; Lee et al., 1997) would provide both
a plausible mechanistic explanation for their infection, and would also explain the
presence of proviral sequences in the naive subsets of both CD4 and CD8
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lymphocytes in peripheral blood. Infection of an immature progenitor cell followed by
differentiation into a mature productively infected single positive CD8 cell is a novel
mechanism ofHIV-1 entry into a non-CD4 expressing cells.
Destruction of CD8 precursor cells would also explain the eventual failure of
CD8 homeostasis and decline in circulating numbers of first naive and then memory
CD8 lymphocytes on disease progression (Roederer et al., 1996; Roederer et al.,
1995), and the recovery in numbers of naive CD8" (and CD4+) lymphocytes generally
observed after commencement of antiviral treatment (Arno et al., 1998; Bohler et al.,
1999).
Evidence for the quiescent nature of HIV-1 infection in CD8 naive
lymphocytes, consistent with thymic infection, is provided by the great stability of the
infected CD8 population on anti-retroviral therapy and indirectly by the genetic
relationship between the CD8 and CD4 populations. Combination treatment achieved
a complete clearance of circulating viremia in the majority of study subjects (Table 4),
while over the period of virus suppression ranging from 1-11 months, there was no
consistent reduction in frequencies of infected CD8 lymphocytes. Over the same
period, frequencies of infected naive and memory subsets of CD4 lymphocytes
showed a modest decline, consistent with previous kinetic studies reporting half-lives
of proviral sequences from 21-58 weeks (Bruisten et al., 1998; Izopet et al., 1998;
Vanharmelen J et al, 1997; Ibanez et al, 1999).
Since CD8+ T-cells mainly control viral replication, it seems reasonable to
assume that infection of CD8 naive cells, a cell type normally resistant to infection
would have major pathogenic consequences, including increasing the reservoir of
infected cells and disturbing the CD8 arm of the immune response. Our evidence for
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infection of the CD45RA" population of peripheral CD8 lymphocytes highlights the
need for future work in assessing the exact mechanism of peripheral CD8 lymphocyte
infection in vivo. In the future, phenotypic characterisation of variants infecting the
two cell types should indicate whether CD4-independent entry of HIV-1 can occur.
Investigating the biological properties of the proviral sequences detected in CD8
lymphocytes would prove beneficial. This could be assessed by analysing virus or
PCR-generated fragments of DNA sequence obtained directly from different T-cell
types in PBMCs and constructing them into infectious clones which can then be
further characterised for individual cellular tropism. Future in-depth analysis of the
effects of HIV-1 infection within both mature and immature CD4 and CD8 T
lymphocytes in fresh human thymus and lymph nodes samples could also provide
clearer information about the thymic abnormalities that are known to occur upon
disease progression. Determinsing the cellular distribution of HIV-1 proviral
sequences within the thymus and lymphoid tissues may give rise to potentially
interesting investigations. Increasing studies on the turnover of HIV-1 infected CD8
lymphocytes in vivo, such as the acquisition of antiviral resistance during treatment
relapse, will provide information on the dynamics and consequences of CD8 infection
in the peripheral circulation, and potentially, on the mechanisms underlying the loss of
CD8 lymphocytes on disease progression.
3.5.3 Effects of HAART on infected CD4 and CD8 T lymphocytes
Treatment of HIV infection with anti-retroviral drugs involves blocking virus
replication so detailed observations in individuals treated with powerful anti-
retrovirals can provide further information on the role of viral replication in HIV
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pathogenesis and the dynamics of this process. Combinations of drugs that inhibit
viral reverse transcriptase and protease control infection with HIV-1 in many
individuals by reducing the levels of RNA in plasma and depleting the pools of virus in
lymphoid tissue. This sustained reduction in viral replication delays disease
progression and prolongs survival. In this study we analysed the effect of antiviral
treatment on the distribution of infected lymphoid cells.
In clinical practice, the most useful marker of progressive deterioration has
been the absolute number of CD4+ T-cells. Lymphocyte subsets change in absolute
number and character over the course of HIV infection. An increase in CD4+ cell
counts has been noted in HIV-infected individuals following HAART over several
months. Although HARRT treatment dramatically decreases plasma viral load and
effectively suppresses viral replication to undetectable levels (<400 RNA copies per
ml), the plasma concentration of HIV-1 proviral DNA has been found to decrease
only slowly. This could provide a basis for continued virus replication, and the rapid
rebound of viral replication occurring after cessation of drug therapy.
So far, there is little information on the dynamics of infection in the peripheral
blood of individuals undergoing anti-retroviral therapy. While most viral production is
believed to take place in the lymphoid tissue, there is a real need to examinse the
levels of productively infected cells in the periphery. In this study we analysed the
effects of antiretroviral therapy on five study subjects and found that while particular
individuals were undergoing HAART there was an appreciable difference in the
distribution of infected cells in vivo. Our observations indicate that many individuals
harbor HIV provirus in all populations of CD4 and CD8 cells while undergoing
therapy. There was remarkable individual variation in the frequencies of infected cells
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in each subset. Infected naive and memory cells were observed to decline during
HAART. While we were not able to detect any HIV-1 DNA in the CD8 memory cell
population of individuals analysed we did detect HIV DNA in the CD8 naive cell
subset. No correlation was observed between the decrease in viral load observed with
the CD4 subsets and the CD8RA cells during the course of anti-retroviral therapy.
Despite the apparent success of antiretroviral therapy in suppressing plasma
HIV-1 RNA for long periods, long-lived reservoirs of infectious virus remain in CD4+
T-cells and perhaps other cells, suggesting the need for continued long-term
treatment. In this study, frequencies of infected naive and memory subpopulations of
CD4+ T lymphocytes declined slowly during HAART treatment with half-lives of
infected cells of approximately 6 months, in agreement with previous studies (Ibanez
et al., 1999; van Harmelen et al., 1997; Izopet et al., 1998; Bruistein et al., 1998).
Frequencies of infected naive CD8 lymphocytes were more stable, with no observable
decline over 6-12 months, although a larger number of patients are required to
substantiate this observation.
After completion of this thesis project, further work was recently
carried out to examinse the quiescent nature of HIV-1 infection in CD8 naive
lymphocytes (McBreen et al., 2000). A method was designed to quantify complete
proviral sequences (i.e that span the primer binding site [OBS} and U5 region; C-
LTR-primers) and initial transcripts (primers amplifying the region immediately
downstream from the PBS (pan-LTR). No observations were made between the two
sets of primers, concluding that there is no evidence for the existence of significant
numbers of incomplete transcripts that might be associated with abortively infected
cells (Stevenson et al., 1990; Zack et al., 1990; Zack et al., 1992). This stability of
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the proviral load in the CD8 cells during effective antiretroviral therapy is also
consistent with stably integrated proviral sequences in the this lympocyte subset.
Indeed, CD8 lymphocytes themselves could represent a reservoir for H3V-1 which
may persist for long periods at low levels in many treated individuals despite the use
of maximally suppressive antiretroviral regimens.
The availability of quantitative data on plasma viral load in patients entering
potent antiviral therapy has revealed that the half-life of plasma virions is only 6 hours
and the great majority of the virus population turns over within a few days (Ho et al.,
1995; Wei et al., 1995, Perelson et al., 1996). Even so viral replication continues at a
rate of 150 replication cycles a year (Coffin et al., 1995) and underlies the rapid
evolution of the population in the plasma. Despite this, phylogenetic studies show that
lineages of related sequences can be detected over long periods in the circulation
(Holmes et al., 1992; Leigh Brown and Cleland et al., 1996).
Regardless of their mechanism of decline, the absence of naive-phenotype T
lymphocytes theorectically limits immune responses to new antigens. In persons with
late-stage HIV-1 infection who have immune collapse and loss of all CD4+ T-cell
subsets, concern over preferential loss of specific CD4 T-cell subsets may be
irrelevant. In the era of effective antiretroviral therapy, concern over the restorative
capacity of essential CD4+ and CD8+ T-cell subsets may become more relevant.
Without HAART HIV-1 infection leads to progressive deterioration of the immune
system and eventual death from opportunistic infection or AIDS-related malignancy in
the majority of cases.
For further understanding of HIV pathogenesis during disease progression, it
is important to analyse whether the suppression of virus replication caused by
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combinations of antivirals results in the reappearance of variants containing resistance
mutations. Investigations into the replacement of the original proviral population by





Like other retroviruses, HIV-1 is characterised by a high degree of genetic
variablility. HIV-1 infection is associated with a progressive deterioration of the host
immune system as a consequence of chronic viral replication in susceptible host T-
cells. The destruction of the host immune system should predict a progressive loss of
host adaptive pressures over the course of HIV disease. The spectrum of genetically
diverse variants found in a viral population within an infected individual is responsive
to the selective forces of evolution. In primary infection, there is a relatively narrow
distribution of genetic variants (Zhang et al., 1993). The complex mixture of genetic
variants that subsequently arise during the course of an infection (Holmes et al., 1992;
Kuiken et al., 1992; Wain-Hobson et al., 1989) results from competition and selection
among the variants in response to immunologic pressure for change and alterations in
cell tropism and replication efficiency (Coffin et al., 1992., Hwang et al., 1992).
Selection due to cell tropism and replication efficiency could result in discrete
populations of viruses with distinct genetic and biologic features found within specific
tissue types (Epstein et al., 1991; Keys et al., 1993). HIV-1 is susceptible to genetic
recombination and has an error-prone reverse transcriptase enzyme, which combined
with the absence of proofreading leads to a misincorporation rate of 10"4 to 10"5 per
base, or approximately one misincorporation per genome per replication cycle (Pathak
et al., 1990; Preston et al., 1988) and (Ricchetti et al., 1990., Roberts et al., 1988).
With 109 new virions produced each day and a half-life of approximately 6h, an HIV-
1 infected individual harbours a swarm of closely related viruses that comprise the so
called HIV-1 quasispecies. These HIV-1 variants have been shown to differ in the
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biological properties such as replication rate, cell tropism, and synctium-inducing (SI)
capacity (Asjo et al., 1986; Choeetal., 1996; Tersmette et al., 1989).
HIV-1 shows considerable sequence diversity between different isolates,
particularly those from geographically distinct regions, where divergence has taken
place over a number ofyears. Sequence diversity is seen within isolates from the same
individual as well as between HIV strains infecting different individuals (Levy, 1993).
The degree of sequence variation is not uniform throughout the genome; for example
gag and pol are more conserved than env (Levy, 1993). In particular, the region of
the viral genome that encodes gpl20 shows an extremely high degree of diversity,
concentrated into five hypervariable domains (VI-V5) interspersed among less
variable regions (C1-C4) (Levy, 1993).
4.2 The third variable (V3) domain of the envelope glycoprotein.
V3, the third variable domain in the gpl20 subunit of HIV-1 determinses
several biological properties of the virus such as cell tropism, cytopathicity and
fusogenicity. The V3 domain forms an exposed, accessible loop on the surface of the
viral particles (Moore et al., 1994) and induces the production of V3 antibodies
detectable either after natural infection or following specific immunisation (Zwart et
al., 1991). Moreover this region is a determinsant for cellular tropism and viral
infectivity (Hwang et al., 1991; Shioda et al., 1992). It contains 35 aminso acids
arranged in a disulphide loop. The tip of the loop is considered the principal
neutralising domain because virus neutralising antibodies directed against this region
block HIV-1 infection of primary lymphocytes and macrophages. V3 is less variable
than is VI or V2 and contains a relatively conserved motif Gly-Pro-Gly, at the central
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tip of the loop. In general, the GPG motif is highly conserved among HIV-1 isolates,
and sequences near the cysteine residues at the bottom of the loop also show little
variability (Luciw et al., 1996). The most extensive variation is observed in the
regions flanking the GPG sequence at aminso acids 10 to 14 and 25 to 29. In addition
sequence variation is higher in the group of Si-inducing isolates than in the NSI-
inducing isolates (Fouchier et al., 1992).
Over the course of infection, the virus an individual can carry broadens in
tropism and biological variability. Small changes in the envelope glycoprotein aminso
acid composition can lead to large differences in phenotype and biological properties
such as replication rate, cellular tropism and syncytium-inducing capacity (Asjo et al.,
1990; Tersmette et al., 1989). After seroconversion, sequence diversity expands,
yielding HIV-1 variants with distinct characteristics such as slow or rapid replication
kinetics, syncytium induction, and tropism for particular cell types in addition to
primary T-helper lymphocytes (Asjo et al., 1986; Evans et al., 1987; Gartner et al.,
1986; Roos et al., 1992; Schuitemaker et al., 1992). Virus isolated in the early
asymptomatic phase of infection is predominsantly slowly replicating, macrophage
tropic, and nonsynctium-inducing (NSI) in vitro (Connor et al., 1993; Roos et al.,
1992; Schuitemaker et al., 1992). During disease progression HIV-1 isolates display
increased replication rates and reduced macrophage tropism (Koot et al., 1993;
Schuitemaker et al., 1992; Tersmette et al., 1989). Although initial infection is limited
to macrophage-tropic virus incapable of causing syncytia in vitro (NSI), sequence
variation occurs rapidly. As a predominsant HIV species is maintained over time,
swarms of quasispecies, of subtly altered viruses emerge with broadened tropism
(lymphocytes and macrophages) and increased cytopathogenicity (synctium-inducing,
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SI). Initially the SI capacity of HIV-1 isolates was determinsed by scoring syncytium
formation upon inoculation of PBMC's with virus or cocultivation of PBMC with
virus-infected cells. Alternatively, the SI capacity of HIV-1 was determinsed by using
MT2 cells as an indicator, since MT2 cells selectively support replication of SI
variants (Schuitemaker et al., 1992).
The V3 domain of HIV-1 gpl20 has been demonstrated to be a major
determinsant of the SI capacities of virus isolates (Dewolf et al., 1994). Comparison
of V3 domains from a panel of SI and NSI HIV-1 variants resulted in a clear
correlation between viral phenotype and V3 conformation. In SI isolates, positively
charged aminso acid residues were found at position 11 and/or position 25 in V3,
whereas in NSI isolates both residues were either negatively charged or uncharged.
Basic aminso acids are known to play an important role in the SI phenotype. Analysis
of natural variants of HIV-1 coupled with studies on point mutations introduced into
V3 molecular clones of virus, indicates that basic aminso acids in one or more
positions 11, 24, 25, 29 and 32 (see figure 4.1) confer an SI phenotype, whereas
hydrophobic aminso acids in these positions correlate with a NSI phenotype
(Chesebro et al., 1992; de Jong et al., 1992; Fouchier et al., 1992; Milich et al.,
1993). Conversion within the NSI V3 loop of a negatively charged aspartate into a
positively charged arginine (D to R) at position 25, or an aspartate switch to
asparagine (D to N) at position 29 is sufficient to gain the SI phenotype (de Jong et
al., 1992).
The appearance of SI viruses often heralds worsening disease and heightened
replication rates, with a decrease in the number of circulating CD4 lymphocytes. The
rates at which these events occur vary among individuals, but increased viral burden
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and increased viral cytopathogenicity appear closely correlated with CD4 decline and
poor prognosis. The SI phenotype correlates with increased V3 sequence
heterogeneity with a broad range of substitutions, insertions and deletions at many
positions between the disulphide-bridged cysteine residues (Chesebro et al., 1992;
Milich et al., 1993). In contrast, V3 sequences from NSI isolates show few sequence
differences from each other or from a consensus sequence of 133 North American
isolates (LaRosa et al., 1990) that comprise predominsantly subtype B variants of
HIV-1 (Louwagie etal., 1993).
Changes in the in vitro phenotype of virus isolated from PBMCs can occur
during different stages of disease progression. Donaldson et al found a highly
restricted distribution of HIV in the body preceding the onset of AIDS with proviral
sequences recovered from PBMCs, spleen and lymph nodes. In contrast, proviral
sequences from patients who died from complications associated with AIDS were
also distributed in the CNS and in lung and bowel tissues in addition to the lymphoid
tissue (Hien et al., 1994). The apparent redistribution of virus upon disease
progression occurs at the same stage of disease as the change from an NSI to an SI
phenotype (Donaldson et al., 1994).
Although isolates become more cytopathogenic and often non-MT in vitro,
the redistribution of HIV in vivo involves organs such as brains and lungs and other
tissues in which the main targets of infection are reported to be tissue macrophages,
microglia (in the CNS), and other non-lymphocyte cell types (Koenig et al., 1986).
V3 loop sequences from lymphoid and non-lymphoid tissues showed a highly
restricted sequence variability and a low overall charge of the encoded aminso acid
sequence compared with those of standard laboratory isolates of HIV-1. The low
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charge and the restriction in sequence variability was similar to isolates with an NSI
and macrophage-tropic phenotype in vitro. All patients, irrespective of disease
progression, were found to be infected with the predicted NSI/MT phenotype.
Most of the published sequences of SI variants used for sequence comparisons
were derived from isolates of HIV-1 that were passaged extensively in cell culture,
therefore it is possible that whatever selection constraints restricts sequence diversity
in vivo are absent in the conditions used for virus culture ands that virus is free to drift
away from the subtype B consensus sequence. It is also possible that a V3 or V2 loop
with a large positive charge may confer a growth advantage in vitro, leading to
selective isolation of variants bearing such divergent sequences from a heterogeneous
population. Perhaps designation of V3 as a hypervariable region may be unduly
influenced by the characteristics of cultured isolates of HIV-1 and may not reflect the
relative homogeneity of sequences in this region in vivo (Donaldson et al, 1994).
Phenotypic differences may underlie differences in in vivo cellular tropism.
HIV-1 variation between different tissues, such as blood, spleen and brain has
indicated that distinct quasispecies have evolved independently (Ball et al., 1994;
Epstein et al., 1991; Pang et al, 1991) with considerable variation even within a
single organ (Delassus et al, 1992). Morris et al have recently shown the complexity
of viral populations infecting non-lymphoid tissues such as the brain. These complex
viral populations were rendered more diverse by recombination, and could provide a
powerful adaptive mechanism for the spread of virus with new phenotypes, such as
antiviral resistance or escape from cytotoxic T-cell recognition, into existing tissue-
adapted virus populations (Morris et al, 1999).
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In addition, escape from anti-V3 loop neutralising antibodies resulting from
aminso acid substitutions within and outside the V3 loop has been demonstrated both
in vivo and in vitro (McKeating el al., 1989; Nara et al., 1990).
4.3 Sequence variation in selected cell subsets
Populations of HIV variants infecting PBMCs in vitro are variable at different
stages of disease progression. On the basis of this, it is clearly important to investigate
the in vivo association between virus distribution, phenotype and nucleotide sequence
diversity during different stages of disease progression. Comparisons of sequences
from the env gene of variants in different lymphocyte subsets will allow inferences
concerning the rate of turnover within the peripheral circulation. In this study, detailed
sequence comparisons of the V3 loop and flanking regions of virus variants were
carried out in CD4 and CD8 naive and memory cells from seven HIV-1 seropositive
individuals. Sequences from the V1/V2 loops and flanking regions were also analysed
from three seropositive individuals in the same cell populations. Plasma RNA was
extracted, amplified and sequenced from another three individuals and compared with
V1/V2 and V3 sequences derived from the corresponding individuals' cell subsets.
Comparisons of V3 charge and sequence diversity of the inferred aminso acid
sequences of the V3 region were made between different T-cell subsets and
individuals in this study. Rooted trees were constructed using the MEGA (Kumar et
al., 1993) package with the sequences HIV MN arid HIV HXB2 as an outgroup and
the Jukes Cantor method to account for multiple substitutions. The bootstrap
resampling method was used (100 replicates) to assess the robustness of each branch
in the tree constructed.
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4.5 RESULTS
To investigate the possible genetic partitioning and differences in predicted
phenotype ofHIV infecting CD4 and CD8 lymphocytes, proviral sequences of the V3
hypervariable region of env were compared. From seven individuals previously
analysed (p2, p3, p8, pl2, pl3, pl4 and p 15) in Chapter 3, approximately 10 clones
derived from amplified DNA extracted from the separated lymphocyte subsets were
sequenced. Further genetic partitioning analysis in the V1/V2 hypervariable region of
env was also carried out in two individuals p3 and p8.
The majority of the study subjects were male homosexuals while the remainder
were in the risk group of intravenous drug users. Their ages ranged from 24 to 51 at
the time of sampling. General information for each study subject is listed in Table 4.1.
DNA from each cell subset was extracted according to the protocol described in
section 2.5. Extracted DNA was amplified in the V3 and V1/V2 regions using primers
as previously described (refer to section 2.5.2). PCR amplified DNA was then used
for further molecular investigations.
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Risk Group3 Viral Load Rxb CD4 count0 CD8 count0
P02 M/49 AH 514,5000 No 29 416
P03 M/34 AH 116,000 Yes 74 772
P08 M/45 IDU 460,000 No 280 1185
P12 F/38 IDU 64.680 Yes 329 380
P13 M/51 PAH 67,980 No 354 1317
P14 F/24 P-Het <513 Yes 360 442
P15 M/33 PAH 60,589 No 748 1016
* These samples were also analysed in Chapter 3.
a
: Risk Groups: AH = AJDS Homosexual; PAH = Pre-AIDS Homosexual; IDU =
Intravenous Drug User; P-Het = Pre-AIDS Heterosexual
b: Anti-retroviral therapy. Details of duration are listed in table 2.1.
c: CD4 and CD8 counts at the time the sample was taken.
4.5.1 Estimation of Viral Load
PCR amplified DNA was cloned into pGEM-T vector using poly (T)
overhangs (refer to section 2.7). Proviral DNA from clones were sequenced using the
Sequenase version 2.0 kit (USB) following the manufacturers protocol (refer to
section 2.8.1). The sequence dataset for the V3 region extended from positions 6957-
7381 in the HIVMN genomic sequence (Genbank accession number Ml 7449), while
the V1/V2 sequences were compared from positions 3539-6944. Sequences were
then aligned and diversity estimated using the Simmonic 2000 Sequence Editor
package. To investigate the possible genetic partitioning and differences in predicted
phenotype ofHIV infecting CD4 and CD8 lymphocytes, proviral sequences of the V3
161
hypervariable region of em were compared (Figs. 4.1). From 7 study subjects,
approximately 10 clones derived from amplified DNA extracted from the separated
lymphocyte subsets were sequenced. The combined set of V3 sequences and V1/V2
sequences from each individual were monophyletic, and distinct from those of
previously published V3 region sequences of clade B isolates: HIVSF2 (K02007),
fflVRF (Ml7451), HIVOYI (M26727), HIVLAI (K02013), fflVJRFL (M74978),
fflVYU2 (M93258), HIVCAM1 (D10112), HIVNY5CG (M38431), HIVHAN
(U43131), HIVWMJ22 (M12507), and HIVSFAAA (M65024). This comparison
provided no evidence for inter-sample or exogenous laboratory contaminsation.
Phylogenetic analysis was carried out using the MEGA program. Distribution of
pairwise distances were carried out using the Systat statistical package.
Two regions of FHV-1 proviral DNA, V1/V2 and V3 were successfully
amplified by nested PCR from the naive and memory CD4 and CD8 T lymphocytes of
p3 and p8 (VI/V2 region) and p2, p3, p8, pi2, pi3, pl4 and p 15 (V3 region),
respectively. Each PCR amplified DNA was cloned and ten clones from each library
sequenced. The proviral loads in the samples analysed were sufficiently high to ensure
that multiple templates were sampled in the lpg aliquots used for sequencing. The
exception was the naive subset from p8; combined with the evidence for potential
contaminsation (Table 3.2), sequences from this subset in the phlyogenetic analysis
shown in Fig 4.3 have been omitted. No association between the detection of HIV-1
proviral DNA and the disease progression or risk groups was observed within samples
from the naive and memory subsets (data not shown).
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Fig. 4.1. Phylogenetic analysis of V3 region sequences from different lymphocyte
subsets of seven study subjects (study numbers in circles). Symbols: CD8
CD45RA+ (naive) cells; "Q": CD4 CD45RA+; CD8 CD45RO+; CD4
CD45RO+; cDNA sequences from plasma (pi4). Trees were rooted using the
HIV-1 mn sequence, scale bar indicated under tree. Clades with -^70 /o bootstrap
















Sequence diversity within lymphocyte subsets, and the degree of partitioning
between them varied considerably between the study subjects. Phylogenetic analysis
was carried out using sequences from the V1/V2 and V3 regions from a range of CD4
and CD8 naive and memory cells from a number of patients. Divergence between
nucleotide sequences was estimated using Jukes-Cantor distances (scale indicated
below tree), and the phylogentic tree constructed from the distance matrix by the
neighbour-joining method. The robustness of groupings was indicated by bootstrap
resampling of 100 datasets, with values of >70% indicated on branches. Phylogenetic
analysis of nucleotide for the V1/V2 and V3 regions revealed a variety of
relationships between variants recovered from different subsets within different
individuals. By comparing the sequences observed with published V1/V2 and V3
sequences of clade B isolates, no evidence was provided for inter-sample or
exogenous contaminsation.
4.5.2 Phylogenetic analysis of V3 aminso acid sequences from CD4 and CD8
naive and memory cells.
V3 sequences from the naive CD4 and CD8 subsets of p 15 grouped together
and showed mean diversities of 0.002 - 0.0064, similar to the mean pairwise distance
between subsets (0.0071) (Fig 4.1). In marked contrast, sequences from CD8
lymphocytes of pl4 were distinct from all other cell types, forminsg a separate clade
supported in 100% of bootstrap re-samplings. The mean pairwise distance between
the CD8 and CD4 lymphocytes ranged from 0.113 (CD4+, CD45RA+) to 0.119
(CD4+, CD45RO+), much greater than the diversity with the CD8 population
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(0.0076). There was no correlation between sequence diversity in any of the subsets
with disease progression, nor with proviral load (data not shown).
Amongst the six study subjects from whom CD8 lymphocyte sequences were
obtained, five showed either partial or complete separation from CD4 virus
populations. In contrast only one of six study subjects showed any evidence for
separation of CD4 naive and memory subsets (p8) (Fig 4.2). Viral phenotype was
predicted according to the translation of the nucleotide between positions Cys301 and
Cys336 in the V3 region. This method can be used to predict in vitro phenotype and
co-receptor usage of variants from the different lymphocyte subsets (Fig. 4.3). In
general, if the positively charged aminso acids arginine (R) and lysine (K) were
observed at positions 11 or 25 counted from the first cysteine (Cys 301) in the V3
loop, variants were predicted as SI strains, otherwise they were predicted as NSI
strains. In general, SI strains were also known as T-cell tropic using CXCR4 as co-
receptors whereas NSI strains are preferentially macrophage-tropic and use CCR5 as
co-receptor.
Most sequences contained neutral or acidic residues at these sites, indicative
of an NSI, CCR5-dependent phenotype. The aminso acid residue at position 11 was
uncharged (in general S) and the residues at position 25 and 29 were either negatively
charged (E or D) or uncharged (Q). The exceptions were p8 and pl4. Changes in
phenotype and tropism of virus isolates are known to occur during disease
progression. In these individuals V3 sequences from certain subsets (p8: CD4+,
CD45RA lymphocytes; pi4: CD4+ lymphocytes and plasma) contained arginine
residues at position 306 along with several other aminso acid changes in V3 and
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Fig. 4.2 Consensus V3 and flanking region sequences of lymphocyte subsets from
seven study subjects. Separate consensus sequences were calculated for the two
phylogenetic groupings of CD8 sequences from p3 and p8. Amino acid residues
numbered according to HIV-1hxb2; positions 306 and 320 indicated; basic residues
contributing to an SI phenotype indicated in bold. Symbols: sequence identity
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flanking regions. These sequences formed phylogenetically distinct clades that
grouped separately from the predicted NSI, R5 variants from the other subsets.
4.5.3 Phylogenetic analysis of V1/V2 nucleotide sequences from CD4 and CD8
nai've and memory cells.
More extensive and different patterns of partitioning of variants from CD4 and
CD8 lymphocytes were observed on sequence comparison of the V1/V2
hypervariable region (Fig. 4.3). Sequences from p3 showed complete separation of
CD4+, CD45RA and CD45RO' subsets, each of which were distinct from CD8
sequences (which formed two distinct clades. Although there were two clades of CD8
sequences in V3 (Figs. 4.1, 4.2), there was no evidence for partitioning of the
different memory phenotypes of the CD4 lymphocytes. In p8, CD8+ CD45RO+ cells
contained variants that were distinct from every other cell type analysed. Although
there was little partitioning of CD4 naive and memory subsets in V1/V2, CD4+,
CD45RA+ cells contained a distinct population of variants in the V3 region which had
a predicted SI, X4 phenotype (Figs. 4.1, 4.2).
4.5.4 Comparison of lymphocyte and plasma derived RNA sequences.
To investigate which of the lymphocyte subsets contained the most actively
replicating virus population, we compared lymphocyte and plasma-derived RNA
sequences from three individuals (Figs. 4.1, 4.3), who showed clear
compartmentalization of CD4 and CD8 sequences in V3 (pl4) or V1/V2 (p3, p8).
Different sequence relationships were observed in each case. For pi4, sequences in
the V3 region from plasma grouped most closely with those from CD4 nai've and
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Fig. 4.3. Phylogenetic analysis of V1/V2 hypervariable region sequences from
different lymphocyte subsets of two study subjects (study numbers in circles).
Symbols: CD8 CD45RA+ (naive) cells; "Q": CD4 CD45RA+; CD8
CD45RO+; CD4 CD45RO+; cDNA sequences from plasma. Trees were
rooted using the HIV-Imn sequence; scale bar indicated under tree. Clades with
>70% bootstrap supported indicated by number on branch.
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memory subsets; the presence of an arginine residue at position 11 predicted an SI,
X4 phenotype. Similarly, sequences from p8 in the V1/V2 region were most similar to
the CD4 population, particularly the naive subset, and were particularly distinct from
those detected in the CD8 memory population. However, in p3, plasma sequences
formed at least 3 groups in V1/V2, at least one of which was more closely related to




Human immunodeficiency virus type-1 phenotype variability plays an
important role in AIDS pathogenesis. In early asymptomatic HIV-1 infection slow-
replicating macrophage-tropic NSI
HIV-1 variants are predominsant (Schuitemaker et al., 1992; Van't Wout et
al., 1994). In the course of infection, HIV-1 isolates display increased replication
rates (Tersmette et ah, 1989; Connor et al., 1994) and reduced tropism for
macrophages (Schuitemaker et al., 1992). In 50% of infected individuals syncytium-
inducing (SI) isolates emerge in the course of infection coinciding with an accelerated
loss of CD4-positive T lymphocytes, rapid disease progression, and reduced survival
time following AIDS diagnosis (reviewed in van't Wout et al, 1998). Variable
domains of the HIV-1 envelope molecule gpl20 play a prominsent role in
determinsing viral phenotype. Both V1/V2 and V3 domains were found to be
important determinsants for HIV-1 tropism (O'Brien et al., 1990; Hwang et al., 1991;
Cheng-Mayer et al., 1990; Shioda et al., 1990; Koito et al., 1994; Westervelt et ah,
1992) and SI capacity (DeJong et ah, 1992; Freed et ah, 1995; Fouchier et al., 1992;
Groenik et al., 1993; Sullivan et al., 1993) although other parts of the viral genome
were shown to be involved as well (Cheng-Mayer et al., 1991; Fouchier et al., 1994).
To investigate whether differences in the envelope region ofHIV-1 reflected specific
cellular adaptation, we compared nucleotide sequences in the V1/V2 and V3 regions
from infected CD4 and CD8 naive and memory T lymphocytes between HIV-1
infected individuals.
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4.6.1 Phenotypic diversity of BTV-1 within the CD4 and CD8 naive and memory
T-cells.
The third variable domain (V3) of the human immunodeficiency virus type 1
external envelope contains determinsants of cell tropism, cytopathicity, and infectivity
and neutralising V3 antibodies are able to block attachment of the virus or subsequent
post-binding events. This study encompassed sequence comparisons of the V3 region
in the CD4 and CD8 naive and memory cell subsets from six study subjects. Cloning
and sequencing of the entire V3 region revealed in five patients variants infecting CD8
lymphocytes were partially or completely genetically distinct in the V3 region from
those recovered from CD4 lymphocytes, and showed a greater degree of
compartmentalization than observed between naive and memory subsets of CD4
lymphocytes. In addition, residues at positions 306 and 320 predicted a preferential
distribution of synctium-inducing, CXCR4-dependent variants in CD4 lymphocytes
(pl4).
Even more marked sequence differences were observed upon sequence
comparison of the V1/V2 hypervariable region, with evidence for recombination
between these regions in at least one study subject (p8). The complexity of viral
populations within T lymphocytes produced by recombination could provide a
powerful adaptive mechanism for the spread of virus with new phenotypes, such as
antiviral resistance or escape from cytotoxic T-cell recognition.
Cell-free HIV-1 circulating in plasma more closely resembled variants
infecting CD4 lymphocytes. Viruses isolated from CD4 memory/effector cells have
been found to be more genotypically related to those found in the plasma (Ostrowski
etal., 1999).
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Sequences recovered from the CD8 lymphocytes were frequently distinct from
those from CD4 lymphocytes, whereas the CD45RA+ and RO+ subsets of the latter
were generally undifferentiated from each other. Although there was great individual
variation in the sequence relationships between different T-cell types, the observation
that CD8 lymphocytes of pi 4 retained a low charge, likely CCR5-dependent V3 loop
sequence when both subsets of CD4 lymphocytes and the plasma population switched
to a probable CXCR4 phenotype argues for slower turnover of the CD8 population in
this case. The temporal differences, rather than a difference in cellular tropism, may
therefore underlie the genetic differences between CD4 and CD8 lymphocytes in this
and the other study subjects.
4.6.2 HIV-1 tropism in vivo.
Peripheral CD8 lymphocytes express low levels of CD4 on mitogenic and
antigenic stimulation in vitro, and it has been hypothesised that this allows productive
infection of CD8 lymphocytes in vivo to occur (refer to Chapter 3 introduction).
However, it is possible that genetic variants of HEV-1 evolve during persistent
infection to infect T-cells by a non-CD4 dependent mechanism; high levels of virus
replication and extensive depletion of the CD4 target population may contribute to
this switch.
Briefly summarising, these observations provide the phylogenetic evidence for
infection of the CD45RA+ population of CD8 lymphocytes while additionally
identifying the complexity of individual variants infecting CD4 and CD8 T
lymphocytes in vivo. In this study we have observed consistent genetic differences in
the V1/V2 and V3 hypervariable regions of all samples analysed. However, it is
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difficult to know whether the different sequences obtained represent genuine diversity
of HIV within thaT-cell type or whether each cell type purified consists of a
heterogenous population of cells at different stages of activation. Divergent genetic
differences observed between the CD4 and CD8 lymphocytes analysed may also
explain the alternating frequency of turnover between the naive and memory subsets
studied earlier (refer to Chapter 3 introduction). While phenotypic characterisation of
HIV variants infecting CD4 and CD8 lymphocyte would clearly be of value, and the
genetic differences observed in V3 and V1/V2 provide evidence for a genetic
difference between the CD4 and CD8 populations, CD4-independent infection would
likely remain cell-cycle dependent or perhaps become more so if based on expression
of high levels of co-receptors.
In the future, phenotypic characterisation of variants infecting the two cell
types should indicate whether CD4-independent entry of HIV-1 can occur. This may
be achieved by phenotyping HIV populations in vivo without prior virus isolation by
amplification and expression of partial or whole env sequences. Env sequences can be
substituted into a proviral backbone, or cloned into a separate expression vector
which can be transfected with an e«v-deleted proviral clone to generate pseudotypes.
Designing pseudotypes which accurately reflect the properties of HIV-1 encoded
proteins in vivo will provide further information on the mechanisms of viral infectivity
and cellular tropism. Comparing sequences from the amplified sequence molecules
will also allow accurate measurement of population diversity including the extent of in
vivo recombination. It is hypothesised that minsor changes in the env sequence could
mask subtle adaptive changes associated with HIV replication. This work is currently
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Human immunodeficiency virus, the aetiological agent of AIDS, can establish
productive or latent infections in CD4+ T lymphocytes and monocytes in culture, and
these alternative states of viral-gene expression could readily account for the
damaging consequences of infection and the difficulties in developing a protective
vaccine. Provirus-containing lymphocytes in PBMCs and lymph nodes are generally
transcriptionally inactive and are not destroyed by HIV infection, either because of
infection with a defective virus or because virus expression is inhibited. Latently
infected cells could escape detection and destruction by host defences and
disseminsate infection in and between individuals in the face of natural or vaccine-
induced immunity. A series of immunocytochemical techniques was used to
determinse the distribution of infected cells in the lymphoid population to allow
comparison with the frequencies detected by PCR. The combination of cell sorting
and immunocytochemical identification may extend the knowledge of the distribution
of infected cells in the lymphoid population to a wider range of cell types, and allow
the frequencies of infected cells in PBMCs to be compared with those in lymphoid
tissue.
The distribution of actively and latently infected T-cellsallows a more accurate
evaluation of the in vivo tropism of HIV, reveals more about the dynamics of infected
cell turnover, and provides information on the mechanism of lymphocyte depletion
upon disease progression. Sequential incubations with monoclonal antibodies and
labelling with fast red, fast blue, and diaminsobenzidine (DAB) allowed the
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distribution of three cell surface or internal markers to be determinsed. Staining for
the CD4 and CD8 cell surface markers from cultured cells was achieved using this
method and allowed infection to be detected by analysing expression of the p24
antigen within the identified cells. In-situ PCR was also used to detect HIV proviral
sequences in selected lymph node and spleen tissue sections.
5.2 IMMUNOCYTOCHEMISTRY
Immunocytochemical techniques, invented by A.H Coons (Coons et al., 1941;
Coons et al., 1955) have gradually, with modifications and improvements, contributed
hugely to our understanding of human pathology. The continued refinement of these
tools has significantly expanded the capabilities of the pathologist in diagnostic
procedures. Immunocytochemistry is the identification of a tissue constituent or cells
in situ by means of a specific antigen-antibody reaction, tagged by a microscopically
visible label. Immunocytochemical techniques have been shown to be useful for the
localisation of viral proteins present in individual cells. The detection of HIV-1, HIV-
2 and SIV viral proteins has been reasonably successful and this technique has
allowed our further understanding of the natural history and host-virus interactions in
patients with these infections. Immunocytochemistry on tissue sections is also an
important diagnostic and research tool in all branches of pathology. In
neuropathology, the localisation of cell types or structural proteins by
immunocytochemisry in human post-mortem tissues is of major importance in
determinsing the aetiology or mechanisms of disease processes.
The presence of HIV-1 in brain tissue has been demonstrated by in-situ
hybridisation for specific HIV-1 mRNA (Saito el al., 1994; Ranki et al., 1995),
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immunohistochemical staining for viral antigen (Wiley et al., 1986), amplification of
extracted DNA by PCR (Achim et al., 1994) and in-situ PCR for proviral DNA
(Nuovo et al., 1994; Bagasra et al., 1996, Strappe et al., 1997). HIV-encephalitis
(HIVE) is a direct effect ofHIV-1 infection of the CNS and occurs in a proportion of
untreated AIDS patients. In 1991, a consensus study defined the term HIVE as the
presence of a constellation of histopathologic findings such as microglial nodules,
multi-nucleated giant T-cells (MGCs) and/or immunocytochemically detected HIV
antigens in brain parenchymal cells (Budka et al., 1991). The presence of HIV-1
antigens or nucleic acid must be demonstrated by immunohistochemistry staining or
nucleic-acid-based detecting techniques. These techniques are a helpful adjunct to the
diagnosis of HIVE even though HIVE can be diagnosed by the presence of giant T-
cells alone. Microglial nodules are focally concentrated collections of microglial cells,
macrophages and lymphocytes and have been observed in both grey and white matter
(reviewed in Bell et al., 1998).
HIV-1 replicates in lymph nodes (LN) and microglial cells and the detection of
HIV provirus in tissues at central sites of the body may further confirm the presence
ofHIV. Other potential mechanisms for persistence involve the survival of an inactive
form of the virus that retains the potential to give rise to infectious virus. Potential
reservoirs for HIV infection include anatomical sites such as the gut, the male genital
tract, and the CNS in those cells which do not display productive infection. A
substantial fraction of the total lymphocyte pool is located in the gut associated
lymphoid tissues (GALT). There is evidence that HIV-1 is trapped by follicular
dendritic cells within LN germinsal centres (GC), which subsequently infect CD4+ T-
cells as they migrate through GC to the paracortex (Embretson et al., 1993; Pantaleo
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et al., 1993). Several investigators have also demonstrated the presence of HIV
virions (Ludewig et al., 1995; Rappersburger et al., 1988; Stingl et ah, 1990),
proviral DNA (Zambruno et al., 1991) and RNA transcripts (Giannetti et al., 1993)
within Langerhans cells. Langerhans cells infected with HIV-1 are defective in their
ability to induce a primary immune response (Blauvelt et ah, 1995) and may transmit
the virus to the T-cell compartments of lymph nodes (Stingl et al., 1990).
HIV-1 infection of the central nervous system (CNS) was thought to be
limited to the microglial cells (Lipton et al., 1992) but recently there has been
accumulating evidence that astrocytes are also a target for infection (Dow et al.,
1992; Genis et al., 1992; Epstein et al., 1993; Benos et al., 1994; Tornatore et ah,
1994; Nuovo et al., 1994; Balluz et al., 1996; Takahashi et al., 1996; Niikura et al.,
1996). The level of HIV-1 replication in astrocytes is low but a persistent restricted
infection clearly develops (Tornatore et al., 1994; Brack-Werner et al., 1992).
In addition to CD4+ and CD8+ HIV-specific T-cells, HIV might interfere with
other cell types whose function is crucial for the generation of effective immune
responses (i.e. monocytes/macrophages and dendritic cells). These specialised antigen
presenting cells (APCs) are central to the induction of humoral and cell-mediated
immune responses. Interference with APC function might be the result either of
quantitative depletion of direct cytopathogenicity or suboptimal formation of major
histocompatibility complex (MHC)-antigenic peptide complexes.
Besides lymphocytes, cells of the macrophage lineage are major target T-cells
for HIV-1. HIV-1 infected macrophages persist in tissues for extended periods of
time containing latent proviral DNA or large numbers of infectious particles within
cytoplasmic vacuoles (Meltzer MS et al., 1990; Embretson et al., 1993). Furthermore
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monocytes/macrophages may be important as vehicles for viral disseminsation
throughout the body. In tissues such as the lung and the brain, HIV-1 is located
primarily in macrophage-like cells (i.e. alveolar macrophages and microglia).
Macrophages are also believed to be a vehicle for the transmission of the virus
between individuals because of mucosal infection, and in haemophiliacs it was found
that a crucial property of the HIV-1 variant which was transmitted is its cellular
tropism (Milman G et al.3 1994).
Concentration of HIV-1 virions on the surface of follicular dendritic cells
(FDCs) in the germinsal centers of lymphoid tissue occurs during the translation from
the acute to the chronic phase of HIV infection. Formation of immune complexes (i.e.
HIV bound with immunoglobulin and complement) and their seeding in the FDC
network are physiological mechanisms generally devoted to the clearance of the
pathogen within the reticuloendothelial (lymphoid/macrophage) system, and to the
generation and maintenance of effective immune responses, respectively. However, in
HIV infection these mechanisms lead to the formation of a stable reservoir of
infectious virions that form a continuous source for the infection of CD4+ T-cells,
which ultimately result in the destruction of the lymphoid tissue. FDCs may transmit
infection to these cells as they migrate through lymphoid follicles. Latently infected
lymphocytes and macrophages constitute an intracellular reservoir large enough
ultimately to contribute to much of the immune depletion in AIDS (Embretson et al.,
1993). B cells also traffic through follicle centres but it is not yet clear as to whether
these cells pose any real threat to neighbouring T-cells. Although CD4 expressing B
cell lines supported in vitro infection of HIV-1, conclusive evidence for the in vivo
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infection of B cells has yet to be presented (Von Laer et al., 1990; Davis et al.,
1991).
Langerhans cells (LCs) constitute 1-3 per cent of the intra-epidermal cell
population (Caughman et al., 1986), but also diffusely populate non-cutaneous
stratified epithelia, including that of the female genital tract (Breathnach et al., 1988).
Several investigators have demonstrated the presence of HIV virions (Ludewig et al.,
1995; Rappersburger et al., 1988; Stingl et al., 1990), proviral DNA (Zambruno et al,
1991) and RNA transcripts (Giannetti et al., 1993) within LCs. As part of the
physiological process of antigen processing and presentation, LCs carrying HIV
migrate towards the T-cell areas of lymphoid tissue.
In the thymus, both lymphocytes and epithelial cells were found to be
susceptible to H3V-1 infection (Numazaki et al., 1989). The virus can also infect T-
cells of the CNS, thereby causing much of the dementia associated with AIDS. The
major target T-cells for HIV-1 in the CNS are the microglia, although the astrocytes
and, possibly, brain capillary endothelial cells can also be infected (Moses et al.,
1996).
5.3 LOCALISATION OF INTRACELLULAR ANTIGENS
Antibody will not penetrate into cells if applied directly to living cultures. For
the localisation of intracellular antigens, therefore, the first consideration is to find a
suitable method for rendering cell membranes permeable to the antibodies, thus
allowing access to the antigen. The 'universal' fixative tends to be formalin, which
causes cross-linking of proteins with fixed tissue. Formalin removes the lipids from
cells and severely distorts the teritary structure of proteins, causing protein
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precipitation (Poulter et al., 1983). It is important to wash the fixed cells thoroughly
between this treatment and the application of the first antibody.
However, the routine methods of fixation for human post-mortem tissues and
cells are considered less than optimal when immunocytochemistry is to be used as a
research technique. Many methods have been used in an attempt to recover
immunoreactivity within formalin-fixed tissues and cultured PBMCs. These include
trypsinisation, proteolytic enzymes (Denk el al., 1977; Finley et al., 1982), alkaline
hydrolysis in NaOH solutions (Shi et al., 1992), treatment with detergents (Meehan et
al., 1989) and the use of formic acid to unmask antigenic sites (Kitamoto et al.,
1987). To improve the reactivity of epitopes that are masked by formalin fixation two
practical approaches are used. Firstly, protease digestion of formalin-fixed sections to
'unmask' antigenic sites and secondly microwave heating of slides enables efficient
antigen retrieval prior to immunohistochemical staining. Microwave antigen retrieval
methodology is a powerful tool for obtaining optimal immunohistochemical results in
formalin-fixed, paraffin-embedded tissue sections (McQuaid et al., 1995). Cattoretti
and Suurmeijer suggested that heat and hydrolysis may both denature and break the
tissue proteins at or near the links made by the formalin between adjacent aminso
acids and thought it conceivable that self-assembly of unfolded protein chains with
subsequent restoration of antigenic sites occurs when the retrieval solution is allowed
to cool (Cattoretti et al., Suurmeijer et al., 1995).
If techniques such as antigen retrieval could be used to visualise antigens that
were otherwise undetectable, the range of useful immunohistochemical methods
would be greatly expanded. A simplified method for antigen retrieval could reduce the
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incidence of false-negative immunostaining results. In clinical applications this may
translate into increased diagnostic accuracy and improved patient care.
5.4 STAINING METHODS
There are many immuno-enzymatic staining methods which can be used to
localise antigens. The choice is based on the individual needs of each laboratory, such
as the type of specimen being investigated, the degree of sensitivity required, and the
processing time and cost requirements. Immuno-cytochemical techniques are used to
identify antigens in specific cell types and to co-localise multiple antigens in individual
cells. To detect sequentially two antigens in single sections, co-localisation protocols
typically use primary antibodies raised in two different species (van der Loos et al.,
1995, Hermiston et al., 1992). In detecting two antisera raised in the same species,
however, recognition of both primary antibodies by the secondary antibodies is a
major concern. This problem can be overcome by a number of methods. Blocking the
antigenicity of the first primary antibody before application of the second primary
antibody can be achieved by either eluting the antibody itself (Tramu et al., 1978) or
by masking the antibody completely by depositing a permanent reaction product such
as silver granules (Roth et al., 1990. Alternatively, primary antibodies can be directly
conjugated to fluorophores (Stengl and Hildebrand et al., 1990), enzymes (Bootsma
et al., 1984), or other molecules (Hartig et al., 1995; Wurden and Homberg et al.,
1993) so that the conjugate itself can then be detected instead of detecting the
immunoglobulin portion of the primary antibody.
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5.4.1 Direct method
In this technique, an enzyme-labelled primary antibody reacts with the antigen
in the tissue. Subsequent use of substrate and chromogen concludes the reaction
sequence. Because this method utilises only one antibody, it can be completed
quickly, and non-specific reactions are limited. However, since staining involves only
one labelled antibody, little signal amplification is achieved. This method is used only
rarely for detection of viruses.
5.4.2 Indirect method
In this method, an unconjugated primary antibody binds to the antigen. An
enzyme-labelled secondary antibody directed against the primary antibody (now the
antigen) is then applied, followed by the substrate-chromogen solution. If the primary
antibody is made in rabbit or mouse, the secondary antibody must be directed against
rabbit or mouse immunoglobulins, respectively. This method is more versatile than the
direct method because a variety of primary antibodies from the same species can be
used with the same labelled secondary antibody. The procedure is also several times
more sensitive than the direct method because several secondary antibodies are likely
to react with different epitopes on the primary antibody.
5.4.3 Avidin-Biotin procedure
As with intracellular antigens, the immunohistochemical localisation of cell
surface antigens provides clear-cut answers to questions about antigen localisation.
To do this, immunocytochemical techniques such as the Avidin-Biotin Complex
procedure using Fluorescein and Diaminsobenzidine were used in the detection of
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infected cell types. The most relevant advantages of the Avidin-Biotin methods are
their sensitivity and versatility. The sensitivity of Avidin-Biotin methods makes them
particularly suitable for immunolocalisation of antigens by means of monoclonal
antibodies (MABs). Avidin has on its surface four hydrophobic pockets that behave as
specific binding sites for four Biotin residues. However due to the molecular
orientation of the Biotin-binding sites, fewer than four molecules of Biotin will bind.
Currently two Avidin-Biotin methods are in frequent use - the ABC method and the
labelled Avidin-Biotin (LAB) technique. Both methods require a Biotinylated
antibody as a link antibody. Biotinylation is a mild process, whereby Biotin is
covalently attached to the antibody. Open sites on Avidin from the Avidin-Biotin
complex or enzyme-labelled Avidin bind to the Biotin on the link antibody. Avidin can
be labelled with markers, such as fluorochrome, an enzyme peroxidase or
phosphastase, ferritin and gold particles (Poulter et al., 1983).
A means of enhancing the sensitivity of Avidin-Biotin systems in solid-phase
assays was reported by Bobrow et al (1989). The method employs horseradish
peroxidase (HRP) to catalyse the deposition of Biotinylated tyramide onto proteins
attached to the substrate. The binding of the tyramide to the proteins at or near the
site of HRP activity is believed to be due to the production of free radicals by the
oxygen that is liberated by the HRP. The Biotin sites on the bound tyramide are
subsequently used for attachment of Avidin, which is conjugated to HRP. The HRP is
then used to catalyse a colour reaction (Bobrow et al., 1989). Adams et al (1992)
showed that the Biotin amplification procedure has great utility for a variety of
applications in neuro-anatomic experiments, lectin histochemistry, and
immunohistochemistry because it provides greater sensitivity than standard
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procedures. One of the attractive features of this method, aside from the increased
sensitivity that it offers, is that it greatly increases the versatility of all procedures to
which it can be applied. A potential problem of the increased sensitivity afforded by
the amplified Biotin method is the possibility of increasing non-specific staining due to
endogenous Biotin.
5.5 MONOCLONAL ANTIBODIES AS IMMUNOCYTOCHEMICAL
REAGENTS.
MAbs have proven to be useful in the diagnosis of infectious disease. In
particular, they have enhanced existing techniques for the rapid detection of microbial
antigens. MAbs differ from polyclonal antibodies in that MAbs are usually raised in
mice while polyclonal antibodies are usually raised in the rabbit. MAbs to HIV-1 Gag
p24 or Env gp41 have been used in several studies on paraffin embedded brain tissue
with various forms of enzymatic pre-treatment (Ranki et al., 1995; Esiri et al., 1991;
Davis et at, 1992). The DuPont HIV MAb to p24 core protein has been shown to
produce excellent HIV labelling compared to 11 other MAbs tested (Cartun et at,
1988). Peripheral blood lymphocytes experimentally infected with HIV and
subsequently fixed with formalin have demonstrated immunocytochemical labelling
with the HIV MAb at the light microscopy level as well as at the ultrastructural level.
In addition, HIV p24 immunoreactivity in dendritic reticulum cells and interfollicular
histocytes in the lymph nodes of AIDS-related-complex patients has been
demonstrated with this procedure. The DuPont anti-HIV-l-MAb p24 has also
produced excellent labelling of mononuclear and multinucleated perivascular
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inflammatory cells in autopsy brain specimens from patients with AIDS encephalitis
(Strappe et al., 1997).
Rapid virus diagnosis relies heavily on indirect immunofluoresence to detect
viral antigens (Fox et al., 1990). This technique involves testing cells from clinical
specimens or tissue culture, for the presence of specific virus antigens by incubating
them with, for example, rabbit-anti-virus antibodies. The immune complex is
thoroughly washed and bound antibody is detected, following incubation with
fluorescein isothiocyanate conjugated to anti-rabbit antibody, by ultraviolet light
microscopy.
The development of MAbs for use as immunofluorescent reagents to detect
microbial antigens in clinical specimens is not without difficulties. Success depends on
the selection of MAbs that possess the necessary affinity, range of reactivity and
physiochemical stability. Many MAbs have been shown to react with unrelated
proteins, with the result that uninfected cells may display non-specific apparent
positivity. Other MAbs have had difficulties in linking to the fluorescein
isothiocyanate (Tiffin et al., 1987). In this study the DuPont anti-HIV-l-p24 MAb
was used with the routine ABC technique to detect the p24 antigen, since this
technique has been proven reliable for sensitive HIV detection (Donaldson et al.,
1994; Strappe et al., 1997).
5.6 IN-SITU PCR AMPLIFICATION
For years, the gold standard for viral diagnosis was to isolate virus in cell
culture. This technique took several days or even weeks to produce results and only
detected viable virus. The PCR was discovered in 1985 and is the most widely used
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technique that allows the direct detection of both RNA and DNA viruses in clinical
specimens.
Methods to demonstrate the presence of productive HIV-1 infection in PM
lymphoid tissue include immunohistochemistry for viral antigen (Donaldson et al.,
1994) and in-situ hybridisation for specific mRNA (Ranki et ah, 1995). Standard in
situ hybridisation methods for detecting viral DNA can be highly specific but are not
as sensitive in detecting HIV-1 proviral DNA, hence the need for HIV-1 in situ gene
amplification. Haase et al 1990 first demonstrated the cellular localisation of single
copies of lentiviral DNA in sheep choroid plexus cells by PCR in situ hybridisation
(PCR-ISH) where the amplified DNA was detected by hybridisation of an internal
oligonucleotide probe. Direct in situ PCR (IS-PCR) allows the detection of cellular
genes and viral sequences in non-disrupted cells and tissue sections and involves the
incorporation during the PCR process of a labelled nucleotide (e.g. Biotin
digoxigenin) which can be detected by immunological methods. Previous studies
using PCR-ISH have demonstrated the presence of HIV-1 DNA in both formalin-
fixed and frozen brain tissue (Takashi et al., 1996, Bagasra et al., 1996) and also in
lymphoid tissue (Embretson et al; Pantaleo et al., 1993), cervical tissue (Nuovo et al.,
1994) and fixed cells (Bagasra et al., 1992, 1993). IS-PCR is potentially a more
sensitive technique used for the detection of single copy genes by the incorporation of
more labelled nucleotides compared to the hybridisation of a labelled probe. However
false-positive signals can occur due to filling in of gaps or nicks in the genomic DNA
by the Taq polymerase using a primer independent DNA repair mechanism (Long et
al., 1993; Nuovo et al., 1994). Microwave pretreatment of the tissue sections
combined with hot-start PCR with the appropriate controls can alleviate primer
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independent polymerisation and increase the sensitivity of the reaction. Inclusion of
positive and negative controls for every experiment is also a vital additional safeguard.
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5.7 RESULTS
5.7.1 Detection of CD4 and CD8 expression on PBMCs infected with synctium
and non-syncytium inducing isolates of HIV-1.
PBMCs were infected with either a non-syncytium inducing isolate (NSI) or a
syncytium inducing isolate (SI) of HIV-1. After cultivation, the cells were washed
with PBS, and immersed in ice-cold acetone. The cells were then suspended in
formalin which permeabilised the cell membranes for antibody interaction with
intracellular antigens. Single label staining reactions were carried out on these cells to
detect HIV and cell surface antigens using various immunocytochemical techniques
and colour substrates. The monoclonal avidin-biotin complex (ABC) procedure was
utilised to detect two cell surface markers CD4 and CD8 both individually and
combined on a single well. CD4+ and CD8+ T-cells were both individually stained
with fast red and fast blue using a biotinylated rabbit anti-mouse conjugate.
CD4+ T-cells were detected with an in vitro conjugated complex of mouse
primary antibody, biotinylated rabbit anti-mouse and normal rabbit serum complex,
and developed by the avidin-biotin/alkaline-phosphatase (ABC-AP) technique with
naphthol-AS-MX-phosphate/Fast Blue BB (figure 5.1). Although not apparent from
some low-power images, T-cells appeared as small round cells. CD8+ T-cells were
detected by another single label reaction and stained with the fast red substrate using
the same methodology as described above (figure 5.2). Cells that were stained using
the fast red complex as antibody label revealed a dark red colour, with some paler
pink coloured cells in the background. This background shade could be accounted for
extracellular debris or dead cells that may also have linked to the fast red substrate.
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Figure 5.1. Single label. Detection of CD4+ T-cells using the Avidin-Biotin/Alkaline
Phosphatase (ABC/AP) technique with naphthol-AS-MX-phosphate/Fast Blue BB.
Magnification x400. NSI isolate.
Figure 5.2. Single label. Detection of CD8+ T-cells using the Avidin-Biotin/Alkaline
Phosphatase )ABC-AP) technique with naphthol-AS-MX-phosphate/Fast Red.
Magnification x400. SI isolate.
The details of the basic double immunolabelling protocol used are outlined in
figure 5.3 and results examined from cells infected with an SI isolate of HIV-1 stained
red (CD4 cells) and blue (CD8 cells) (figure 5.3 and figure 5.3.1). Both antibodies
used in this technique demonstrated precise localisation of antigen-antibody
complexes with minimal non-specific background staining. Morever, to investigate the
reproducibility of staining results, these experiments were repeated several times on
different days with the same working conditions.
5.7.2 Immunocytochemical identification of the p24 antigen (alone) in CD4 and
CD8 cells after infection with HIV-1.
Labelling of the intracellular p24 antigen with diaminobenzidine (DAB) was
achieved using the monoclonal ABC procedure. Uninfected cells were exposed to
exactly the same procedures as HIV-1 positive cells to serve as negative controls. In
addition, infected cells with an omission of the primary antibody were also included as
a negative control. The attachment of monoclonal antibodies to the infected cell was
indicated by a reddish-brown precipitate formed by the action of the peroxidase
enzyme in association with hydrogen peroxide and the diaminobenzidine substrate
(DAB). With DAB, the p24 antigen-positive cells could be easily identified on cells
infected with either the SI and NSI isolate. Positive cells stained reddish-brown while
negative cells remained colourless since no counterstain was utilised (figure 5.4;
figure 5.4.1; figure 5.4.2. Negative controls, in which the primary antibody was
omitted, and the normal, HIV-1 negative controls, showed no positive p24 signal with
the ABC technique. This confirmed the specificity of the p24 mAb (DuPont) with the
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Figure 5.3 and Fig 5.3.1, Double label reaction. Detection ofCD4+ and CD8+ T -
cells using the Avidin-Biotin/Alkaline Phosphatase (ABC-AP) technique on an Si
isolate ofHIV-1. CD4+ cells were detected using Fast Red and CD8+ cells detected
with fast bjue substrate.
Figure 5.3. Magnification x400
CD4+ cells- Fast Red (RED ARROWS). CD8+ cells - Fast Blue (BLUE ARROWS).
SI isolate of fflV-1.
Fig 5.3.1. Magnification xlOO.
CD4+ cells- Fast Red (RED ARROWS) CD8+ cells - Fast Blue (BLUE ARROWS).
SI isolate ofHIV-1.
Figure 5.4. Double label reaction. Detection of CD4+ T-cells using the ABC-AP
technique on an NSI isolate ofHLV-1. CD4+ cells were detected using the Fast Red
substrate while the p24 antigen was detected using the DAB substrate (brown
precipitate - red arrows). p24+ CD4+ cells stained a red-brown colour (blue arrow).
Cells negative for CD4 and p24 (black arrows). Magnification x 200.
Figure 5.4.1 (left) and Figure 5.4.2 (right). Double immunolabelling staining for
p24+CD4+ cells on an NSI isolate ofHIV-1. Typical p24 staining (brown precipitate)
was observed (red arrow). A portion of CD4+ cells on these slides were double-
stained with HIV-1 p24 MAb (blue arrows), although some of them remained
negative (black arrows). Magnification xlOO.
ABC technique and showed that non-specific signals were not amplified. These results
were duplicated on different days utilising the same reaction conditions.
Immunofluoresence has been reported as a useful tool in multiple labelling for
demonstrating the cellular localisation of viral proteins. In this study, detecting the
p24 antigen with the fluorescent substrate, FITC, gave inconclusive results and
limited the application of immunofluorescence with formalin-fixed cells. Following the
procedure outlined in 2.8.1 and using fluorescein avidin D to detect p24 positive cells
it was surprising to find some uninfected cells giving off the same bright green
fluorescence as the infected cells (data not shown). In addition to this, background
fluorescence was prominent making it quite difficult to determine which cells were
positive for the HIV-1 p24 antigen. To try to reduce the background fluorescence the
slides were firstly incubated in hydrogen peroxide in methanol for five minutes but this
method proved inconclusive as it was difficult to visualise individual cells.
Due to the inconclusive results, an alternative secondary antibody, FITC rabbit
anti-mouse was tried instead on the CD4 and CD8 cells on individual slides (no
avidin-biotin reaction) and the CD4+ and CD8+ T-cells were clearly identified by
bright green fluorescence. The p24 monoclonal and synctia were evidently fluorescent
but not as intensely as on the CD8 and CD4 monoclonal (figure 5.5).
A double label reaction was carried out on the p24 antigen with FITC and
CD4 with Fast Red. Under the light microscope, approximately 85-90% of CD4+
cells stained a clear red. FITC labelled rabbit anti-mouse was used to detect p24
antigen on the same cells and when the slide was viewed under the UV light, it
became apparent that the fast red substrate was also giving a fluorescent red colour.
Positive cells were indicated by the presence of a bright green fluorescence amongst
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Figure 5.5. Immunoflourescent staining of CD8+ T lymphocytes. p24
immunofluoFescent staining was evidently fluorescent although not as intensely as the
fluorescene observed with CD8+ T cells. Magnification xlOO.
the red cells but this was rarely achieved, most T-cells usually giving the fluorescent
red colour. One probable cause of the non-specific staining in this type of
immunofluorescence procedure was the fact that perhaps the FITC-labelled rabbit
anti-mouse secondary antibody was also acting with primary CD4 mouse monoclonal
from the first incubation. Inconsistent results revealed that the procedure was
extremely delicate and other factors including the concentration of primary antibody,
biotinylated secondary antibody, avidin, the duration of incubation times, even the
diluents might also contribute to non-specific staining. Therefore, to eliminate the
problem of non-specific staining is a major task for further optimisation of the ABC
technique with immunofluoresence.
5.7.3 Double immunocytochemical labelling of the CD4 and CD8 cells infected
with HIV-1.
To evaluate the sensitivity of immunocytochemistry in detecting CD4 and
CD8 infected cells, HIV-1 DNA in individual CD4+ or CD8+ T-cells was detected
using the fast red or fast blue complex in conjunction with diaminobenzidine (DAB)
for the p24 antigen. CD4 positive cells were identified from both SI and NSI cultures,
respectively (figures 5.6 and 5.6.1). Staining of CD8+ T-cells and the p24 antigen
allowed direct visualisation of infected CD8+ T-cells. PBMCs from an NSI culture
were fixed and the CD8+ T-cells were stained with fast blue and counterstained for
the HIV-1 p24 antigen. The occurrence of rare p24+ individual CD8+ T-cells
indicated that HIV could indeed infect some of these cells (figure 5.7). The p24
antigen was observed in other unstained cells as well as CD8+ T-cells (see arrows;
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Figure 5.6. Double label reaction. Detection ofCD4+ T-cells from an SI isolate of
HIV-1 using the ABC-AP technique. CD4+ cells were detected using the Fast Blue
substrate (blue arrow) while the p24 antigen was detected using the DAB substrate
(brown precipitate, red arrow). p24+ CD4+ cells stained a red-brown colour (as
indicated by black arrows. Magnification xlOO.
Figure 5.6.1. Double immuno-labelling staining for p24/CD4 cells from an NSI
isolate of H3V-1. Typical p24 staining was observed. Most of the p24 positive cells
were double-stained with Fast Blue (as indicated by black arrows), but some CD4+ T-
cells remained p24 negative (red arrows). Magnification xlOO
Figure 5.7. Double label reaction. Detection of CD8+ T cells using the ABC-AP
technique from an SI isolate ofHIV-1. CD8+ cells were detected using the Fast Blue
substrate (blue arrow) while the p24 antigen was detected using the DAB substrate
(brown precipitate- red arrow). p24+ CD8+ cells stained a blue-brown colour (black
arrows). Magnification x200.
Double immuno-labelling staining of p24 (DAB) and CD8 (Fast Blue) demonstrating
that some of these p24 positive cells are CD8 positive (as indicated by arrows).
Magnification xlOO SI isolate.
Figure 5.7.1 Figure 5.7.2
figure 5.7). The proportion of the CD8+ T-cells co-expressing the p24 antigen was
lower than those observed with the CD4+ T-cells (figure 5.7.1 and figure 5.7.2).
Similar micrographs also showed CD8+ T-cells stained with fast red and p24 with
DAB (figure 5.7.3 and figure 5.7.4). The red arrow indicated a cell which is both p24
negative and CD4 negative, the blue arrow indicates a positive signal for p24 antigen
expression and the black arrows indicate both CD4 and p24 antigen expression (figure
5.7.3 & 5.7.4). These findings confirm the presence ofHIV-1 in the CD4+ and CD8+
T-cells of PBMCs cultured with isolates ofHIV-1.
5.7.4 Detection of CD4, CD8 and p24 antigen expression by triple label
reactions.
Immunocytochemical identification of the p24 antigen in CD4+ and CD8+ T-
cells on the same slide can be achieved by a triple labelling reaction. This technique
involves labelling three monoclonals, CD4, CD8 and p24 using fast blue, fast red and
fast yellow respectively. On individual control wells using one MAb and the
respective stain, it was evident that all three cell surface and internal markers existed,
but a triple label caused a mass of colour mixture on the well which made it difficult
to interpret HIV-infected cells (data not shown). The staining pattern was blurred and
background staining also increased.
In the next series of experiments a clearer staining pattern was observed.
Replacement of the fast yellow complex with the DAB substrate for detecting the p24
antigen gave much clearer results. This triple label reaction included CD4 stained with
fast red, CD8 with fast blue and p24 with DAB (figure 5.8). Closer analysis was




Figure 5.7.3 & 5.7.4. Double immuno-labelling staining of p24 (DAB) and CD8
(Fast Red) demonstrating that some p24 positive cells are CD8 positive (as indicated
by arrows). Magnification xlOO. NSI isolates
Red Arrow indicates a negative signal for both p24 antigen and CD8+ T-cells.
Blue Arrow indicates a positive signal for the p24 antigen alone.
Black arrow indicates a positive signal for both p24 and CD8 T-cells.
Figure 5.8. Triple label reaction. Detection of CD4 and CD8+ T cells using the ABC-
AP technique from an NSI isolate ofHIV-1. CD8+ cells were detected using the Fast
Blue substrate (blue arrow). CD4+ cells were detected using the Fast red substrate
(red arrow) and the p24+ antigen was detected using the DAB substrate (brown
precipitate). p24+ CD8+ cells stained a blue-brown colour (black arrows).
Magnification x200.
Figure 5.8.1 Figure 5.8.2
Triple immuno-labelling staining of p24 (DAB), CD4(Fast Red), and CD8 (Fast
Blue). p24 (brown) stained with both CD4+ T-cells and CD8+ T-cells (see arrows).
Magnification x40.
arrows in figure 5.8.1 and figure 5.8.2). This procedure allowed accurate analysis of
the three markers which were clearly distinct from each other, indicating that our
procedure precluded any cross-reactivities between the three different stains. All of
the staining techniques were repeated several times on different days with the same
working conditions and reproducible immunocytochemical staining results were
obtained. More multiple staining reactions are required to show some of the viral
characterisitics ofHIV-1 in vivo.
5.7.5 Detection of HTV-1 p24-positive cells by IS-PCR
In this study, we demonstrated the increased sensitivity of direct in situ PCR
for HIV-1 DNA in formalin-fixed, paraffin-embedded lymph node and spleen tissue
sections by biotin amplification using the tyramide signal amplification detection
system. Lymph node (LN) and spleen tissue sections from HIV-1 seropositive
individuals and donor controls were subjected to in-situ PCR using gag-specific
primers. All of the tissue sections analysed were positive for the HIV-1 provirus
(figure 5.9). Uninfected tissue sections subjected to the same procedure did not
demonstrate any positive provirus (data not shown). Most tissue sections survive the
in situ PCR procedure. Equivocal results are rarely noted with positive cells
demonstrating dense nuclear staining. Detection of incorporated biotin using the
tyramide signal amplification produced a strong dark nuclear staining with the DAB
substrate after 30 cycles of the two step PCR. In addition to the strong staining
intensity, these microwave irradiated sections showed good cellular structure and
morphology.
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Figure 5.9. Detection of p24 positive cells in the lymph node tissue sections from a
seropositive individual using in situ PCR. Proviral positive cells were demonstrated
by a dark nuclear stain (black arrows) compared to that ofuninfected cells (red
arrows). Magnification x 400.
In this experiment, a combination of microwave irradiation of tissue sections
and the use of a 30 cycle PCR showed that no primer-independent false-positive
signals were detected. The negative controls included amplification reactions with the
omission of one primer, both primers, Taq polymerase and biotin-dUTP. 30 cycles of
IS-PCR were also performed on HIV-1 negative tissue with no positive signal being
detected after incorporating the avidin-biotin-alkaline-phosphatase method.
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5.8 DISCUSSION
Immunocytochemistry has been reported as a useful multi-labelling tool in
detecting and demonstrating the cellular localisation of viral proteins. The exact
interaction between HTV-1 and different T-cell types is poorly understood. It was
believed that direct and productive infection of these cells in-vivo might be
responsible for many of the clinical abnormalities found in HIV-1 infected individuals.
Study of infected blood cells has focused chiefly on CD4 lymphocytes in the past.
This part of the study was aimed to investigate further the cellular distribution of
HIV-1 infection in PBMCs by visually demonstrating HIV-1 infecting CD8+ T
lymphocytes in-vitro. The CD8 T-cell function is essential in maintaining the possible
homeostasis of the immune system. Because it is still held widely that lentiviruses do
not infect CD8+ T-cells, the disruption of this cytotoxic function has been neglected as
a potential indirect mechanism of lentivirus-induced immune dysfunction.
5.8.1 Single, double and triple label expression of CD4, CD8 and HIV-1 p24
antigen.
The preliminary strategy in this study was to complete firstly a single stain
with one primary antibody using a Biotinylated secondary antibody and a colour
substrate to give a positive label. CD4+ and CD8+ T lymphocytes were characterised
in this way. A relatively new aspect in the field of immunocytochemical staining is the
application of an amplification method for double immunostainings with primary
antibodies from the same species. Double immunolabellings are an easy and
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convenient method to use in immunocytochemistry, but not usually for co-
localisation, where one colour product tends to swamp the other. We demonstrated
here the efficiency and the reliability of this method, using antibody pairs that are
known to label easily distinguishable cell types
Double immunolabellings involved using a second primary antibody and
secondary Biotinylated antibody before detection using the ABC-AP technique with
either fast blue or fast red as chromogen. Although one label was developed to
completion before commencing with the second, the cells retain their antigenicity (a
beneficial feature of this method). Double immunostaining techniques were also used
to detect intracytoplasmic viral antigen and the cell surface that is being infected. The
purpose of this was not only viral detection but also the identification of the cellular
host of HIV-1. With optimal conditions, the immunocytochemical technique
demonstrated a clear population of p24 positive CD8+ and CD4+ cells which were
simultaneously identified using the fast red, fast blue and DAB substrate as internal
and cell surface markers respectively. Results were validated by a number of
independent experts comprised of a neuropathologist and a collaborating post¬
doctoral researcher working in the immunocytochemistry field.
5.8.2 Immunocytochemical identification of the HIV-1 p24 antigen.
We found that immunocytochemical markers of the p24 antigen, employed
here under carefully optimised conditions, labelled numerous HIV positive CD8+ and
CD4+ T-cells in vitro. By identifying the presence of detectable virus in the CD8+ T-
cells, we can confirm yet another significant factor correlating with the severity of
lymphoid damage observed with HIV-1 infection during disease progression.
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Although immunofluoresence methods have considerable advantages in
revealing several co-localised antigens, the double immunofluorescent technique used
here to detect p24 antigen using an FITC-labelled secondary antibody could not
detect antigen in cells that were positive by ABC-AP detection. Some stains revealed
high background fluorescence which made it difficult to distinguish particular cell
types. Several technical problems occurred while applying this technique, such as
different pre-treatments required for the two working antibodies, cross-reaction
because the monoclonal antibodies were raised in the same species, and also in
balancing the intensity of the two positive signals. We had also had little success using
fluorophore (FITC)-tagged secondary antibodies or Avidin-fluorophores as the
second label to detect the in-vitro conjugated secondary/primary antibody complex
calling into question the sensitivity of these fluorescent methods. In our experiments,
even routine single immunofluorescent methods rendered unsatisfactory results with
CD4 and CD8 MAbs. There was considerable cross-recombination of colours at the
end-point which resulted in confusion when trying to read the results. Therefore,
enzymatic labelling took precedence in this study, because end-results were more
easily interpreted, and permanant. Furthermore, the colour intensity of each stain may
be developed to achieve the optimal contrast for the single and double-label profiles.
The combination of the ABC-AP and Fast Red/Fast Blue/DAB seems to be
the optimal method presently available for double and triple immuno-labelling and co-
localisation studies given the low sensitivity and high background of antibodies and
methodology available for immunofluoresence. These results have, however, not been
confirmed by other investigators. The optimising investigations described above
suggest that further refinement of the immunocytochemical technique could assist in
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enhancing the staining sensitivity. Perhaps when more sensitive antibodies are
available, which can be used at high titres, fluorescent labelling may be preferred since
different fluorophores can be differentiated by appropriate filter combinations and are
suitable for confocal microscopy. The ABC-AP method used in this study offers an
alternative technique that can be used instead of existing techniques, irrespective of
the source of antibodies.
At present, the immunofluoresence (EF) detection sensitivity of HIV antigens
has seriously limited its application and it is still used mainly as a research tool.
Further improvements are required within this field before IF can be used extensively
for HIV in clinical diagnostics. The techniques discussed above therefore had their
potential problems and limitations. For immunofluorescence, the use of multiple
amplification steps in connection with the sensitivity of detection systems such as the
ABC-IF did not provide better detection sensitivity. Instead, the complicated staining
protocols and the achievement of full optimisation with each of the new reagents in
each protocol restricted the application of these methods in this study. The problems
of non-specific staining of background debris and inconsistent results remain the most
significant obstacles in an endeavour to improve and promote immunofluoresence for
future use in relation to HIV in the clinical diagnostic and medical research fields.
The tyramide signal amplification (TSA) method was not used in this study,
but does represent a possible way forward since it is a promising tool when
conventional IF methods fail to detect specific signals (Dr Ting-Huei Wang, personal
communication). Confocal microscopy is an essential method in characterising the
exacT-cellular localisation of antigens using multiple IF labelling in the same tissue
section. Since in many circumstances the availability of primary antibodies is limited,
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the TSA method can be critical for double IF labelling with unconjugated primary
antibodies raised in the same host species. The benefit of using TSA-IF also provides
an opportunity for the development and improvement of double-labelling
immunofluoresence (Wang et al., 1999). The tyramide signal amplification (TSA) has
been shown to not only increase the intensity of immunohistochemical staining but
also numerically detect more HIV-1 antigen expressing cells in brain tissue (Strappe et
al, 1997).
5.8.3 Detection of HIV-1 positive cells by in-situ PCR.
Primary infection with HIV-1 is generally followed by a burst of viremia with
or without clinical symptoms. This is in turn followed by a prolonged period of
clinical latency. During this period there is little if any detectable viremia, the numbers
of infected cells in the blood are low, and it is extremely difficult to demonstrate virus
expression in these cells. In recent years, a new approach, in-situ PCR, has been used
to amplify specific genetic elements within intacT-cells. In comparison to standard
PCR techniques, in-situ PCR has demonstrated high levels of proviral harbouring
PBMCs in HIV-1 infected individuals. It is claimed that the results are extremely
sensitive because the cell itself acts as the amplification vessel and one copy of target
sequence can be demonstrated in individual cells (Bagasra et al., 1993; Nuovo et al.,
1992; Chiu et al., 1992). In this part of the study we looked at the distribution of HIV
in the PBMC's of lymph node and spleen sections and these results indicate a major
localisation of HIV-infected cells in these lymphoid organs. Of note however, high
levels of HIV expression have been observed in regions other than the lymph nodes,
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such as adenoids and tonsils (Pantaleo et al., 1993). It is also likely that HIV disease is
active in the lymphoid tissue even throughout the period of clinical latency.
In order to have effective clearance of HIV, it is important that virus-specific
CTLs are concentrated mainly in lymphoid tissue during the early phases of infection.
Naive lymphocytes traffic between secondary lymphoid organs, probably until they die
or are activated by a specific antigen. Memory cells on the other hand, display a
migratory capacity to a broad range of tertiary lymphoid organs such as the skin or
intestinal laminsa propria and also to sites of inflammation. Rapid spreading of HIV
infection within the naive and memory cells can lead to high levels of virus replication
which may occur in lymphoid organs.
The very close proximity between reactive CD4+ T-cells and CD8+ T-cells
seen in HIV-1 infected lymph nodes strongly suggest that passage of virus could
occur by cell-cell transfer. If infection can occur by cell-cell transfer then the immune
response to HIV infection may result in a greater transmission to uninfected cells.
Follicular dendritic cells were shown to trap the virus in the lymph node by carrying
virus on their surface, which would facilitate infection of adhering T-cells (Cameron et
al., 1992). A previous study comparing the different T-cell subsets that exist within
the lymph nodes and blood has shown that B cells and CD4+ T-cells predominsate in
the lymph nodes (Emilie et al., 1990). As CD4+ T-pells are susceptible to latent
infection early in the course of disease, they ar-e potentially able to pass virus to
closely adjacent T-cells such as the CD8+ naive cell lineage within the lymph nodes.
HIV-1 p24 protein is a viral structural protein, which is only expressed during
productive infectioiy HIV-1 is able to infect several different T-cell lines non-
productively aod cells in vivo such as astrocytes without expression of structural
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proteins. In addition, HAART has suppressed viral replication in many of these
cellular targets in vivo. Under these conditions it may be extremely difficult to detect
virus antigen expression in infected cells. A different technique will be required to
investigate the frequency and distribution of latently infected cells, which highlights
the potential value of in situ techniques. As immunocytochemical p24 detection only
reveals productively infected cells it is important to use techniques such as in-situ
PCR to detect how many cells are latently infected, particularly in individuals where
HAART suppresses productive infection.
Besides lymphocytes, cells of the macrophage lineage are major target T-cells
forHIV-1 (Gartner et at, 1986; Nicholson et a/., 1986; Von Briesen et al., 1990). HIV-
1 infected macrophages persist in tissues for extended periods of time containing
latent proviral DNA or large numbers of infectious particles within cytoplasmic
vacuoles (Meltzer et al., 1990). Furthermore monocytes/macrophages may be
important as vehicles for viral disseminsation throughout the body (Levy et al., 1993;
Weiss et al., 1993). Carriage of HIV-1 by dendritic cells may facilitate the lysis and
loss of antigen specific T lymphocytes in AIDS (Cameron et al., 1992).
For in-situ PCR however, improvements can also be made. Protocols with
better specificity, as well as new methods to prevent the spread of the PCR amplicons
need to be developed. Future developments should involve establishing reproducible
protocols with good sensitivity and specificity. Meanwhile, the techniques used in this
study are current research tools and the results suggest that further investment in
optimisation is worth pursuing.
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5.8.4 Summary
In summary, this study confirms the results of the earlier PCR experiments by
demonstrating that HIV-1 can infect cytotoxic T lymphocytes in vivo. It is known that
these cells decline in number in untreated AIDS patients and it may be that loss of
these cells and their function in AIDS is a more significant factor in the advancing
immune incompetence than the loss of T-helper cell function, as previously mentioned
(refer to section 1.8.2.1). The ABC-AP technique is a useful tool in the
developmental progression of immunocytochemistry, especially in detection of HIV-1
p24 antigen with CD4+ and CD8+ T lymphocytes. The sensitivity of detection was
greatly enhanced, and the ABC-AP technique was considered to be another beneficial
tool for the p24 investigations in the cells analysed. Our experiments also
demonstrated that in situ PCR can be accomplished in cell populations known to
carry the HIV-1 provirus. Further development and validation of in-situ PCR in
localising and quantifying HIV infected cells in vivo could be combined with a laser
capture micro-dissection microscope providing a powerful method to detect, separate,
genetically characterise and clone sequences from HIV infected cell types from
different tissues.
213
CHAPTER SIX: GENERAL DISCUSSION
Implications of HIV infection for the immune system
The pathogenesis of an infectious disease involves interactions between the
infectious agent and the host's immunological response to the challenge. In HIV-1
infection, these interactions appear to have fundamental consequences for many
different aspects of the disease. Disruption of the T-cell network and suppression of
the cellular immune response in HIV disease result in opportunistic infections and
neoplasms that contribute to AIDS-related morbidity and mortality. Despite the recent
advances observed with antiretroviral therapy, there is still no cure for AIDS or HIV
infection. Drug therapy, although promising, remains problematic because of crippling
side effects, vast expense and poor compliance. In addition, only 10% of people
infected with HIV live in countries where an adequate supply of HIV drugs is
available, while limited resources make sophisticated HIV therapy beyond the reach of
the other 90% (UNAIDS/WHO, 1999).
The understanding of disease caused by HIV-1 has been hampered by the
complexity of the interactions of this virus with the human immune system. HIV
infection in vivo is a dynamic process involving continuous rounds of infection,
replication and cell death. The immunological hallmark of successful infection with
HIV-1 is a progressive decline in CD4 T-cell count which ultimately results in the
appearance of infections characteristic of AIDS. As well as predominsantly infecting
CD4+ cells, HIV also infects cells of the monocytic/macrophage lineage, which
express low level CD4+ and MHC class II. The turnover of CD4+ T-cells during HIV
infection is thought to be rapid, with the entire population of peripheral CD4+ T-cells
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estimated to be replaced on average every 15 days (Ho et al., 1995). While the great
majority of infected individuals do not present clinical signs of disease for extended
periods, virus replication remains high, especially in reservoirs such as the lymph
nodes and spleen (Donaldson et al., 1994). In patients who die of AIDS related
illnesses, infection is extensive, targeting brain, lung, colon and liver cells as well as
lymphoid tissue (Donaldson et al., 1994). Persistent and high levels of virus
replication result in the loss and destruction of normal lymphoid architecture. As the
immune system chronically deteriorates, virus and virus-infected cells are less
efficiently removed by the host.
Persistence of virus in the host in the presence of ineffective immune system
clearance results in the state of chronic immune system activation. Activation of cells
in the course of the immune response further favours the spread and establishment of
HIV in new target CD4+ T-cells and macrophages. Progression of HIV infection is
characterised by complex dysregulation of T-helper cell maturation and development
which can involve the T-cells themselves and/or antigen presenting cells (reviewed in
Copeland etal., 1996).
The analysis of the number and type of cells that HIV infects in the lymphoid
system, and the discovery of widespread covert infection in macrophages and CD4+
T-cells at early stages brings a fresh perspective to understanding the pathogenesis of
disease and an increased appreciation of difficulties in treating and preventing
infection. The potential for understanding the mechanism of immune dysregulation
and cell targetting by HIV in general was recently enhanced by the discovery of
secondary co-receptors for HIV-1 entry into target T-cells (Feng et al., 1996; Bleul et
al., 1996, Alkhatib et al., 1996; Choe et al., 1996; Berger et al., 1997; Oberlin et al.,
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1996; Dragic et al., 1996). These discoveries not only provide insight into the
mechanism of viral entry, but also explain the mechanism by which early viremia
progresses to immunodeficiency. Acquistion of the ability to use additional co-
receptors may broaden viral tropism and influence disease pathogenesis.
The 'tap and drain' hypothesis
HIV infection is seen as a Titanic struggle between the virus and the immune
system. 3.5 x 106 CD4+ T-cells are lost daily in HIV infected individuals and since in
most normal individuals the decline in total CD4+ T-cell numbers over time is very
gradual, the conclusion is that an almost equivalent number must be regenerated to
reconstitute the peripheral pool. A number of studies have recently described an
analogy where the HIV seropositive patient can be compared to a bathtub, in which a
drain (HIV) causes a steady loss of water (the T-lymphocytes), while a tap (the
thymus) steadily strives to maintain the water level. The putative gene controlling the
CD4:CD8 ratio operates at a pre-thymic level, and the undifferentiated precursor, all
of the CD4/CD8 lineage, is genetically geared to preferentially give rise to either
CD4+ or CD8+ T-cells. During HIV infection, an increased loss of CD4+ T-cells
results in an increased production of CD3+ T-cells which are maintained at a constant
level in high-ratio individuals who produce T-cells with a balance favouring CD4+ T-
cells over CD8+T-cells. The decline in this production is slower and less pronounced,
compared with low-ratio seropositive individuals, who preferentially produce CD8+
T-cells in response to a CD3+ T-cell depleting event, and hence undergo more
marked CD8+T-cell lymphocytosis. The evidence suggests that seropositive
individuals genetically predisposed to a high CD4:CD8 ratio would be more efficient
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in replenishing CD4" T-cell losses than those predisposed to a low CD4:CD8 ratio. Of
course, this hypothesis assumes that the 'drain' would be equal in different patients,
and that different exogenous factors such as therapeutic interventions would not
interfere with the 'tap and drain' balance (Ho et al., 1995; Heeney et al., 1995;
Amadori etal., 1996).
However, HIV may also impair T-cell regeneration by targeting and damaging
the thymus (tap) itself. The architecture of the thymus is disrupted in AIDS patients
(McCune et al., 1997; Ho et al., 1995) although the extent to which thymus
dysfunction contributes to the development of AIDS remains unclear. It is known
however, that any alteration of thymopoiesis would limit the production of naive T-
lymphocytes (water) which is consistent with the preferential depletion of these cells
in HIV-infected individuals (Roederer et al., 1997). Histopathologic lesions in the
thymus of AIDS patients have been observed which suggests some degree of thymus
dysfuntion (Haynes et al., 1998; McCune et al., 1997) which may result from the
emergence of X4 viruses that target thymic progenitors (Pedroza-Martins et al.,
1998). Severe congenital thymus defects have also been observed in HIV-infected
infants that progress rapidly to disease (Kourtis et al., 1996; Nahmias et al., 1998),
suggesting that the mechanisms of T-cell depletion is in part thymus dependent.
Thymopoiesis is critical to the restoration of normal T-cell numbers after profound T-
cell depletion, as is seen following bone-marrow transplantation. Thus, HIV-induced
thymic damage may impair the regeneration of CD4 and CD8 T-cells in patients with
severely depleted numbers of T-cells.
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HIV infected CD8+ T lymphocytes in vivo.
In vivo infection of CD8 lymphocytes has been described for HIV-1 (Huang el
al., 1999; Mercure etal., 1993; Livingstone el a!., 1996; Yang et al., 1998; Flamand
et al., 1998), for simian immunodeficiency viruses in sooty mangabeys (SIVmac)
(Dean et al., 1996) and African green monkeys (SIVagm) (Muruayama et al., 1999)
and for lentiviruses infecting other mammals, such as feline immunodeficiency virus
(English et al., 1993; Dean et al., 1996). In this study, frequencies of infection,
proviral contaminsation and genetic relationships between HIV-1 variants infecting
naive and memory CD4 and CD8 lymphocytes were investigated. Significant infection
of the naive subset of CD8 T lymphocytes was detected in 8 study subjects at
frequencies ranging from 31-1444 proviral copies/106 cells, more frequently than in
CD3+, CD8+ lymphocytes expressing the RO isoform of CD45 (n=3, 20-259
copies/106 cells). In agreement with previous studies there was no evidence for a
similar preferential infection of CD4 naive lymphocytes.
The propensity of T lymphocytes to die, as evidenced by spontaneous
apoptosis, is increased in HIV-1 infected patients and in SIV-infected macaques
(Ameisen et al., 1991; Estaquier et al., 1994; Gougeon et al., 1993, Meyaard et al.,
1994). Evidence has also been presented suggesting that the SIVmac may target the
thymus of experimentally infected macaques, and infect immature lymphocytes
expressing both CD4 and CD8 during thymopoiesis (Dean et al., 1996). Similarly,
infection of CD4+, CD8+ thymocytes in human thymic implants in SCID mice leads
to the subsequent appearance of HIV-infected CD8+, CD4- lymphocytes in the
peripheral circulation (Kitchen et al., 1997; Lee et al., 1997). The work carried out in
this thesis provides supporting evidence for the contribution of intrathymic infection
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in the pre-activated, antigen naive population of CD8 lymphocytes in vivo. HIV-1
infection of CD4+, CD8+ immature thymocytes destined to become CD8
lymphocytes during thymic maturation would provide both a plausible mechanistic
explanation for their infection, and would also explain the presence of proviral
sequences in the naive subsets of both CD4 and CD8 lymphocytes in peripheral blood.
Decline in total lymphocyte numbers has been attributed to a failure of T
lymphocyte homeostasis, although the observation of a delayed although substantial
decline in CD8 frequencies suggests that their production is also impaired or that their
destruction in the periphery occurs at a similar intensity to that of CD4 lymphocytes.
Contributory information on the influence of HIV on CD8-lymphocyte mediated
immunity is provided by several studies investigating the dynamics of production of
CD8 lymphocytes in HIV-infected individuals, and the effect of HAART on turnover.
Investigation of T-cell turnover by expression of the Ki-67 antigen or by labelling of
cells with [2H]-labelled deuterium or by BrdU in experimentally infected macaques
with SIV indicated increased turnover of both CD4 and CD8 cells upon disease
progression (Rodriguezalfageme el al., 1998; Hellerstein et al., 1999; Sachsenberg et
al., 1998; Rosenweig et al., 1998; Mohri et al., 1998) and specifically of CD8
lymphocytes by investigations of telomere length. (Wolthers et al., 1996).
Combination monoclonal antibody cell separation techniques and in-situ PCR
for proviral sequences established that HIV infects a wide range of cell types in the
PBMC population, including CD8 lymphocytes. Ultimately, it is important to identify
whether these infected CD8 T lymphocytes are productively or latently infected.
Clearly, immunostaining to identify viral protein is insufficient and much work needs
to be carried out to improve the limitations of this technique (as discussed in Chapter
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3). Evidence of HIV distribution within the lymphoid areas such as the lymph nodes
and spleen was also presented in this thesis project. Lymphocyte depletion is the
major abnormality seen in the spleen with HIV-1 infected-individuals (Pantaleo et cil,
1994; Levy et al., 1998). Lymph nodes are commonly sites for opportunistic infection
in AIDS, usually resulting in lymphadenopathy. Generally infections are multiple and
are sometimes found in association with neoplasms. It could be speculated that CD8
lymphocytes themselves could represent a reservoir for HIV-1 which may persist for
long periods at low levels in many treated individuals despite the use of maximally
suppressive antiretroviral regimens. CD8 T lymphocytes are known to traffic within
the CNS and they may also represent a target for infection during AIDS alongside
other targeted cells within the CNS such as microglial cells, multinucleated giant T-
cells (MGCs) and brain macrophages (reviewed in Bell, 1998). Infected cells release
toxic cellular factors leading to tissue damage and apoptosis (Esser et al., 1998).
Therefore, HIV-1 is likely to have its damaging effect indirectly in tissue of the CNS.
Common problems occurring after infection of these cell types include HIV-1 specific
neuropathology and many opportunistic infections (Gray et al., 1996; Price et al.,
1996; Bell et al., 1998; Esser et al., 1998).
Recent work undertaken post thesis completion
Recently, it has been suggested that there is a possibility that CD8
lymphocytes purified by negative selection may contain null (CD4-,CD8-) cells. In this
thesis project it was not possible to positively select for CD4 and CD8 T lymphocytes
prior to the separation of naive and memory cells since positive selection can
potentially alter the activation status of isolated cells and therefore the isoform of
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CD45 expressed on the cell surface. However, after completing all the work detailed
in this thesis, further experiments were undertaken to address this issue. In the
attached manuscript T-cells from the PBMCs of 7 new individuals were positively
selected for CD4 and CD8 lymphocytes. Purified CD8 lymphocytes prepared in this
way showed a range of proviral loads (Table 3, McBreen et al., 2000, manuscript
attached) similar to those found in CD8 lymphocytes isolated by the negative
selection. In addition, examinsation of the HIV proviral sequences detected in CD8-
positive lymphocytes supports the conclusion that the proviral sequences obtained
from the negative selection procedure used in this thesis project were not likely to
have originated from null cells. This provides support for the validity of results in the
main project.
Evidence that the positive and negative selection procedures used to separate
CD4 and CD8 T lymphocytes are highly effective at removing monocytes and other
non-T lymphocytes from purified cells has also been shown in the attached manuscript
(McBreen et al., 2000). Previous studies have documented a relatively low frequency
of infection of monocytes in PBMCs in vivo which makes it highly unlikely that
monocytes could contribute significantly to the proviral loads detected in CD4 and
CD8 T lymphocytes in this study (Hsia et al., 1995; Schnittman et al., 1989;
Livingstone et ai, 1996).
Further work was also carried out to examinse the quiescent nature of HIV-1
infection in CD8 naive lymphocytes. A method was designed to quantify complete
proviral sequences (i.e. that span the primer binding site [PBS} and U5 region; C-
LTR-primers) and initial transcripts (primers amplifying the region immediately
downstream from the PBS (pan-LTR). Within the expected accuracy of the limiting
221
dilution method used for proviral quantitation, no observations were made between
the two sets of primers for an excess of incomplete proviral sequences indicating that
the sequences detected in both CD4 and CD8 lymphocytes were complete. Their
stable integration in the cellular genome has been suggested by previous studies
investigating the half-lives of proviral DNA in PBMCs in vivo and the observations in
this thesis document the stability of proviral load in CD8 lymphocytes in individuals
receiving antiretroviral therapy. From this data it can be concluded that there is no
evidence for the existence of significant numbers of incomplete transcripts which
might be associated with abortively infected cells.
Future Investigations
At present it remains unclear whether HIV-infected CD8 lymphocytes in vivo
represent recent thymic emigrants or recently activated naive CD8 lymphocytes.
Identifying the maturation stage of infected CD8 lymphocytes will give a broader
insight into the mechanism and effect of their infection on immune function. Future
experiments involve separating CD3+ lymphocytes into CD4-CD8- and CD8+CD4+
subsets using MACS beads and subsequently sorting cells with cell surface markers
CD69 and CD1 to differentiate between immature thymic emigrants and recently
activated naive CD8 lymphocytes. Limiting dilution PCR will be carried out on the
sorted cell subsets to analyse for HIV proviral sequences. The frequency of
productively infected cells will be assayed by p24 antigen staining of fixed
immobilised cells.
Although HIV sequences can be detected in CD8 lymphocytes present in
PBMCs, there is currently no information on whether the cells are actively infected
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with HIV, or whether this can be induced by mitogenic or antigenic stimulation. It
would be interesting to investigate whether CD8 lymphocytes have the potential to
produce infectious virus. This could be achieved by developing a fully quantitative
infectivity assay for separated lymphocytes. Simple bulk culture of purified CD8
lymphocytes is evidently insufficient to carry out this analysis. A quantitative method
is crucial in order to calculate the contribution of contaminsating CD4 lymphocytes
within the isolated CD8 lymphocytes.
Further development and validation of the methods used in this study to
localise and quantify HIV-infected cells in vivo such as p24 antigen
immmunocytochemistry and in-situ PCR would prove very useful in not only allowing
precise localisation but also in defining the genetic characterisation of variants
infecting particular cell types in vivo. New studies involving cell isolation using a laser
capture microdissection microscope would provide a powerful method to detect,
separate, genetically characterise and clone sequences from HIV-1 infected cell types
in different tissues. These methods could measure the frequency and viral expression
of HIV infecting cells in the lymphoid tissue and infiltrates by co-localising with cell
surface markers such as CD3, CD4, CD8 and CD14 which would allow identification
of infected cell types.
Forthcominsg studies should also focus on phenotypically characterising
variants infecting the two cell types by applying a pseudotyping method to
characterise the properties of entire gpl20 sequences amplified by PCR from purified
CD4 and CD8 lymphocytes. This would not only provide further information on co-
receptor usage but would also indicate whether CD4-independent entry of HIV-1 can
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occur by avoiding the potential selection effects observed when carrying out in-vitro
culture.
In summary, this study provides extensive evidence for the infection of CD4
and CD8 naive and memory cells in vivo, signifying that HIV has a broader tropism
for cell types in vivo than previously thought. The primary outcome of many viral
infections is immune containment rather than the eradication of infection. In order to
develop an effective vaccine, HIV-specific Th cell responses as well as virus-specific
CTLs should be induced. The stronger the response the broader its direction, resulting
in increased opportunity for variant virus strains could be controlled efficiently.
Exactly how to elicit these responses still remains to be established. The most
effective antigen delivery vehicle and routes of adminsistration have also yet to be
defined.
Although many questions remained unanswered, in particular concerning the
process underlying CD4 lymphocyte decline as well as the mechanisms of CD8+ T-
cell infection, much is understood about how to treat HIV effectively. The recent
development and use of HAART has provided optimism that T-cell immune
competence can be restored in patients with chronic infection and preserved in those
with acute infection. The aim is to improve the capacity for T-cells to regenerate
effectively with a reduction in T-cell activation which may prevent anergy and
apoptosis which together may ameliorate the CD4 and CD8 T-cell deficiencies and
dysfunction noted in this thesis project. The hope must be that the increased
understanding of HIV infection which new therapies have provided and new reliable
assays which quantify HIV levels lead us to a greater understanding of the therapeutic
constraints on HIV replication and eventually to a prophylactic vaccine.
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To investigate the mechanism and functional significance of infection of CD8+ lymphocytes by human
immunodeficiency virus type 1 (HIV-1) in vivo, we determined frequencies of infection, proviral conformation,
and genetic relationships between HIV-1 variants infecting naive (CD45RA+) and memory (CD45RO+)
peripheral blood CD4+ and CD8+ lymphocytes. Infection of CD3+ CD8+ CD45RA"1" cells was detected in 9 of
16 study subjects at frequencies ranging from 30 to 1,400 proviral copies/106 cells, more frequently than CD3+
CD8+ lymphocytes expressing the RO isoform of CD45 (n = 2, 70 and 260 copies /106 cells). In agreement with
previous studies, there was no evidence for a similar preferential infection of CD4+ naive lymphocytes. Proviral
sequences in both CD4+ and CD8+ lymphocyte subsets were complete, as assessed by quantitation using
primers from the long terminal repeat region spanning the tRNA primer binding site. In six of the seven study
subjects investigated, variants infecting CD8+ lymphocytes were partially or completely genetically distinct in
the V3 region from those recovered from CD4+ lymphocytes and showed a greater degree of compartmental-
ization than observed between naive and memory subsets of CD4+ lymphocytes. In two study subjects, arginine
substitutions at position 306, associated with use of the chemokine coreceptor CXCR4, were preferentially
found in CD4 lymphocytes. These population differences may have originated through different times of
infection rather than necessarily indicating a difference in their biological properties. The preferential distri¬
bution of HIV-1 in naive CD8+ lymphocytes indeed suggests that infection occurred early in T-lymphocyte
ontogeny, such as during maturation in the thymus. Destruction of cells destined to become CD8+ lymphocytes
may be a major factor in the decline in CD8+ lymphocyte frequencies and function on disease progression and
may contribute directly to the observed immunodeficiency in AIDS.
CD4+ lymphocytes are considered to be the principal target
of human immunodeficiency virus type 1 (HIV-1), but more
recently a number of studies have shown the in vivo infection
of other lymphoid cell types including CD8+ T lymphocytes
(12, 21, 31, 33, 51). CD8+ T cells are a major immunological
defence against HIV-1 infection. In most individuals, HIV
mediates a strong specific cytotoxic activity that eliminates
productively infected cells. This response also blocks intracel¬
lular viral replication in CD4 cells by production and secretion
of a number of soluble inhibitory factors such as macrophage
inflammatory proteins la and lf3 and RANTES (regulated
upon activation, normal T-cell expressed and secreted), inter-
leukin-16, and other, as yet unidentified factors (17, 32). Dur¬
ing the course of infection, there is a gradual loss of CD4 cells;
after an initial increase in the number of cytotoxic T cells, the
CD8 cell number similarly falls during disease progression
(29). The observed decline in both the number of CD8 cells
and specific HIV cytotoxic activity coincides with an increase in
viral load and may ultimately be a contributory factor to the
eventual collapse of the immune system and the development
of AIDS.
The mechanisms leading to CD8 T-cell dysfunction and de¬
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pletion are still unclear. CD8 T-cell function may be the indi¬
rectly influenced by a defective HIV-l-specific CD4 T helper
response that is necessary for the maturation and function of
cytotoxic T cells. It has also been demonstrated after antigenic
stimulation some CD8 T cells develop a state of unresponsive¬
ness and eventual death is mediated via apoptosis (19, 30).
However, it has been observed that productive HIV-1 infection
of cytotoxic T lymphocytes in vitro and in vivo in animal mod¬
els can occur (47). The peripheral interaction between CD4
and CD8 cells occurring in vivo as part of the immune response
may allow direct transmission of infection to the CD8 lympho¬
cytes. Alternatively, it is possible that damage to or deficiency
of the thymus may also confer direct infection. HIV-1 may
infect and destroy both intrathymic T progenitor cells (CD3~
CD4+ CD8~), double-positive thymocytes (CD3+ CD4+
CD8+) (4, 49) and mature CD3hl CD8+ thymocytes (28). Re¬
cent studies alternatively suggest that infection of CD8 lym¬
phocytes may occur by a conventional CD4-dependent mech¬
anism, as CD4 expression is up-regulated following activation
through the T-cell receptor complex (12, 49, 51).
Information on the mechanisms of CD8 lymphocyte infec¬
tion can be obtained by analysis of relative frequencies of
infection of CD8 lymphocytes expressing the CD45RA (naive)
and CD45RO (memory/effector) isoforms, as has been previ¬
ously described for CD4 lymphocyte infection (36). Abortive
or noncytopathic infection of double-positive (CD4+ CD8+)
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Pi F IDU 14,000 10 98 834 <10 0.9 <10 11
p2 M MH 514,500 29 1,106 587 107 10 (9.4) <10 8.0
p3 M MH 116,000 74 133 278 1,444 1.2 (0.1) <10 3.8
p4 M MH 18,000 130 596 4,272 <10 5.4 <10 58
p5 M MH <400 232 686 457 422 6.2 (1.5) 67 6.2(17)
p6 F Het 52,000 265 866 1,566 <10 7.9 <10 21
P7 M IDU/Het 48,000 267 95 520 <10 0.9 <10 7.1
p8 M IDU 460,000 280 4,307 2,137 22 39 (180) 259 29 (21)
p9 M MH >750,000 282 575 2,321 40 5.2(13) <10 32
plO M MH 81,540 301 1,307 464 622 12(1.9) <10 6.3
pll M MH 661,000 311 834 3,916 <10 7.6 20 53 (270)
pl2 F IDU 64,680 329 55 115 <10 0.5 <10 1.6
pl3 M MH 67,980 354 115 222 71 1.0 (1.5) <10 3.0
pl4 F Het <513 360 533 980 119 4.9 (4.1) <10 13
pl5 M MH 60,589 748 653 Negative 31 5.9 (19) <10 <0.1
pl6 M MH 1,680 850 143 25 <10 1.3 <10 0.3
a F, female; M, male.
b Abbreviations: IDU, injecting drug user; MH, male homosexual; Het, infection acquired through heterosexual contact.
c Estimated contribution of contaminating CD4 cells to proviral load (percent of total) detected in CD8 lymphocytes, using mean purity data from controls (Table 4).
thymocytes during maturation in the thymus would produce
differentiated, naive CD8+ lymphocytes in the circulation that
contained stably integrated HIV proviral sequences. However,
if infection occurred during the phase of CD4 expression after
antigenic stimulation of CD8 lymphocytes, then proviral se¬
quences would be preferentially distributed in the memory/
effector population, as the activation process would result in a
change of phenotype from CD45RA+ to CD45RO+. In this
study, we investigated the frequency of HIV infection in CD4
and CD8 naive and memory cell populations separated from
peripheral blood mononuclear cells (PBMCs) of HlV-seropos-
itive individuals by quantitative PCR for HIV-1 proviral se¬
quences. We also investigated possible genetic differences be¬
tween variants of HIV-1 isolated from each of the lymphocyte
subsets that might relate to time of infection or determine
differences in cellular tropism.
MATERIALS AND METHODS
Samples and clinical details of study patients. Samples (20 to 30 ml) of whole
blood anticoagulated with EDTA were collected from seropositive individuals
attending the genitourinary medicine clinic or the infectious disease unit in
Edinburgh. CD4 counts, viral load information, and risk groups from the patient
group in whom distribution of HIV in naive and memory subsets of CD4 and
CD8 lymphocytes were analyzed (Table 1). Plasma virus loads were determined
by a commercially available PCR (Roche Monitor, Lewes, East Sussex, United
Kingdom). Further samples were collected from five healthy, HIV-seronegative
control for cell purity measurements.
Cell separations. Blood samples were diluted with an equal volume of phos¬
phate-buffered saline and PBMCs were isolated by density centrifugation over a
Ficoll-Hypaque gradient (Lymphoprep; Nycomed). T lymphocytes were purified
from PBMCs using a negative selection pan-T isolation kit on an automated
MACS cell sorter (Miltenyi Biotec). CD8+ and CD4+ lymphocytes were isolated
from the purified T cells by positive selection using CD8- and CD4-conjugated
MACS beads. Naive and memory subsets of CD4 and CD8 lymphocytes were
separated from PBMCs by initial separation into CD4+ and CD8+ lymphocytes
by negative selection (Miltenyi Biotec). Naive and memory subsets of isolated
CD4 and CD8 lymphocytes by obtained by positive selection using CD45RA- and
CD45RO-conjugated MACS beads.
Analysis of the purity of isolated subsets by flow cytometry. For analyses in this
report, the following combinations of labeled monoclonal antibodies were used
(10 fxl per 105 cells; 30 min at 4°C): (i) fluorescein isothiocyanate isomer 1
(FITC)-conjugated CD8, phycoerythrin (PE)-conjugated CD3, and phyco-
erythrin-Cy5 (Cy5)-conjugated CD4; (ii) FITC-CD45RA and PE-CD45RO; (iii)
FITC-CD45RA, PE-CD45RO, and Cy5-CD4; (iv) FITC-CD45RO, PE-CD45RA,
and Cy5-CD4; (v) FITC-CD45RA, PE-CD45RO, and Cy5-CD8; and (vi) FITC-
CD45RO, PE-CD45RA, and Cy5-CD8 (DAKO, Glostrup, Denmark). Cells
were washed twice in phosphate-buffered saline with 2% bovine serum albumin
and fixed in 200 p.1 of 2% formalin. The purity of the isolated CD4+ CD45RA+,
CD4+ CD45RO+, CD8+ CD45RA+, and CD8+ CD45RO+ cell populations
was assessed on a Coulter Epics Elite after gating on lymphocytes based on their
forward and side scatter characteristics. Each analysis was based on a minimum
of b,UUU events.
Detection and quantitation of HIV sequences. DNA was extracted from iso¬
lated cell subsets as previously described (44). HIV proviral sequences were
quantified by limiting-dilution nested PCR (44, 54) using nested sets of highly
conserved PCR primers from the long terminal repeat (LTR) region. Pan-LTR
primers were 5'-GRAACCCACTGCTTAASSCTCAA-3' (outer, sense) 5'-TG
TTCGGGCGCCACTGCTAGAGA-3' (outer, antisense), 5'-CTCAATAAAGC
TTGCCTTGAG-3' (inner, sense), and 5'-GAGGGATCTCTAGNYACCAGA
GT-3' (inner, antisense) (5' base positions 506,626,524, and 578, respectively, in
the HXB2 genome). Complete LTR (C-LTR) primers were 5'-ACTCTGGT
RNCTAGAGATCCCTC-3' (outer, sense), 5' -GGCGTACTCACCAGTCG
CCG-3' (outer, antisense), 5'-TCTCTAGCAGTGGCGCCCGAAC-3' (inner,
sense), and 5'-TCAGCAAGCCGAGTCCTG-3' (inner, antisense) (5' base po¬
sitions 578, 735, 626, and 692, respectively, in the HXB2 genome). Both primary
and secondary PCRs for pan-LTR and C-LTR primers were carried out using the
following parameters: 94°C for 18 s, 55°C for 21 s, and 72°C for 1.5 min for 30
cycles, followed by a final extension step of 72°C for 6 min. PCR amplicons were
run at 150 V for 30 min on 2% agarose gels containing 0.5 }xg of ethidium
bromide/ml and visualized under UV light.
Quantification was performed by limiting-dilution PCR as previously de¬
scribed (44). Nucleotide sequences from the V3 region (patient samples p2, p3,
p4, pi 1, pl3, pl4, and pl5) were amplified using previously described primers
(24, 40, 43). To serve as negative controls, parallel separations, extractions, and
amplifications were carried out with PBMCs isolated from bufly coats leukocytes
derived from HIV-negative blood. HIV-1 DNA could be detected in CD4 T
lymphocytes and CD8 T lymphocytes from HIV-seropositive individuals but not
in any negative controls.
Cloning of the PCR products. Amplified DNA was ligated into a plasmid
vector prior to nucleotide sequencing using the pGEM-T vector system (Pro-
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TABLE 2. Purity of isolated pan-T and CD8+ lymphocytes










1 2.6 98.1 0.2 99.0
2 0.5 96.4 0.2 98.2
3 0.1 99.8 0.3 96.0
4 0.1 96.7 0.4 97.3
Mean 0.6 98.2 0.3 97.3
HIV positive
1 2.5 94.0 0.4 97.2
2 1.3 98.0 0.5 99.0
3 0.7 99.0 0.5 96.4
Mean 1.5 97.0 0.4 97.5
mega, Southampton, United Kingdom). The ligated product was transformed
into competent cells (JM109; Promega) and plated on Luria-Bertani plates (200
jig of ampicillin/ml). The plasmid DNA was denatured by incubation with 1/10
volume of 2 M sodium hydroxide-2 mM EDTA at 37°C for 30 min. DNA was
precipitated by addition of 1/10 volume of 3 M sodium acetate and 2 volumes of
ethanol and incubation at —20°C overnight.
Nucleotide sequencing and analysis. Dideoxynucleotide sequencing was car¬
ried out with a U.S. Biochemical Sequenase 2.0 kit (Amersham Life Science,
Piscataway, N.J.) with [35S]dATP, and patient plasma samples were sequenced
using a Thermosequenase radiolabeled terminator cycle sequencing kit accord¬
ing to the manufacturer's instructions.
Sequences were aligned and distances were estimated using the Simmonic
2000 sequence editor package. Phylogenetic analysis was carried out using the
MEGA program (27). The nucleotide sequences from V1/V2 and V3 amplified
from each of the study subjects were compared with each other and with a range
of standard HIV-1 variants. Each set of sequences from the four study subjects
was monophyletic in both genomic regions and distinct from those of the pub¬
lished sequences of subtype B: HIVSF2 (K02007), HIVRF (M17451), HIVOYI
(M26727), HIVLAI (K02013), HIVJRFL (M74978), HIVYU2 (M93258),
HIVCAM1 (D10112), HIVNY5CG (M38431), HIVHAN (U43131), HIVWMJ22
(Ml2507), and HIVSFAAA (M65024).
Nucleotide sequence accession numbers. Nucleotide sequences obtained in
this study have been submitted to GenBank and assigned accession numbers
AF353734 through AF353941.
RESULTS
Detection of HIV proviral sequences in CD8 lymphocytes. T
lymphocytes were separated from PBMCs by negative selec¬
tion using immobilized magnetic beads. Fluorescence-acti¬
vated cell sorting analysis showed substantial purity of the
separated T cells, with >94% of cells coexpressing CD3 and
CD45 (mean, 97.4%) (Table 2). Monocyte contamination, de¬
tected by the expression of CD14 and CD45, was minimal
(<3%; mean, 1.1%). Purified CD3+ lymphocytes were subse¬
quently separated by positive selection for CD8 expression
and, in a separate step carried on the remaining cells, for CD4.
Analysis of the purity of selected CD8 lymphocytes revealed
extremely low numbers of contaminating CD4 lymphocytes
(Table 2; Fig. 1), in no case exceeding 0.5% of the total pop¬
ulation. Knowledge of this frequency combined with quantita¬
tion of proviral load in purified CD8 and CD4 lymphocytes
allowed calculation in worst-case situations (i.e., 0.5% CD4
contamination) of the contribution of CD4 lymphocytes to the
proviral load detected in CD8 lymphocytes (see below).
Having established the effectiveness of the cell separation
method, we separated samples from seven HIV-infected indi¬
viduals into CD4 and CD8 T lymphocytes and assayed them for
HIV proviral DNA sequences using highly conserved primers
from the LTR. These pan-LTR primers amplify DNA se¬
quences immediately downstream from the tRNA primer bind¬
ing site and are therefore potentially able to detect incomplete
transcripts resulting from abortively infected cells (18, 52).
Frequencies of infected cells ranged from 30 to 670 proviral
copies/106 CD4 lymphocytes and from 8 to 500 /105 CD8 lym¬
phocytes. The worst-case scenario, where CD4 lymphocytes
comprise 0.5% of the CD8 population (see above), failed to
account for the proviral sequences detected in CD8 lympho¬
cytes in at least five of the seven samples (Table 3; Fig. 2A).
Maximum contributions from contaminating CD4 lymphocytes
ranged from <5% in these four samples and 27 and 33% in the
remaining two. These latter samples contained low proviral
loads in the CD8 lymphocyte subset (<10 copies/106 cells).
Similar results were obtained on retesting proviral loads using
a different set of primers (C-LTR) (Table 3). In this case, CD4
contamination accounted for <1% of proviral load detected in
five samples and for 16 and 44% in the remaining two).
Detection of complete proviral transcripts. To determine
whether proviral sequences detected in CD4 and CD8 lympho¬
cytes were incomplete or complete transcripts, DNA samples
from each subset were quantified using a second set of primers
spanning the region on either side of the primer binding site.
Quantitation of the plasmid HXB2 demonstrated that pan-
LTR and C-LTR primers had equal sensitivities (data not
shown), and so the detection of greater proviral loads using the
pan-LTR primers in CD4 or CD8 lymphocytes would indicate
the presence of incomplete proviral transcripts. Proviral loads
using the two sets of primers were comparable in each case,
with no evidence for higher virus loads detected with the pan-
LTR primers (median ratio of pan-LTR to C-LTR, 0.638; Z =
0.76 using Wilcoxon signed rank test; P = 0.445 [not signifi¬
cant]).
Distribution of HIV in naive and memory subsets of CD4
and CD8 lymphocytes. To obtain phenotypically unchanged
CD4+ and CD8+ T lymphocytes for separation of naive and
memory subsets, it was necessary to use negative selection to
isolate CD4 and CD8 lymphocytes prior to positive selection
with CD45RA and CD45RO monoclonal antibodies. The
purity of the isolated CD4+ CD45RA+, CD4+ CD45RO+,
CD8+ CD45RA+, and CD8+ CD45RO+ cell populations
from five HIV-l-negative individuals and one HIV-l-positive
individual was determined (Table 4). CD4+ lymphocytes con¬
tained 0.9 to 1.3% contaminating CD8+ cells, similar to that
found in the sample from the HIV-positive sample (0.7 to
1.2%). Contamination of the separated CD8+ lymphocytes by
CD4+ cells was similarly low (0.8 to 1.7%). As described above
for CD4 and CD8 lymphocytes separated by positive selection,
the contribution of contaminating CD4+ lymphocytes could
not account for the proviral load detected in the majority if
CD8 lymphocytes samples (see below).
HIV sequences in DNA from each of the purified lympho¬
cyte subsets of the 16 study subjects was quantified by limiting
dilution (Table 1; Fig. 2B and C). HIV-1 proviral DNA was
detected in the CD4 naive and CD4 memory subsets of all
patients studied (between 55 and 4,307 provirus copies per 106
cells) except in the CD4 memory subset of pl5 (Table 1). The
frequency of infection and proportion of virus load contributed
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FIG. 1. Analysis by three-color flow cytometry of CD8 lymphocytes purified by positive selection from PBMCs of three HIV-positive (+ve)
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by naive and memory subsets of CD4 lymphocytes varied with
absolute CD4 count. CD4 naive lymphocytes contributed the
majority of infected cells in those with high CD4 counts (r =
0.703, P = 0.02), while memory cells were predominantly in¬
fected in individuals with low CD4 counts (r = -0.450, P =
0.08).
HIV DNA was also detected in nine samples of separated
CD8+ CD45RA+ lymphocytes, and in three CD8+ CD45RO+
subsets from 10 of the 16 individuals. The contribution of
contaminating CD4 lymphocytes to the measured virus loads
was small or insignificant in 10 of these samples (Table 1), and
these were considered to represent infection of CDS lympho¬
cytes. In eight individuals, HIV preferentially infected the na¬
ive subset of CD8 T lymphocytes, with proviral frequencies
ranging from 25 to and 1,440 provirus copies per 106 cells).
There was a tendency for higher frequencies of infected CD8+
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TABLE 3. Frequencies of infection of CD4 and CD8 lymphocytes and contribution of contaminating CD4 lymphocytes
to the proviral load detected in CD8 lymphocytes
QfnHv Qtihiffl CD4 (proviral copies/
Proviral contaminationa CD8 (proviral copies/ % Mean (range)
OLUUy oUUJLCL 106 CD4 lymphocytes) Minimum Mean Maximum 106 CD8 lymphocytes) CD4 contribution6
Pan-T LTR primers
p!7 215 0.41 0.73 1.01 101 0.72 (0.40-1.00)
pl8 309 0.59 1.05 1.45 23 4.55 (2.55-6.31)
pl9 672 1.28 2.28 3.16 56 4.07 (2.28-5.64)
p20 579 1.10 1.96 2.72 10 19.6 (11.0-27.2)
p21 30 0.06 0.10 0.14 19 0.53 (0.30-0.74)
p22 563 1.07 1.91 2.65 8 23.8 (13.4-33.1)
p23 551 1.05 1.87 2.59 499 0.37 (0.21-0.52)
C-LTR primers
p!7 216 0.41 0.73 1.01 505 0.14 (0.08-0.20)
pl8 514 0.98 1.74 2.42 585 0.30 (0.17-0.41)
pl9 52 0.10 0.18 0.24 56 0.31 (0.31-0.44)
p20 901 1.71 3.05 4.23 9.6 31.82 (17.8-44.1)
P21 63 0.12 0.21 0.30 29 0.74 (0.41-1.02)
p22 271 0.51 0.92 1.27 8 11.48 (6.4-15.92)
" Contribution of CD4 lymphocytes to proviral load detected in CD8 lymphocyte subset, corresponding to minimum (0.19%), mean (0.34%), and maximum (0.47%)
contamination levels observed in control experiments (Table 2), expressed as copies per 106 cells.
b Percentage of proviral load in CD8 lymphocyte subset attributable to CD4 contamination.
CD45RA+ cells to be found in individuals with lower CD4
counts, although this difference did not reach statistical signif¬
icance (P = 0.286). Frequencies of HIV-infected CD8 lympho¬
cytes did not correlate with disease status, risk group, antiviral
therapy, or total CD4 lymphocyte counts. There was no corre¬
lation between frequency of infection of CD8 cells with either
CD4 subset.
Effect of antiviral therapy on CD4 and CD8 lymphocyte
infection. CD4 and CD8 naive and memory lymphocyte sub¬
sets were separated from pretreatment and sequential post-
treatment samples collected from five individuals receiving
combination antiviral treatment and then analyzed for proviral
sequences (Table 5). Treated individuals showed rises in cir¬
culating CD4 counts and reductions in circulating viremia.
Despite the effectiveness of the antiviral therapy, the distribu¬
tion and frequency of infected cells in each of the subsets
remained relatively stable, in all cases remaining within a ±1-
log10 range of the levels detected in the initial samples. Infec¬
tion of CD8 lymphocytes remained detectable in the three
individuals whose first samples were positive, while the two
individuals with negative CD8 lymphocytes in the pretreatment
samples remained negative during treatment. There was evi¬
dence for a decline in the frequency of infected CD4+
CD45RA+ and CD4+ CD45RO+ lymphocytes over the course
of treatment (r = -0.428; P = 0.098 and r = 0.545; P = 0.029
respectively). A similar decrease in the frequencies of infected
CD8+ CD45RA+ cells was not observed, although fewer ob¬
servations were made (r = 0.070; P = 0.870).
Sequence comparison of HIV infecting different lymphocyte
subsets. To investigate the possible genetic partitioning and
differences in predicted phenotype of HIV infecting CD4 and
CD8 lymphocytes, proviral sequences of the V3 hypervariable
region of env were compared (Fig. 3 and 4). From seven study
subjects, approximately 10 clones derived from amplified DNA
extracted from the separated lymphocyte subsets were se¬
quenced. The combined set of V3 sequences from each indi¬
vidual were monophyletic and distinct from those of previously
published V3 region sequences (data not shown).
Sequence diversity within lymphocyte subsets and the degree
of partitioning between them varied considerably between the
study subjects. V3 sequences from the naive CD4 and CD8
subsets of pl5 grouped together and showed mean diversities
of 0.002 to 0.0064, similar to the mean pairwise distance be¬
tween subsets (0.0071). In marked contrast, sequences from
CD8 lymphocytes of pl4 were distinct from all other cell types,
forming a separate clade supported in 100% of bootstrap re¬
samplings. In this individual, the mean pairwise distance be¬
tween the CD8 and CD4 lymphocytes ranged from 0.113
(CD4+ CD45RA+) to 0.119 (CD4+ CD45RO+), much greater
than the diversity within the CD8 population (0.0076). There
was no correlation between sequence diversity in any of the
subsets with disease progression, nor was there correlation
with proviral load (data not shown).
Among the six study subjects from whom CD8 lymphocyte
sequences were obtained, five showed either partial or com¬
plete separation from CD4 virus populations. In contrast, only
one of six study subjects showed any evidence for separation of
CD4 naive and memory subsets (p8) (Fig. 4). Most sequences
contained neutral or acidic residues at positions 306 and 320.
However, sequences of certain subsets of lymphocytes from p8
(CD4+ CD45RA+) and pl4 (CD4+ lymphocytes and plasma)
contained arginine residues at position 306 along with several
other amino acid changes in V3 and flanking regions. These
sequences formed phylogenetically distinct clades that grouped
separately from variants found in other subsets.
DISCUSSION
The use of magnetic bead separation provides an effective
method to isolate subsets of lymphocytes that can be assayed
for HIV infection by conventional PCR. One of the problems
with the technique when used to investigate infection of CD8
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FIG. 2. Comparison of net proviral load in CD4 and CD8 lymphocytes separated by positive selection (A), and in CD4 lymphocytes (B) and
CD8 lymphocytes (C) separated by negative selection, followed by positive selection for CD45RA and CD45RO.
lymphocytes is the possibility that even low-level contamina¬
tion by CD4 lymphocytes may produce false positive results.
To verify that CD8 lymphocytes were infected, we combined
purity measurements with calculations of the contribution to
proviral load of contaminating CD4 lymphocytes. Using posi¬
tive selection methods to isolate CD4 and CD8 lymphocytes,
we demonstrated that CD4 contamination could not account
for the proviral load detected in the separated CD8 lympho-
TABLE 4. CD3, CD4, and CD8 expression on isolated CD4+ CD45RA+, CD4+ CD45RO+, CD8+ CD45RA+,
and CD8+ CD45RO+ lymphocytes"
CD3 expression (%) CD4 expression (%) CD8 expression (%)
Sample CD4+ CD4+ CD8+ CD8+ CD4+ CD4+ CD8+ CD8 + CD4 + CD4+ CD8+ CD8+
RA+ RO+ RA+ RO + RA+ RO+ RA+ RO + RA+ RO+ RA+ RO+
HIV negative
1 79.1 98.7 98.7 68.5 73.4 93.9 2.5 2.4 2.3 1.9 93.1 60.9
2 97.2 93.8 99.2 97.6 95.6 90.9 0.4 1.3 0.6 0.3 98.4 97.5
3 98.9 99.9 98.4 91.8 96.1 97.1 0.9 2.6 1.6 1.3 92.6 79.2
4 99.4 99.2 88.4 96.8 95.2 96.5 0.1 0.3 0 0 84.2 91.0
5 99.2 97.6 88.8 50.2 98.1 95.3 0 0 1.7 0 80.9 45.6
Mean 97.6 97.6 94.7 81.0 91.7 86.5 7 1.6 1.3 0.9 83.3 70.1
HIV positive 94.8 97.8 94.5 92.8 95.1 94.7 0.8 1.3 1.2 0.7 89.8 78.8
" RA+ and RO+, CD45RA+ and CD45ROL
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TABLE 5. Infection of lymphocyte subsets of study subjects receiving combination antiviral therapy
Proviral copies/106 cells
Time (days) CD4 Circulating plasma
Patient Therapy" since start of . . virus load (genome CD4+ CD8+
treatment eoun |J" eq of RNA/ml)6
CD45RA+ CD45RO+ CD45RA+ CD45RO+
pl Pre 0 10 14,000 98 834 Neg Neg
+ 27 150 1,700 34 239 Neg Neg
p9 Pre 0 283 750,000 575 2,321 40 Neg
+ 48 3,000 72 1,807 215 Neg
plO Pre 0 301 81,540
+ 49 7 Neg 1,307 464 622 Neg
+ 62 466 Neg 533 533 697 Neg
+ 100 Neg 878 364 1,049 Neg
+ 115 + 667 577 2,764 Neg
+ 154 428 ± 1,498 1,390 489 Neg
Stop 360 349 16,000 734 2,884 435 Neg
pl2 Pre 0 329 64,680 55 115 Neg Neg
+ 14 477 Neg 15 188 Neg Neg
+ 41 540 Neg 19 119 Neg Neg
+ 100 442 Neg 9 48 Neg Neg
+ 340 207 Neg 18 56 Neg Neg
p!4 Pre 0 360 Neg 533 980 119 Neg
+ 27 418 Neg 158 1,307 203 Neg
+ 153 465 Neg 351 183 144 Neg
" Combination treatment over study period. Pre, sample collected pretreatment (tested in Table 1); +, sample affected while on treatment; stop, treatment stopped
because of side effects.
b Neg, <400 genome eq/ml; ±, equivocal result.
cytes from at least five of the seven samples tested (Table 3). A
similar conclusion was drawn from comparison of frequencies
of infected CD45RA+ and CD45RO+ CD8 lymphocytes with
measurements of CD4 contamination (Table 1). The purity of
T cells isolated by the pan-T negative selection method and in
particular the lack of significant monocyte contamination (Ta¬
ble 2) provided evidence against a significant contribution to
proviral load by other cell types in the PBMC population.
Further evidence was provided by lack of a correlation be¬
tween frequencies of infected CD4 lymphocytes and detection
of proviral sequences in either the CD3+, CD8+, CD8H
CD45RA+ or CD3+, CD8+, CD8+ CD45RO+ populations
(Tables 1 and 3). For example, the sample with the highest
frequency of infected CD4 lymphocytes (p4) contained unde¬
tectable frequencies of CD8 infection; similarly, the sample
with the highest CD8 proviral load contained relative low fre¬
quencies of infection of both subsets of CD4 cells. Third,
although there was considerable intersubject variability in the
detection of CD8 lymphocyte infection, longitudinal sampling
of the same individual over time revealed remarkable stabil¬
ity in proviral loads in each of the lymphocyte subsets. For
example, pretreatment samples from pi and pl2 contained
undetectable frequencies of infected CD8 lymphocytes, while
samples subsequently remained negative. The remaining indi¬
viduals with infected CD8 lymphocytes pretreatment remained
PCR positive subsequently. The consistency of provirus detec¬
tion in the lymphocyte subset argues against sporadic contam¬
ination by CD4 lymphocytes as a reason for our observations.
Finally, CD4 contamination would not account for the fre¬
quent genetic differences observed in the V3 hypervariable
regions between variants recovered from CD8 with those from
the CD45RA+ and CD45RO+ subpopulations of CD4 lym¬
phocytes (Fig. 3).
In this study, expression of the RA and RO isoforms of
CD45 was used to select between two functionally different
subsets of T lymphocytes (naive and memory /effector, respec¬
tively) in the peripheral circulation. The separation method
had to be modified to avoid potential cellular activation and
resulting change in CD45 expression that may occur during the
two rounds of positive selection required by the original meth¬
od (positive selection for CD8 or CD4, followed by bead re¬
moval and positive selection by CD45RA or CD45RO mono¬
clonal antibodies). Evidence for the effectiveness of the second
method is provided by the similarity in the combined frequen¬
cies of infected CD45RA " and CD45RO+ CD8 and CD4 cells
with those measured in CD8 and CD4 lymphocytes separated
by positive selection in this (Fig. 2) and previous (31) studies.
It is unlikely that CD8 lymphocytes were significantly contam¬
inated with CD4 lymphocytes with Nef-induced down-regula¬
tion of CD4 expression. It has been long established that the
proportion of provirus-positive PBMCs that are actively in¬
fected with HIV is extremely low. PBMCs expressing HIV
mRNAs detectable by in situ hybridization were undetectable
or present only at very low frequencies (16), frequencies con¬
siderably adrift from the numbers of PBMCs containing pro¬
viral DNA sequences (42, 44). More recently, quantitative
PCR methods to detect multiply spliced mRNA transcripts
(from which nef is translated) have been developed. They have
confirmed that few, if any, cells in the peripheral circulation
contain transcriptionally active HIV (2). In a variety of HIV-
infected individuals, frequencies of multiply spliced mRNA
ranged from 0 to 700 copies per 2 X 105 PBMCs. As a pro¬
ductively infected cell expresses at least 100 to 1,000 spliced
transcripts, the expression detected in vivo can be accounted
for by a few or even single virus-expressing cells in the sample.
These frequencies are considerably adrift from the numbers of
provirus-positive cells detected in the CD8 fraction purified by






















FIG. 3. Phylogenetic analysis of V3 region sequences from different lymphocyte subsets of seven study subjects. Symbols: •, CD8+ CD45RA+
(naive) cells; O, CD4+ CD45RA+ cells; ■, CD8+ CD45RO+ cells; □, CD4+ CD45RO+ cells; ■>, cDNA sequences from plasma (pl4). Trees were
rooted using the HIV-1MN sequence; a scale bar indicated at the bottom. Clades with >70% bootstrap supported are indicated by numbers on
branches.
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Quantitation of proviral sequences in these two subsets in¬
dicated that the CD45RA+ (naive) subset was infected with
HIV-1 in vivo, in contrast to the distribution of proviral se¬
quences in the RO and RA subsets of CD4+ lymphocytes.
Separate identification of HIV-1 infection in naive and mem¬
ory/effector cells provides information on the time of infection
of T cells relative to maturation and activation, which in turn
provides indirect information on the likely mechanisms under¬
lying infection of peripheral CD8 lymphocytes. While expres¬
sion of CD45RA and CD45RO has been the most commonly
used method for separating naive and memory/effector cells,
expression of other markers in combination with CD45 has
been used to more strictly define functionally distinct subsets.
Markers of cellular activation such as CD38 expression and
down-regulation of CD27 and CD28 have been used to identify
effector from memory and naive CD8+ lymphocytes (8,14,15,
20, 35). Expression of CD62L in combination with CD45RA
has been used to define purer populations of naive CD4 cells,
as there is evidence that a proportion of memory CD4 cells of
HIV-positive individuals express CD45RA (36, 39). Whether
abnormal expression of CD45RA on the CD8 lymphocytes of
HIV-positive lymphocytes also occurs has not been deter¬
mined. Recently it has been reported that the isoform of CD45
expressed on memory cells may ultimately revert to RA, po¬
tentially producing a subset of CD45RA+ cells functionally
distinct from the naive phenotype (3).
While it is possible that a proportion of the CD45RA+ CD4
and CD8 populations analyzed in our study may have originally
been memory cells, the predominance of HIV-1 infection in
the CD8 CD45RA+ subset argues empirically that the main
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FIG. 4. Consensus V3 and flanking region sequences of lymphocyte subsets from seven study subjects. Separate consensus sequences were
calculated for the two phylogenetic groupings of CD8 sequences from p3 and p8. Amino acid residues are numbered according to HIV-1hxb2;
positions 306 and 320 are indicated; basic residues are indicated in bold. Symbols: ., sequence identity with HIV-1MN; ?, variable sites without 75%
majority consensus residue.
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target CD8 lymphocyte is the naive subpopulation. For exam¬
ple, it is unlikely that the infected CD8 cells detected are
memory revertants, as it would be likely that a similar fre¬
quency of nonrevertant CD45RO+ lymphocytes would also be
infected.
Infection of naive cells has been documented extensively in
CD4 lymphocytes (36, 41, 45) and is confirmed in this study,
although in contrast to our findings, frequencies of infected
CD45RA+ have been reported to be lower than in the
CD45RO+ effector/memory population. The latter cells are
considered to be the main contributors to the pool of infected
lymphocytes in vivo, where cellular activation on antigenic
stimulation produces cells susceptible to infection and destruc¬
tion by HIV-1 (9, 11, 48, 52, 53). Indeed, productive infection
of naive CD4 lymphocytes in vitro by laboratory isolates of
HIV-1 is demonstrably inefficient, most likely through lack of
T-cell activation necessary for efficient reverse transcription
and integration of the HIV genome after entry (9, 11, 39, 46,
48, 52, 53), and because they do not express the CCR5 che-
mokine coreceptor required for the entry of primary (non-
syncytium-inducing) variants (5, 34). Hypotheses developed to
account for the infection of naive CD4 lymphocytes may also
be relevant for the infection of naive CD8 lymphocytes in vivo
reported here.
There are several potential mechanisms for the infection of
CD8 lymphocytes, although most would not predict the pref¬
erential distribution of infection in the naive subset. Peripheral
CD8 lymphocytes express low levels of CD4 on mitogenic and
antigenic stimulation in vitro, and it has been hypothesized
that this allows productive infection of CD8 lymphocytes in
vivo to occur (12, 25, 51). This hypothesis is supported by our
recent finding that CD4 expression can be detected on the
CD69+, activated subpopulation of CD8 lymphocytes in PB-
MCs of both HIV-negative and HIV-positive individuals (S.
Imlach et al., unpublished data), but the requirement for cel¬
lular activation suggests that the CD45RO+ population would
be the main reservoir of infected CD8 lymphocytes. The ab¬
sence of any measurable excess of incomplete proviral tran¬
scripts in CD8 lymphocytes (Table 3) provides further evi¬
dence against active infection of this subset.
It is possible that genetic variants of HIV-1 evolve during
persistent infection to infect cells by a non-CD4-dependent
mechanism; high levels of virus replication and extensive de¬
pletion of the CD4 target population may contribute to this
switch. While phenotypic characterization of HIV variants in¬
fecting CD4 and CD8 lymphocytes would clearly be of value,
and the genetic differences observed in V3 provide evidence
for a genetic difference between the CD4 and CD8 popu¬
lations, CD4-independent infection would likely remain cell
cycle-dependent, or perhaps become more so if based on ex¬
pression of high levels of coreceptors, and again would pref¬
erentially target the memory/effector CD8 cell population.
HIV-1 infection of CD4+ CD8+ immature thymocytes des¬
tined to become CD8 lymphocytes during thymic maturation
(26, 28) would provide both a plausible mechanistic explana¬
tion for their infection, and would also explain the presence of
proviral sequences in the naive subsets of both CD4 and CD8
lymphocytes in peripheral blood. The thymus represents a ma-
Vol. 75, 2001 HIV-1 INFECTION OF CD8 NAIVE LYMPHOCYTES 4101
jor target for HIV-1 infection in vivo, and destruction of thy-
mopoietic areas is observed on autopsy examination of AIDS
cases. Destruction of CD8 precursor cells would also explain
the eventual failure of CD8 homeostasis and decline in circu¬
lating numbers of first naive and then memory CD8 lympho¬
cytes on disease progression (37, 38), as well as the recovery in
numbers of naive CD8+ (and CD4+) lymphocytes generally
observed after commencement of antiviral treatment (1, 6).
Without biopsy material, it was not possible to directly observe
the replication of HIV within thymocytes. Indeed, proviral
sequences in naive cells in peripheral blood can be detected
only in circumstances where thymocytes survive infection with
HIV and mature into CD4 and CD8 lymphocytes. Survival of
infected cells may occur because the infecting virus was defec¬
tive or because the provirus integrated into a site in the host
chromosome that prevented transcription. As documented for
naive CD4 lymphocytes in the peripheral circulation, where
frequencies of provirus-positive cells were approximately 100-
fold greater than infectivity titers (36), it is likely that the vast
majority of integrated proviral sequences detected in naive
CD8 lymphocytes would also be defective. The presence of
culturable virus from this subset therefore provides little infor¬
mation on the degree of CD8 destruction that occurs in the
thymus.
Evidence for the quiescent nature of HIV-1 infection in CD8
naive lymphocytes, consistent with thymic infection, is pro¬
vided by the observation of equivalence in proviral load in CD8
lymphocytes between the pan-LTR and C-LTR primers (Table
3), indicating that HIV proviruses were complete and poten¬
tially stably integrated into the cellular genome. Second, we
observed a great stability in frequencies of infected CD8 pop¬
ulation on antiretroviral therapy; combination treatment
achieved a complete clearance of circulating viremia in the
majority of study subjects (Table 5), while over the period of
virus suppression ranging from 1 to 11 months, there was no
consistent reduction in frequencies of infected CD8 lympho¬
cytes. Over the same period, frequencies of infected naive and
memory subsets of CD4 lymphocytes showed a modest decline,
consistent with previous kinetic studies reporting half-lives of
proviral sequences from 21 to 58 weeks (7, 22, 23, 50).
Sequences recovered from the CD8 lymphocytes were fre¬
quently distinct from those from CD4 lymphocytes, whereas
the CD45RA+ and CD45RO " subsets of the latter were gen¬
erally undifferentiated from each other. Although there was
great individual variation in the sequence relationships be¬
tween different cell types, CD8 lymphocytes of pl4 retained V3
sequences that lacked positively charged amino acid residues
associated with a CXCR4-dependent phenotype (10,13), when
both subsets of CD4 lymphocytes and the plasma population
contained variants with arginine residues at these sites and
which were likely to have replaced the original population.
This indicates a slower turnover of the CD8 population in this
individual. Similar differences in rates of cell turnover may
therefore underlie the genetic differences between CD4 and
CD8 lymphocytes in other study subjects.
In summary, the evidence for infection of the CD45RA+
population of peripheral CD8 lymphocytes provides the basis
for testing a number of competing theories for the mechanism
CD8 lymphocyte infection in vivo. In the future, phenotypic
characterization of variants infecting the two cell types should
indicate whether CD4-independent entry of HIV-1 can occur.
Further studies on the turnover of HIV-l-infected CD8 lym¬
phocytes in vivo, such as the acquisition of antiviral resistance
during treatment relapse, will provide information on the dy¬
namics and consequences of CD8 infection and potentially on
the mechanisms underlying the loss of CD8 lymphocytes on
disease progression.
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